EUROPEAN COMMISSION

DIRECTORATE-GENERAL FOR RESEARCH & INNOVATION

SP1-Cooperation

Coordination and support action

Coordination (or networking) actions

FP7-ERANET-2012-RTD

Grant Agreement Number 321570

EuroNanoMed II

EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine

NMP4-CA-2012-321570

SEVENTH FRAMEWORK PROGRAMME

GRANT AGREEMENT No 321570

PROJECT TITLE EuroNanoMed II

Coordination and support action

Coordination (or networking) actions

The **European Union** ("*the Union*"), represented by the **European Commission** (the "*Commission*"),

of the **one part**,

and AGENCE NATIONALE DE LA RECHERCHE, established in Rue de Bercy 212, PARIS, 75012, France represented by Pascale Briand, Directeur Général and/or Freyssinet Philippe, Directeur général adjoint or their authorised representative, the *beneficiary* acting as "*coordinator*" of the *consortium* (the "*coordinator*"), ("*beneficiary no. 1*"),

of the **other part**

HAVE AGREED to the following terms and conditions including those in the following annexes, which form an integral part of this *grant agreement* (the "*grant agreement*").

Annex I - Description of Work
Annex II - General conditions
Annex III - Non applicable
Annex IV - Form A - Accession of *beneficiaries* to the *grant agreement*
Annex V - Form B - Request for accession of a new *beneficiary* to the *grant agreement*
Annex VI - Form C - Financial statement per funding scheme
Annex VII - Form D - Terms of reference for the certificate on the financial statements and Form E - Terms of reference for the certificate on the methodology

Article 1 - Accession to the *grant agreement* of the other *beneficiaries*

1. The *coordinator* shall endeavour to ensure that each legal entity identified below accedes to this *grant agreement* as a *beneficiary*, assuming the rights and obligations established by the *grant agreement* with effect from the date on which the *grant agreement* enters into force, by signing Form A in three originals, countersigned by the *coordinator*.

• **AGENTSCHAP VOOR INNOVATIE DOOR WETENSCHAP EN TECHNOLOGIE,** established in Koning Albert II-laan 35, bus 16 , Brussel, 1030, Belgium represented by Veerle Lories, administrator-general and/or Maarten Sileghem, director strategic research and European programmes or their authorised representative ("*beneficiary no. 2*"),

• **SERVICE PUBLIC DE WALLONIE,** established in Place Josephine Charlotte 2, Jambes, 5100, Belgium represented by Yves Sennen, General Director and/or Pierre Villers, Head of Unit or their authorised representative ("*beneficiary no. 3*"),

• **BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG,** established in Heinemannstrasse 2, BONN, 53175, Germany represented by Liane Horst, Head of Division 511 and/or Herbert Zeisel, Head of Division 511 or their authorised representative ("*beneficiary no. 4*"),

• **VDI TECHNOLOGIEZENTRUM GMBH,** established in VDI-Platz 1, DUESSELDORF, 40468, Germany represented by Sascha Hermann, Managing Director and/or Reinhold Mann, Head of unit or their authorised representative ("*beneficiary no. 5*"),

• **THE ICELANDIC CENTRE FOR RESEARCH,** established in Laugavegur 13, REYKJAVIK, 101, Iceland represented by Hallgrimur Jonasson, Director General or his authorised representative ("*beneficiary no. 6*"),

• **MINISTRY OF HEALTH,** established in 2 Ben Tabai Street, JERUSALEM, 93591, Israel represented by Dov Fast, Senior Deputy Director General or his authorised representative ("*beneficiary no. 7*"),

• **MINISTERO DELLA SALUTE,** established in Via Giorgio Ribotta 5, ROMA, 00144, Italy represented by Massimo Casciello, General Director and/or Gaetano Guglielmi, Senior Medical Officer or their authorised representative ("*beneficiary no. 8*"),

• **REGIONE DEL VENETO,** established in Palazzo Balbi - Dorsoduro 3901, VENEZIA, 30123, Italy represented by Caterina De Pietro, Regional Director or her authorised representative ("*beneficiary no. 9*"),

• **VENETO NANOTECH SCPA,** established in VIA SAN CRISPINO 106, PADOVA, 35129, Italy represented by Nicola Trevisan, CEO and/or Luigi Rossi Luciani, President or their authorised representative ("*beneficiary no. 10*"),

• **LATVIJAS ZINATNU AKADEMIJA,** established in AKADEMIJAS LAUKUMS 1, RIGA, 1050, Latvia represented by Juris Ekmanis, President or his authorised representative ("*beneficiary no. 11*"),

• **Lietuvos mokslo taryba,** established in Gedimino 3, Vilnius, LT01103, Lithuania represented by Eugenijus Butkus, Chairman of the Research Council of Lithuania and/or Ricardas Rotomskis, Project coordinator or their authorised representative ("*beneficiary no. 12*"),

• **NORGES FORSKNINGSRAD,** established in Stensberggata 26, OSLO, 0131, Norway represented by Anne Kjersti Fahlvik, Director or her authorised representative ("*beneficiary no. 13*"),

• **NARODOWE CENTRUM BADAN I ROZWOJU,** established in UL. NOWOGRODZKA 47A, WARSZAWA, 00 695, Poland represented by Krzysztof Kurzydłowski, Director and/or Leszek Grabarczyk, Deputy Director or their authorised representative ("*beneficiary no. 14*"),

• **FUNDACAO PARA A CIENCIA E A TECNOLOGIA,** established in Avenida Dom Carlos I 126, LISBOA, 1249-074, Portugal represented by Pedro Carneiro, Vice-President and/or Paulo Pereira, Vice-President or their authorised representative ("*beneficiary no. 15*"),

• **AUTORITATEA NATIONALA PENTRU CERCETARE STIINTIFICA,** established in MENDELEEV STR 21 25 district1, BUCHAREST, 010362, Romania represented by Prisecaru Tudor, President or his authorised representative ("*beneficiary no. 16*"),

• **Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii,** established in Mendeleev Street 21-25 , Bucharest, 010362, Romania represented by ADRIAN CURAJ, DIRECTOR and/or MAGDA RESIGA, Deputy Director or their authorised representative ("*beneficiary no. 17*"),

• **INSTITUTO DE SALUD CARLOS III,** established in CALLE SINESIO DELGADO 4, MADRID, 28029, Spain represented by JOAQUÍN ARENAS, GENERAL DIRECTOR and MIGUEL ÁNGEL CABO, SECRETARY GENERAL or their authorised representative ("*beneficiary no. 18*"),

• **VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL,** established in VASTRA JARNVAGSGATAN 3, STOCKHOLM, 111 64, Sweden represented by Mille Millnert, Director General or his authorised representative ("*beneficiary no. 19*"),

• **SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG,** established in Wildhainweg 3, Bern, 3012, Switzerland represented by Aysim Yilmaz, Head, Division of Biology and Medicine or her authorised representative ("*beneficiary no. 20*"),

All the *beneficiaries* together form the *consortium* (the "*consortium*").

2. The *coordinator* shall send to the *Commission* one duly completed and signed Form A per *beneficiary* at the latest 45 calendar days after the entry into force of the *grant agreement*. The two remaining signed originals shall be kept, one by the *coordinator* to be made available for consultation at the request of any *beneficiary*, and the other by the *beneficiary* concerned.

3. Should any legal entity identified above, fail or refuse to accede to the *grant agreement* within the deadline established in the previous paragraph, the *Commission* is no longer bound by its offer to the said legal entity(ies). The *consortium* may propose to the *Commission*, within the time-limit to be fixed by the latter, appropriate solutions to ensure the implementation of the *project*. The procedure established in Annex II for amendments to this *grant agreement* will apply.

4. The *beneficiaries* are deemed to have concluded a *consortium agreement* (the "*consortium agreement*") regarding the internal organisation of the *consortium*.

Article 2 - Scope

The Union has decided to grant a financial contribution for the implementation of the *project* as specified in Annex I, called *EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine (EuroNanoMed II)* (the "*project*") within the framework of the *SP1-Cooperation* and under the conditions laid down in this *grant agreement*.

Article 3 - Duration and *start date* of the *project*

The duration of the *project* shall be 48 months from 1st November 2012 (hereinafter referred to as the "*start date*").

Article 4 - Reporting periods and language of reports

The *project* is divided into reporting periods of the following duration:

- P1: from month 1 to month 18
- P2: from month 19 to month 36
- P3: from month 37 to the last month of the *project*.

Any report and deliverable, when appropriate, required by this *grant agreement* shall be in *English*.

Article 5 - Maximum financial contribution of *the Union*

1. The maximum financial contribution of *the Union* to the *project* shall be EUR 1,499,990.00 (*one million four hundred and ninety nine thousand nine hundred and ninety EURO*). The actual financial contribution of *the Union* shall be calculated in accordance with the provisions of this *grant agreement.*

2. Details of the financial contribution of *the Union* are contained in Annex I to this *grant agreement* which includes:

- a table of the estimated breakdown of budget and financial contribution of *the Union* per activity to be carried out by each of the *beneficiaries* under the *project. Beneficiaries* are allowed to transfer budget between different activities and between themselves in so far as the work is carried out as foreseen in Annex I.

3. The bank account of the *coordinator* to which all payments of the financial contribution of *the Union* shall be made is:

Name of account holder: Agence Nationale de la Recherche
Name of bank: Trésor Public RGF Paris
Account reference: FR7610071750000000100088932

Article 6 - Pre-financing

A *pre-financing* of EUR 799,994.66 (*seven hundred and ninety nine thousand nine hundred and ninety four EURO and sixty six cents*) shall be paid to the *coordinator* within 45 days following the date of entry into force of this *grant agreement.* The *coordinator* shall distribute the *pre-financing* only to the *beneficiaries* who have acceded to the *grant agreement* and after the minimum number of *beneficiaries* required by the *Rules for Participation* as detailed in the call for proposals to which the *project* is related, have acceded to the *grant agreement.*

Beneficiaries hereby agree that the amount of EUR *74,999.50* (*seventy four thousand nine hundred and ninety nine EURO and fifty cents*), corresponding to the *beneficiaries'* contribution to the Guarantee Fund referred to in Article II.20 and representing 5% of the maximum financial contribution of *the Union* referred to in Article 5.1, is transferred in their name by the *Commission* from the *pre-financing* into the Guarantee Fund. However, *beneficiaries* are deemed to have received the full *pre-financing* referred to in the first indent and will have to justify it in accordance with the *grant agreement.*

Article 7 - Special clauses

The following special clauses apply to this *grant agreement*:

~~Special clause 9~~

1. Costs incurred by the following *beneficiary(ies)* shall not be taken into consideration for determining the financial contribution of *the Union*:

- BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG

2. Part B of Annex II, with the exception of Article II.23, II.25.2 and II.25.3, and any other financial and payment provisions contained in the *grant agreement* do not apply to *beneficiary(ies)* mentioned in the previous paragraph. This(ese) *beneficiary(ies)* need not submit, in particular, the reports mentioned in Article II.4.1.c) and II.4.4 and is/are not subject to financial audits and controls referred to in Article II.22.

3. When providing services or resources to another beneficiary, this(ese) beneficiary(ies) shall be considered as (a) third party(ies) for the purpose of the application of Article II.3 paragraphs c) and d).

Article 8 - Communication

1. Any communication or request concerning the *grant agreement* shall identify the *grant agreement* number, the nature and details of the request or communication and be submitted to the following addresses:

For the *Commission*: European Commission
Directorate-General for Research & Innovation
G6 - Administration and Finance
B-1049 Brussels, Belgium

For the *coordinator*: Dr. Natalia Martin
AGENCE NATIONALE DE LA RECHERCHE
Biology & Health department
rue Watt 7
Paris 75013
FRANCE

2. For information or documents to be transferred by electronic means, the following addresses shall be used:

For the *Commission*: rtd-contract-dir-g@ec.europa.eu

For the *coordinator*: Natalia.martin@agencerecherche.fr

3. In case of refusal of the notification or absence of the recipient, the *beneficiary* or the *consortium*, as the case may be, is deemed to have been notified on the date of the latest delivery, if notification to the *coordinator* has been sent to one of the addresses mentioned in paragraphs 1 and 2 and to their legal representative. Other *beneficiaries* are deemed to have been notified if notification has been sent to the address mentioned in Article 1.1.

4. Any communication or request relating to the processing of personal data (Article II.13) shall be submitted, using the address(es) for the *Commission* identified in paragraphs 1 and 2, to the Controller responsible for the processing: Head of Unit of G6 - Administration and Finance.

Article 9 - Applicable law and competent court

The financial contribution of *the Union* is a contribution from *the Union* research budget with the aim to implement the 7th Research Framework Programme (FP7) and it is incumbent on the Commission to execute FP7. Accordingly, this *grant agreement* shall be governed by the terms of this *grant agreement*, the European Community and European Union acts related to FP7, the Financial Regulation applicable to the general budget and its implementing rules and other European Community and European Union law and, on a subsidiary basis, by the law of Belgium.

Furthermore the *beneficiary* is aware and agrees that the Commission may take a decision to impose pecuniary obligations, which shall be enforceable in accordance with Article 299 of the Treaty on the Functioning of the European Union and Articles 164 and 192 of the Treaty establishing the *European Atomic Energy Community*.

Notwithstanding the *Commission's* right to directly adopt the recovery decisions referred to in the previous paragraph, the General Court, or on appeal, the Court of Justice of the European Union, shall have sole jurisdiction to hear any dispute between *the Union* and any *beneficiary* concerning the interpretation, application or validity of this *grant agreement* and the validity of the decision mentioned in the second paragraph.

Article 10 - Application of the *grant agreement* provisions

Any provision of this part of the *grant agreement*, shall take precedence over the provisions of any of the Annexes. The provisions of Annex III shall take precedence over the provisions of Annex II, and both shall take precedence over the provisions of Annex I.

The special clauses set out in Article 7 shall take precedence over any other provisions of this *grant agreement*.

Article 11 - Entry into force of the *grant agreement*

This *grant agreement* shall enter into force after its signature by the coordinator and the *Commission*, on the day of the last signature.

Done in two originals in English.

For the *coordinator* done at PARIS

Agence Nationale de la Recherche
Name of the legal entity

Dr Pascale Briand
Name of the legal representative

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy / 75012 Paris
Stamp of the organisation (if applicable)

Signature of legal representative

18 September 2012
Date

For the *Commission* done at Brussels

Herbert von Bose
Director
DG-RTD G

Name of the legal representative

Signature of legal representative

05 OCT. 2012
Date

COMMISSION OF THE EUROPEAN COMMUNITIES
Directorate-General for Science, Research and Development

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

AGENTSCHAP VOOR INNOVATIE DOOR WETENSCHAP EN TECHNOLOGIE, represented for the purpose hereof by Veerle Lories, administrator-general, and/or Maarten Sileghem, director strategic research and European programmes, or her/his/their authorised representative, established in Koning Albert II-laan 35, bus 16 , Brussel, 1030, Belgium acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 2*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **AGENTSCHAP VOOR INNOVATIE DOOR WETENSCHAP EN TECHNOLOGIE**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

AGENTSCHAP VOOR INNOVATIE DOOR WETENSCHAP EN TECHNOLOGIE

Veerle Lories
Name of legal representative(s)

Signature of legal representative(s)

20/9/2012
Date

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND
Le directeur général
Name of legal representative(s)

Signature of legal representative(s)

08 NOV. 2012
Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris
Stamp of the organisation

IWT
Ellipsgebouw
Koning Albert II - laan 35 bus 16
B-1030 Brussel
tel.:+32(0)2 432 42 00 Fax.:+32(0)2 432 43 99
E-mail: info@iwt.be
www.iwt.be

ALLEGATO A Dgr n _____ de'

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

SERVICE PUBLIC DE WALLONIE, represented for the purpose hereof by Yves Sennen, General Director, and/or Pierre Villers, Head of Unit, or her/his/their authorised representative, established in Place Josephine Charlotte 2, Jambes, 5100, Belgium acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 3*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **SERVICE PUBLIC DE WALLONIE**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

SERVICE PUBLIC DE WALLONIE

VILLERS Pierre

Name of legal representative(s)

Signature of legal representative(s)

20/09/2012

Date

Service public de Wallonie
Monsieur Pierre VILLERS
Inspecteur général
Département des Programmes de recherche (DGO6)
Place de la Wallonie, 1 Bât. III
5100 JAMBES

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

08 NOV. 2012

Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG, represented for the purpose hereof by Liane Horst, Head of Division 511, and/or Herbert Zeisel, Head of Division 511, or her/his/their authorised representative, established in Heinemannstrasse 2, BONN, 53175, Germany acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 4*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG

Dr. Herbert Zeisel
Name of legal representative(s)

i.V.
Signature of legal representative(s)

Bonn, den 27.08.2012
Date

Bundesministerium für Bildung und Forschung
Heinemannstraße 2
53175 Bonn
Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND
Le directeur général
Name of legal representative(s)

Signature of legal representative(s)

0 8 NOV. 2012
Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris
Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

VDI TECHNOLOGIEZENTRUM GMBH, represented for the purpose hereof by Sascha Hermann, Managing Director, and/or Reinhold Mann, Head of unit, or her/his/their authorised representative, established in VDI-Platz 1, DUESSELDORF, 40468, Germany acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 5*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **VDI TECHNOLOGIEZENTRUM GMBH**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

VDI TECHNOLOGIEZENTRUM GMBH	AGENCE NATIONALE DE LA RECHERCHE
Sascha Hermann	Pascale Briand
Name of legal representative(s)	Name of legal representative(s)
Signature of legal representative(s)	Signature of legal representative(s)
21.11.2012	27 NOV. 2012
Date	Date
VDI Technologiezentrum GmbH VDI-Platz 1 · D-40468 Düsseldorf Telefon +49 (0) 211 62 14-401	AGENCE NATIONALE DE LA RECHERCHE ANR 212 rue de Bercy - 75012 Paris
Stamp of the organisation	Stamp of the organisation

12/127

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

THE ICELANDIC CENTRE FOR RESEARCH, represented for the purpose hereof by Hallgrimur Jonasson, Director General, or his authorised representative, established in Laugavegur 13, REYKJAVIK, 101, Iceland acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 6*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **THE ICELANDIC CENTRE FOR RESEARCH**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

THE ICELANDIC CENTRE FOR RESEARCH	AGENCE NATIONALE DE LA RECHERCHE
Hallgrimur Jonasson	Pascale BRIAND
Name of legal representative(s)	Le directeur général Name of legal representative(s)
Hallgrimur Jonasson	
Signature of legal representative(s)	Signature of legal representative(s)
30.9.2012	08 NOV. 2012
Date	Date
Stamp of the organisation Rannsóknamiðstöð Íslands The Icelandic Centre for Research www.rannis.is	AGENCE NATIONALE DE LA RECHERCHE ANR 212 rue de Bercy - 75012 Paris Stamp of the organisation

REGIONE DEL VENETO giunta regionale UNITÀ DI PROGETTO RICERCA E INNOVAZIONE

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

MINISTRY OF HEALTH, represented for the purpose hereof by Dov Fast, Senior Deputy Director General, or his authorised representative, established in 2 Ben Tabai Street, JERUSALEM, 93591, Israel acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 7*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **MINISTRY OF HEALTH**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

MINISTRY OF HEALTH

mr. Dov Fast

Name of legal representative(s)

Signature of legal representative(s)

23.9.12

Date

דב פסט
ממנ"ל בכיר למינהל
ומשאבי אנוש

Stamp of the organisation

מדינת ישראל
משרד הבריאות
MINISTRY OF HEALTH
STATE OF ISRAEL

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

08 NOV. 2012

Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

REGIONE del VENETO giunta regionale UNITÀ DI PROGETTO RICERCA E INNOVAZIONE

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

MINISTERO DELLA SALUTE, represented for the purpose hereof by Massimo Casciello, General Director, and/or Gaetano Guglielmi, Senior Medical Officer, or her/his/their authorised representative, established in Via Giorgio Ribotta 5, ROMA, 00144, Italy acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 8*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **MINISTERO DELLA SALUTE**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

MINISTERO DELLA SALUTE

MASSIMO CASCIELLO

Name of legal representative(s)

Signature of legal representative(s)

- 8 NOV. 2012

Date

MINISTERO DELLA SALUTE
DIREZIONE GENERALE DELLA RICERCA SANITARIA
E DELLA VIGILANZA SUGLI ENTI

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

0 8 NOV. 2012

Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

REGIONE DEL VENETO, represented for the purpose hereof by Caterina De Pietro, Regional Director, or her authorised representative, established in Palazzo Balbi - Dorsoduro 3901, VENEZIA, 30123, Italy acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 9*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **REGIONE DEL VENETO**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

REGIONE DEL VENETO

IL DIRIGENTE REGIONALE
Dott.ssa Caterina De Pietro

Name of legal representative(s)

Signature of legal representative(s)

0 4 OTT. 2012

Date

REGIONE DEL VENETO
GIUNTA REGIONALE
Unità di Progetto
Ricerca e Innovazione
Fondamenta Santa Lucia - Cannaregio, 23
30121 Venezia

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

0 8 NOV. 2012

Date

ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

VENETO NANOTECH SCPA, represented for the purpose hereof by Nicola Trevisan, CEO, and/or Luigi Rossi Luciani, President, or her/his/their authorised representative, established in VIA SAN CRISPINO 106, PADOVA, 35129, Italy acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 10*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **VENETO NANOTECH SCPA**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

VENETO NANOTECH SCPA

NICOLA TREVISAN, CEO
Name of legal representative(s)

Signature of legal representative(s)

01 OTT. 2012
Date

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND
Le directeur général
Name of legal representative(s)

Signature of legal representative(s)

08 NOV. 2012
Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

veneto nanotech
small technology big applications
Veneto Nanotech S.C.p.A.
via San Crispino, 106 - 35129 Padova - Italy
tel. +39 049 7705500 - fax +39 049 7705555
C.F., n.ro iscriz. Reg. Imprese di PD e P.IVA 03845260284

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

LATVIJAS ZINATNU AKADEMIJA, represented for the purpose hereof by Juris Ekmanis, President, or his authorised representative, established in AKADEMIJAS LAUKUMS 1, RIGA, 1050, Latvia acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 11*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **LATVIJAS ZINATNU AKADEMIJA**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

LATVIJAS ZINATNU AKADEMIJA

President

JURIS EKMANIS

Name of legal representative(s)

Signature of legal representative(s)

22 NOV 2012

Date

LATVIJAS ZINATNU AKADEMIJA

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

0 8 NOV. 2012

Date

AGENCE NATIONALE DE LA RECHERCHE ANR 212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

Lietuvos mokslo taryba, represented for the purpose hereof by Eugenijus Butkus, Chairman of the Research Council of Lithuania, and/or Ricardas Rotomskis, Project coordinator, or her/his/their authorised representative, established in Gedimino 3, Vilnius, LT01103, Lithuania acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 12*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **Lietuvos mokslo taryba**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

Lietuvos mokslo taryba

Eugenijus Butkus
.....
Name of legal representative(s)

.....
Signature of legal representative(s)

10 LAP. 2012
.....
Date

.....
Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE
Pascale BRIAND

Le directeur général
.....
Name of legal representative(s)

.....
Signature of legal representative(s)

1 4 NOV. 2012
.....
Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris
.....
Stamp of the organisation

ALLEGATO A Dgr n _____ del

REGIONE DEL VENETO
giunta regionale
UNITÀ DI PROGETTO RICERCA E INNOVAZIONE

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

NORGES FORSKNINGSRAD, represented for the purpose hereof by Anne Kjersti Fahlvik, Director, or her authorised representative, established in Stensberggata 26, OSLO, 0131, Norway acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 13*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **NORGES FORSKNINGSRAD**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

NORGES FORSKNINGSRAD

ANNE KJERSTI FAHLVIK

Name of legal representative(s)

Signature of legal representative(s)

09. 20. 12

Date

Stamp of the organisation

The Research Council of Norway
P.O.Box 2700 St. Hanshaugen
NO-0131 OSLO
Tel.: 0047 22 03 70 00

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND
Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

08 Nov. 2012

Date

ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

NARODOWE CENTRUM BADAN I ROZWOJU, represented for the purpose hereof by Krzysztof Kurzydłowski, Director, and/or Leszek Grabarczyk, Deputy Director, or her/his/their authorised representative, established in UL. NOWOGRODZKA 47A, WARSZAWA, 00 695, Poland acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 14*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **NARODOWE CENTRUM BADAN I ROZWOJU**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

NARODOWE CENTRUM BADAN I ROZWOJU

.....

Name of legal representative(s)

NARODOWE CENTRUM BADAŃ I ROZWOJU
prof. dr hab. inż. Krzysztof KURZYDŁOWSKI

.....

Signature of legal representative(s)

2012 -09- 28

.....

Date

NARODOWE CENTRUM
BADAŃ I ROZWOJU
00-695 Warszawa, ul. Nowogrodzka 47a
REGON 141032404, NIP 7010073777

.....(5).....

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

.....

Name of legal representative(s)

.....

Signature of legal representative(s)

0 8 NOV. 2012

.....

Date

AGENCE NATIONALE DE LA RECHERCHE
ANR

.....212 rue de Bercy - 75012 Paris.....

Stamp of the organisation

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

FUNDACAO PARA A CIENCIA E A TECNOLOGIA, represented for the purpose hereof by Pedro Carneiro, Vice-President, and/or Paulo Pereira, Vice-President, or her/his/their authorised representative, established in Avenida Dom Carlos I 126, LISBOA, 1249-074, Portugal acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 15*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **FUNDACAO PARA A CIENCIA E A TECNOLOGIA**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

FUNDACAO PARA A CIENCIA E A TECNOLOGIA

Prof. Paulo Pereira
Name of legal representative(s)

Signature of legal representative(s)

19/09/2012
Date

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

08 NOV. 2012
Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

AUTORITATEA NATIONALA PENTRU CERCETARE STIINTIFICA, represented for the purpose hereof by Prisecaru Tudor, President, or his authorised representative, established in MENDELEEV STR 21 25 district1, BUCHAREST, 010362, Romania acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 16*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **AUTORITATEA NATIONALA PENTRU CERCETARE STIINTIFICA**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

AUTORITATEA NATIONALA PENTRU CERCETARE STIINTIFICA

Tudor Prisecaru

Name of legal representative(s)

Signature of legal representative(s)

01.10.2012

Date

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

08 NOV. 2012

Date

ANR

212 Rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii, represented for the purpose hereof by ADRIAN CURAJ, DIRECTOR, and/or MAGDA RESIGA, Deputy Director, or her/his/their authorised representative, established in Mendeleev Street 21-25 , Bucharest, 010362, Romania acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 17*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii

PROF. ADRIAN CURAJ

Name of legal representative(s)

Signature of legal representative(s)

10.10.2012

Date

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

0 8 NOV. 2012

Date

ANR

212 rue de Bercy - 75012 Paris

Stamp of the organisation

REGIONE DEL VENETO giunta regionale UNITÀ DI PROGETTO RICERCA E INNOVAZIONE

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

INSTITUTO DE SALUD CARLOS III, represented for the purpose hereof by JOAQUÍN ARENAS, GENERAL DIRECTOR, and/or MIGUEL ÁNGEL CABO, SECRETARY GENERAL, or her/his/their authorised representative, established in CALLE SINESIO DELGADO 4-6, MADRID, 28029, Spain acting as its legal authorised representative, hereby consents to become a *beneficiary* (*"beneficiary no. 18"*) to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **INSTITUTO DE SALUD CARLOS III**, the third being sent to the *Commission* by the coordinator in accordanee with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

INSTITUTO DE SALUD CARLOS III

JOAQUIN R. ARENAS

Name of legal representative(s)

Signature of legal representative(s)

25 de 1 2012

Date

MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD INSTITUTO DE SALUD CARLOS III DIRECCIÓN

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND
Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

0 8 NOV. 2012

Date

AGENCE NATIONALE DE LA RECHERCHE ANR 212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT

ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL, represented for the purpose hereof by Mille Millnert, Director General, or his authorised representative, established in VASTRA JARNVAGSGATAN 3, STOCKHOLM, 111 64, Sweden acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 19*") to *grant agreement* N° 321570 (relating to *project "EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine"*) concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL

Mille Millnert, Director General

Name of legal representative(s)

Signature of legal representative(s)

Sep. 20, 2012

Date

SWEDISH RESEARCH COUNCIL
Box 1035, SE-101 38 Stockholm
Visiting address: Västra Järnvägsgatan 3
Phone +46 (0)8546 44 000
Fax +46 (0)8546 44 180
E-mail: vetenskapsradet@vr.se

Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIANT

Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

14 NOV. 2012

Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris

Stamp of the organisation

FP7 GRANT AGREEMENT
ANNEX IV - FORM A - ACCESSION OF BENEFICIARIES TO THE GRANT AGREEMENT

SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG, represented for the purpose hereof by Aysim Yilmaz, Head, Division of Biology and Medicine, or her authorised representative, established in Wildhainweg 3, Bern, 3012, Switzerland acting as its legal authorised representative, hereby consents to become a *beneficiary* ("*beneficiary no. 20*") to *grant agreement* N° 321570 (relating to *project* "*EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine*") concluded between the European Commission and AGENCE NATIONALE DE LA RECHERCHE established in Rue de Bercy - 212, PARIS, 75012, France and accepts in accordance with the provisions of the aforementioned *grant agreement* all the rights and obligations of a *beneficiary*.

Done in 3 copies, of which one shall be kept by the *coordinator* and one by **SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG**, the third being sent to the *Commission* by the coordinator in accordance with Articles 1.1 and 1.2 and Article 8 of the grant agreement.

SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG

Aysim Yilmaz
Name of legal representative(s)

Signature of legal representative(s)

20.9.2012
Date

Schweiz. Nationalfonds
Wildhainweg 3
3001 Bern
Stamp of the organisation

AGENCE NATIONALE DE LA RECHERCHE

Pascale BRIAND
Le directeur général

Name of legal representative(s)

Signature of legal representative(s)

14 NOV. 2012
Date

AGENCE NATIONALE DE LA RECHERCHE
ANR
212 rue de Bercy - 75012 Paris
Stamp of the organisation

SEVENTH FRAMEWORK PROGRAMME

THEME [NMP.2012.1.2-3]
[ERA-NET on Nanomedicine]

Grant agreement for: Coordination and support action

Annex I - "Description of Work"

Project acronym: EuroNanoMed II

Project full title: " EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine "

Grant agreement no: 321570

Version date: 2012-07-03

Table of Contents

Part A

Workplan Tables

A1: Project summary

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per project

General information

Project title [3]	EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine		
Starting date [4]	01/11/2012		
Duration in months [5]	48		
Call (part) identifier [6]	FP7-ERANET-2012-RTD		
Activity code(s) most relevant to your topic [7]	NMP.2012.1.2-3: ERA-NET on Nanomedicine		
Free keywords [8]	nanomedicine, translational research, nanotechnologies, targeted delivery systems, diagnostics, regenerative medicine		

Abstract [9]

Nanomedicine, the application of nanotechnology to health, is a fast-growing field with a large potential for improving diagnostics and therapeutic solutions in many diseases. The EuroNanoMed II (ENM II) consortium, with 20 partners from 17 countries and regions, aims to foster the competitiveness of European nanomedicine actors through the support of translational research projects enhancing transnational and multidisciplinary collaborations between academia, clinical/public health communities and industry. ENM II will be a follow-up of the ERA-NET EuroNanoMed I (ENM I), which launched three joint transnational calls for proposals in three years. The increasing number of submitted proposals in the successive ENM I joint calls and their quality show the need amongst the nanomedicine scientific community for such a targeted initiative. ENM II will be built on the basis of the ENM I accomplishments, and will continue to support transnational innovative RTD projects in nanomedicine through the launch of yearly joint calls for proposals. In addition, ENM II aims to extend the cooperation among its partners through the development of other activities: (i) foster the participation of young European researchers to ENM II activities; ii) develop a strategic agenda for ENM II in close cooperation to the ETP Nanomedicine; iii) create more interactions within the European nanomedicine community and improve communication on nanomedicine to the public; iv) frame and address regulatory, safety and ethical issues associated with nanomedicine; v) monitor the results of the ENM I & ENM II funded research projects and the activities of the ENM II network; and, vi) develop a long-term cooperation framework for European nanomedicine research. Therefore, through joint funding of translational nanomedicine projects and its other activities, ENM II will contribute to enhance coordination of research and resources in this field, thereby shaping the European Research Area in nanomedicine.

A2:
List of Beneficiaries

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

List of Beneficiaries

No	Name	Short name	Country	Project entry month[10]	Project exit month
1	AGENCE NATIONALE DE LA RECHERCHE	ANR	France	1	48
2	AGENTSCHAP VOOR INNOVATIE DOOR WETENSCHAP EN TECHNOLOGIE	IWT	Belgium	1	48
3	SERVICE PUBLIC DE WALLONIE	SPW-DGO6	Belgium	1	48
4	BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG	BMBF	Germany	1	48
5	VDI TECHNOLOGIEZENTRUM GMBH	VDI	Germany	1	48
6	THE ICELANDIC CENTRE FOR RESEARCH	RANNIS	Iceland	1	48
7	MINISTRY OF HEALTH	CSO-MOH	Israel	1	48
8	MINISTERO DELLA SALUTE	IMH	Italy	1	48
9	REGIONE DEL VENETO	VED	Italy	1	48
10	VENETO NANOTECH SCPA	VN	Italy	1	48
11	LATVIJAS ZINATNU AKADEMIJA	LAS	Latvia	1	48
12	Lietuvos mokslo taryba	RCL	Lithuania	1	48
13	NORGES FORSKNINGSRAD	RCN	Norway	1	48
14	NARODOWE CENTRUM BADAN I ROZWOJU	NCBR	Poland	1	48
15	FUNDACAO PARA A CIENCIA E A TECNOLOGIA	FCT	Portugal	1	48
16	AUTORITATEA NATIONALA PENTRU CERCETARE STIINTIFICA	ANCS	Romania	1	48
17	Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii	UEFISCDI	Romania	1	48
18	INSTITUTO DE SALUD CARLOS III	ISCIII	Spain	1	48
19	VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL	SRC	Sweden	1	48
20	SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG	SNSF	Switzerland	1	48

A3: Budget Breakdown

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One Form per Project

Participant number in this project [11]	Participant short name	Ind. costs [13]	Estimated eligible costs (whole duration of the project)				Total receipts	Requested EU contribution
			Coordination / Support (A)	Management (B)	Other (C)	Total A+B+C		
1	ANR	F	127,236.00	191,040.00	0.00	318,276.00	0.00	283,796.00
2	IWT	T	48,360.00	0.00	0.00	48,360.00	0.00	43,121.00
3	SPW-DGO6	F	62,520.00	0.00	0.00	62,520.00	0.00	55,747.00
4	BMBF	T	14,400.00	0.00	0.00	14,400.00	0.00	0.00
5	VDI	A	262,092.00	0.00	0.00	262,092.00	0.00	167,315.00
6	RANNIS	F	39,960.00	0.00	0.00	39,960.00	0.00	35,631.00
7	CSO-MOH	T	123,360.00	0.00	0.00	123,360.00	0.00	109,996.00
8	IMH	F	24,840.00	0.00	0.00	24,840.00	0.00	22,149.00
9	VED	T	17,280.00	0.00	0.00	17,280.00	0.00	15,408.00
10	VN	T	419,080.00	0.00	0.00	419,080.00	0.00	374,763.00
11	LAS	F	18,840.00	0.00	0.00	18,840.00	0.00	16,799.00
12	RCL	F	83,804.00	0.00	0.00	83,804.00	0.00	78,841.00
13	RCN	F	33,374.40	0.00	0.00	33,374.40	0.00	29,758.00
14	NCBR	F	25,680.00	0.00	0.00	25,680.00	0.00	22,898.00
15	FCT	T	69,180.00	0.00	0.00	69,180.00	0.00	61,685.00
16	ANCS	F	17,880.00	0.00	0.00	17,880.00	0.00	15,943.00
17	UEFISCDI	F	22,200.00	0.00	0.00	22,200.00	0.00	19,795.00
18	ISCIII	T	97,896.00	0.00	0.00	97,896.00	0.00	87,290.00
19	SRC	T	47,244.00	0.00	0.00	47,244.00	0.00	42,125.00
20	SNSF	T	18,987.60	0.00	0.00	18,987.60	0.00	16,930.00
Total			1,574,214.00	191,040.00	0.00	1,765,254.00	0.00	1,499,990.00

A3:
Budget Breakdown

ALLEGATO A Dgr n. _____ del

Note that the budget mentioned in this table is the total budget requested by the Beneficiary and associated Third Parties.

34/127

*** The following funding schemes are distinguished**

Collaborative Project (if a distinction is made in the call please state which type of Collaborative project is referred to: (i) Small of medium-scale focused research project, (ii) Large-scale integrating project, (iii) Project targeted to special groups such as SMEs and other smaller actors), Network of Excellence, Coordination Action, Support Action.

1. Project number

The project number has been assigned by the Commission as the unique identifier for your project, and it cannot be changed. The project number **should appear on each page of the grant agreement preparation documents** to prevent errors during its handling.

2. Project acronym

Use the project acronym as indicated in the submitted proposal. It cannot be changed, unless agreed during the negotiations. The same acronym **should appear on each page of the grant agreement preparation documents** to prevent errors during its handling.

3. Project title

Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are possible if agreed during the preparation of the grant agreement.

4. Starting date

Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement, the project will start on the first day of the month following the entry info force of the Grant Agreement (NB : entry into force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a detailed justification on a separate note.

5. Duration

Insert the duration of the project in full months.

6. Call (part) identifier

The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the Commission in the letter inviting to prepare the grant agreement.

7. Activity code

Select the activity code from the drop-down menu.

8. Free keywords

Use the free keywords from your original proposal; changes and additions are possible.

9. Abstract

10. The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start dates being relative to this start date.

11. The number allocated by the Consortium to the participant for this project.

12. Include the funding % for RTD/Innovation – either 50% or 75%

13. Indirect cost model
- **A: Actual Costs**
- **S: Actual Costs Simplified Method**
- **T: Transitional Flat rate**
- **F :Flat Rate**

Workplan Tables

Project number

321570

Project title

EuroNanoMed II—EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine

Call (part) identifier

FP7-ERANET-2012-RTD

Funding scheme

Coordination and support action

WT1
List of work packages

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

LIST OF WORK PACKAGES (WP)

WP Number [53]	WP Title	Type of activity [54]	Lead beneficiary number [55]	Person-months [56]	Start month [57]	End month [58]
WP 1	Management	MGT	1	34.00	1	48
WP 2	Joint funding activities in nanomedicine	COORD	10	57.50	1	48
WP 3	Regulatory Affairs, Ethical and Safety Issues	COORD	5	20.50	1	48
WP 4	Communication and Dissemination	COORD	7	30.00	1	48
WP 5	Monitoring and optimisation of activities	COORD	15	22.10	1	48
WP 6	Strategic Research and Cooperation Agenda	COORD	18	20.90	1	48
			Total	185.00		

WT2: List of Deliverables

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

List of Deliverables - to be submitted for review to EC

Delive-rable Number [61]	Deliverable Title	WP number [53]	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
D1.1	Establishment of the management structures	1	1	3.00	O	PU	1
D1.2	Establishment of the External Advisory Board (EAB)	1	1	4.00	O	PU	4
D1.3	NSC meeting-1 minutes	1	1	3.00	R	PP	1
D1.4	NSC meeting-2 minutes	1	1	3.00	R	PP	7
D1.5	NSC meeting-3 minutes	1	1	3.00	R	PP	12
D1.6	NSC meeting-4 minutes	1	1	3.00	R	PP	19
D1.7	NSC meeting-5 minutes	1	1	3.00	R	PP	24
D1.8	NSC meeting-6 minutes	1	1	3.00	R	PP	31
D1.9	NSC meeting-7 minutes	1	1	3.00	R	PP	36
D1.10	NSC meeting-8 minutes	1	1	3.00	R	PP	43
D1.11	NSC meeting-9 minutes	1	1	3.00	R	PP	47
D2.1	Report on selection of topics for JTC2015 & JTC2016	2	6	5.00	R	PP	22
D2.2	Report on actions to encourage young scientist participation	2	1	4.50	R	PP	24
D2.3	JTC2013 call documents	2	18	3.00	R	CO	2
D2.4	JTC2014 call documents	2	18	3.00	R	CO	13

WT2: List of Deliverables

Deliverable Number [61]	Deliverable Title	WP number [53]	Lead beneficiary number	Estimated indicative person-months	Nature [62]	Dissemination level [63]	Delivery date [64]
D2.5	JTC2015 call documents	2	18	3.00	R	CO	25
D2.6	JTC2016 call documents	2	18	3.00	R	CO	37
D2.7	JTC2013: lists of funded projects and annexes	2	10	9.00	R	PU	9
D2.8	JTC2014: lists of funded projects and annexes	2	10	9.00	R	PU	21
D2.9	JTC2015: lists of funded projects and annexes	2	10	9.00	R	PU	33
D2.10	JTC2016: lists of funded projects and annexes	2	10	9.00	R	PU	45
D3.1	Report on training workshop on regulatory affairs	3	5	7.50	R	PU	14
D3.2	Report on ethical issues and stakeholders attitudes towards the code of conduct	3	16	2.00	R	PU	17
D3.3	Report on expert workshop on ethical issues in nanomedicine	3	7	2.00	R	PU	26
D3.4	Report on expert workshop and coordinators' training on regulatory affairs in nanomedicine	3	5	7.00	R	PU	38
D3.5	Report on relevant safety issues in nanomedicine	3	10	1.00	R	PU	6
D3.6	Update on relevant safety issues in nanomedicine	3	10	1.00	R	PU	44

WT2: List of Deliverables

Delive-rable Number [61]	Deliverable Title	WP number [53]	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
D4.1	Public website updated for ENM II	4	12	3.00	O	PU	3
D4.2	Restricted area of the website and set up of the communication tools and database	4	12	3.00	O	PU	6
D4.3	List of contact persons for other nanomedicine initiatives	4	14	5.10	R	PU	6
D4.4	Report 1 on dissemination by the Eranet	4	7	3.00	R	PU	12
D4.5	Report 2 on dissemination by the Eranet	4	7	3.00	R	PU	24
D4.6	Report 3 on dissemination by the Eranet	4	7	3.00	R	PU	36
D4.7	Report 4 on dissemination by the Eranet	4	7	3.00	R	PU	48
D4.8	Brochure on EuroNanoMed II	4	7	3.00	R	PU	36
D4.9	Video clip 1	4	7	1.30	O	PU	9
D4.10	Video clip 2	4	7	1.30	O	PU	15
D4.11	Video clip 3	4	7	1.30	O	PU	21
D5.1	List of indicators for EuroNanoMed II programme and ENM I & II funded projects	5	15	1.60	R	PP	8
D5.2	Summary table of ENM II partner's expectations regarding ENM programme and performance	5	15	1.50	R	PP	4
D5.3	Report of the stakeholders'	5	15	1.50	R	PP	33

Delive-rable Number [61]	Deliverable Title	WP number [53]	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
	needs and expectations for a long-term sustainable cooperation						
D5.4	Report on the applicants' feedback from the ENM II JTCs and transnational collaborations	5	15	1.50	R	PP	42
D5.5	Mid-term monitoring report of EuroNanoMed II procedures and progress	5	15	3.00	R	PP	24
D5.6	Final monitoring report of EuroNanoMed II procedures and progress	5	15	3.00	R	PP	48
D5.7	Call output report for JTC 2009	5	3	2.50	R	PP	12
D5.8	Call output report for JTC 2010	5	3	2.50	R	PP	24
D5.9	Call output report for JTC 2011	5	3	2.50	R	PP	36
D5.10	Call output report for JTC 2013	5	3	2.50	R	PP	46
D6.1	ENM II strategic research agenda, including national strategies in nanomedicine	6	19	5.00	R	PU	12
D6.2	ENM II strategic agenda update	6	19	5.00	R	PU	42
D6.3	Report on the cost model for a cooperation joint	6	2	5.00	R	PU	44

WT2: List of Deliverables

Delive-rable Number [61]	Deliverable Title	WP number [53]	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
	management hub						
D6.4	Report on the cooperation framework scenarios	6	18	5.00	R	PU	46
			Total	185.00			

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per Work Package

Work package number [53]	WP1	Type of activity [54]	MGT
Work package title	Management		
Start month	1		
End month	48		
Lead beneficiary number [55]	1		

Objectives

• To establish an efficient management of the consortium and the project that will facilitate that all the contractual commitments are met;
• To coordinate and monitor the activities of the ERA-NET, and ensure the achievements of the expected results;
• To ensure an effective communication between partners and stakeholders in collaboration with the WP4 leader.

Description of work and role of partners

The coordinator will conduct the administrative, legal and financial management of the ERA-NET, and the coordination of the project work. The work package leaders (Operating group (OG)) are responsible for the achievement of the expected results and will assist and advise the coordinator. All partners will constitute the steering board of the ERA-NET (Network Steering Committee (NSC)). The web portal developed in WP4 will be used to support the internal communication between partners, and with the other stakeholders.

Task 1.1: Establishment of the management structure (Task leader : ANR, France)
The coordinator will prepare a consortium agreement (CA), which will define the procedures for administrative, financial and legal management of the project and will collect the signatures of all partners. The coordinator will also setup the management bodies. Based on the previous experience of ENM I, three management bodies will be established: the Network Steering Committee (NSC), the Operating Group (OG), and the External Advisory Board (EAB). In addition, for each call, a Call Steering Committee (CSC) will be established. The EAB of ENM I will be refreshed at the beginning of ENM II, and its mission will be to advise the NSC regarding scientific questions, in particular when defining the topics of joint transnational calls. The EAB members will be invited to relevant ENM II NSC meetings and workshops and will be consulted on an ad hoc basis if needed.

Task 1.2: Administrative, legal and financial management of the project (Task leader : ANR, France)
The Coordination Unit will:
• Conduct the contract negotiation with the EC and monitor the periodic project reports (technical and financial) to the EC;
• Do the budget follow-up and the redistribution of the EC financing to the partners;
• Represent the ERA-NET in international and national meetings;
• Manage other administrative tasks and represent the ERA-NET towards the EC.

Task 1.3: Project management (Task leader : ANR, France)
One of the roles of the coordinator is to establish an efficient project management that will facilitate that all the contractual commitments are met. The specific tasks to achieve this goal are:
• Organisation of consortium meetings. The coordinator will prepare, follow up and draft the minutes of the NSC meetings (a kick-off meeting and two NSC meetings per year). A calendar has been developed (see section 2.1f) in order to make the meetings and workshops of different WPs coincide and guarantee an efficient use of resources. This calendar will be regularly adjusted upon approval by the NSC;
• Organisation of other meetings and conference calls with the Operating Group and the EAB (prepare, follow up and draft the minutes);
• Monitoring and organising the work foreseen in this description of work;

WT3: Work package description

• Support and assist the partners on a day to day basis for the preparation of the tasks and deliverables by assuring an efficient and continuous communication (see WP4) with the WP leaders (Operating Group) and the other consortium members.

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
1	ANR	34.00
	Total	34.00

List of deliverables

Delive-rable Number [61]	Deliverable Title	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
D1.1	Establishment of the management structures	1	3.00	O	PU	1
D1.2	Establishment of the External Advisory Board (EAB)	1	4.00	O	PU	4
D1.3	NSC meeting-1 minutes	1	3.00	R	PP	1
D1.4	NSC meeting-2 minutes	1	3.00	R	PP	7
D1.5	NSC meeting-3 minutes	1	3.00	R	PP	12
D1.6	NSC meeting-4 minutes	1	3.00	R	PP	19
D1.7	NSC meeting-5 minutes	1	3.00	R	PP	24
D1.8	NSC meeting-6 minutes	1	3.00	R	PP	31
D1.9	NSC meeting-7 minutes	1	3.00	R	PP	36
D1.10	NSC meeting-8 minutes	1	3.00	R	PP	43
D1.11	NSC meeting-9 minutes	1	3.00	R	PP	47
		Total	34.00			

Description of deliverables

D1.1) Establishment of the management structures: Establishment of the Network Steering Committee (NSC) and operating group (OG) [month 1]

D1.2) Establishment of the External Advisory Board (EAB): [month 4]

D1.3) NSC meeting-1 minutes: [month 1]

D1.4) NSC meeting-2 minutes: [month 7]

D1.5) NSC meeting-3 minutes: [month 12]

D1.6) NSC meeting-4 minutes: [month 19]

D1.7) NSC meeting-5 minutes: [month 24]

D1.8) NSC meeting-6 minutes: [month 31]

D1.9) NSC meeting-7 minutes: [month 36]

D1.10) NSC meeting-8 minutes: [month 43]

D1.11) NSC meeting-9 minutes: [month 47]

Schedule of relevant Milestones

Milestone number [59]	Milestone name	Lead beneficiary number	Delivery date from Annex I [60]	Comments
MS1	Kick-Off meeting	1	1	Minutes

WT3: Work package description

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per Work Package

Work package number [53]	WP2	Type of activity [54]	COORD
Work package title	Joint funding activities in nanomedicine		
Start month	1		
End month	48		
Lead beneficiary number [55]	10		

Objectives

Four joint transnational calls will be operatively managed during the four-year period of EuroNanoMed II. This includes drafting the topics of the calls, defining the procedures, drafting all documents necessary for the calls and related procedures, launching the calls, organising the evaluation and selection of the proposals according to peer-review standards, funding decisions, as well as a follow-up of the funded projects. In addition, activities to support young researchers in the field of nanomedicine will be developed in this work package.
More specifically, the aims of this work package are to:
• Identify priority topics for the calls for proposals linking national strategies and priorities of the ERA-NET partners and international research agendas of relevance to nanomedicine;
• Plan, develop and implement joint funding activities to encourage translational research in the field of nanomedicine;
• Provide a regular and integrated funding opportunity to the nanomedicine community;
• Facilitate transnational collaborations between research teams through direct support to transnational projects;
• Foster the participation of young researchers in the EuroNanoMed joint transnational calls in order to support early independence of young researchers.

Description of work and role of partners

WP2 leaders will be responsible for the design and implementation of joint transnational calls for research projects (one per year). This WP covers all the preparatory work for joint funding activities, such as the selection of the topics, designing the call procedures and documents, encouraging young researchers' participation, as well as the implementation of the funding activities. It is therefore a WP in which all EuroNanoMed II partners will be involved. While the final decision about participation in a JTC will follow the variable geometry system, discussion and selection of the topic will be done by all the ERA-NET partners under the advice of academic, industrial, and clinical experts (EAB and external experts, see Task 2.1). For each JTC, the partners who commit to participate in the joint call will form a Call Steering Committee (CSC). The CSC will take decisions concerning the call procedures, supervise the progress of the call, and make the final funding recommendation to the national/regional funding organisations regarding the proposals to be funded, based on the final ranking list provided by the peer review panel.
The first call, in 2013, is planned to be launched soon after the ERA-NET starts and therefore, in order to be efficient and quick, we plan to have a broad topic and use the same procedures as EuroNanoMed I calls for this first JTC2013. The topic of the JTC2014 is also planned to be around the three sub-topics: targeted drug delivery, diagnostics and regenerative medicine, which are the priorities of the ETP Nanomedicine.

Task 2.1: Definition of strategic priorities for JTC2015 and JTC2016 (Task leader: RANNIS, Iceland)
This task involves defining the scope and priorities of the third and fourth call of this ERA-NET with respect to the academic, industrial, and clinical needs. This task does not cover the JTC2013 and JTC2014 since, for efficiency, the topics for these first ENM II calls have already been decided; the calls will cover the three subfields: targeted drug delivery, diagnostics and regenerative medicine. Building on the experience of EuroNanoMed I, one workshop will be organised at month 19, before the definition of the third call. The EAB and 5-10 external experts will be invited to the workshop to help define the priorities of the future joint calls: JTC2015 and JTC2016. The EAB will play a key role in advising the partners on the focus of the calls, and as such, will be consulted again before the launch of JTC2016. In addition, the updated EuroNanoMed II strategic agenda (task 6.2) will be taken into account for the orientation of the call topics. For each call, the final decision on topics

will be taken by the funding agencies participating in the call, based on their scientific, medical and industrial priorities.

Task 2.2: Foster the participation of young researchers (Task leader: ANR, France; co-leaders: SRC, Sweden, LAS, Latvia)
This task aims to encourage the participation of young researchers to EuroNanoMed II funding activities and increase the attractiveness of multidisciplinary and transversal nanomedicine research within the younger generation of scientists. Two main actions are envisioned to achieve this goal: provide a platform dedicated to young scientists' information and networking and use specific measures to stimulate the participation of young scientists in the ENM II calls.
Firstly, we plan to foster networking of young researchers in the field, to increase exchange of academic information, facilitate technology transfer and provide information about EuroNanoMed funding options for young researchers. This network will be started by putting in relation the young scientists (PhD students, Postdocs, young PIs) involved in the EuroNanoMed I and II funded projects, using email lists and other means of communication in link with WP4. The possibility of creating specific tools on the ENM II website for young researchers, to provide information about mobility options, consortium partners' search, expertise search, etc. will be envisioned. In addition, these young researchers will be encouraged to attend the EuroNanoMed I and II review seminar meetings and present posters of their work (the possibility of endowing poster prizes to add enthusiasm will be explored).
Secondly, we plan to encourage participation of young researchers in the EuroNanoMed calls through specific measures that will be decided by the CSC members. The decisions on the actions to be chosen to support young researchers will take into account the experience of other ERA-NETs (E-Rare-2 JTC2012, etc.) which have launched calls that encourage the participation of young researchers. The possible actions that will be envisioned include: i) adding eligibility criteria for inclusion of at least one young researcher as a partner in a proposal consortium; ii) dedicating a module of the available funding to consortia of young scientists (all the project leaders of such consortia have to be "young scientists"). Challenges and opportunities within the joint calls that are specific for young scientists will be explored.
The definition of "young researchers" will be discussed and decided by the ERA-NET partners, based on existing definitions at the national and European levels (for example the European Research Council definition).

Task 2.3: Design of the procedures and preparation of the Joint Transnational Calls documents (Task leader: ISCIII, Spain, co-leader: ANR, France)
On the basis of the experience gained from the three EuroNanoMed I JTCs, we will improve and refine the already established procedures for submitting, evaluating, selecting and funding the proposals. The first call (JTC2013) will be launched soon after the kick-off meeting of ENM II; therefore the procedure and the submission tool established during the last EuroNanoMed I call, in 2011, will be used. This procedure consisted in one-stage submission and evaluation with international peer review involving external experts and a peer review panel (PRP) meeting. The PRP members meet to discuss each proposal and, after consideration of the evaluation criteria, external reviews and their own discussions, the PRP identifies the top quality proposals recommended for funding and establish a ranking list. For further calls, the procedures will be discussed before each call to evolve with better practices (based on the continuous monitoring from WP5) and related to the topics and the evolution of applications number. For example, a two-stage submission and evaluation process could be envisaged if the number of submitted proposals is expected to be high.
For each call, a Memorandum of Understanding (MoU), a "Joint Transnational Call Governance" document and a call text will be prepared. The MoU will describe the agreement reached by the members of the consortium on the scope of the call, the principles ruling the selection and evaluation procedures (in outline only) and the financial commitments and funding modalities. The "Joint Transnational Call Governance" will describe the agreed-upon call operative procedures. It will include the national or regional funding body partners' eligibility requirements as an annex. The call text will describe the rationale of the call, the topic, the eligibility requirements, deadline for submission of an application, the evaluation criteria and process. In addition, for each JTC, a pre-announcement text will be published at least a month before the JTC launch to warn the scientific community of the JTC topics, countries/regions involved and the general rules. Finally, templates for the submission of proposals (addressed to applicants) and for the evaluation of proposals (addressed to the external reviewers and panel members) will be prepared.

Task 2.4: Setting-up of the call office (Task leader: VN, Italy)
To ensure the continuity with the experience gained in the previous three EuroNanoMed joint calls, the call office will be set up in Veneto Region as a central helpdesk for activities related to the implementation of the calls. It will be responsible for the operational implementation of the calls, until the projects are selected. The Call Office

will serve as contact point for any requests concerning the joint calls, providing information on EuroNanoMed activities, giving advice and information about Joint Calls' eligibility, deadline, etc. The Call Office will also supervise the publication of call texts on the EuroNanoMed website and in the countries participating in a call and will collaborate with the National Contact Points to most efficiently support the applicants. This also involves updating the JTC project submission tool according to the procedures decided for each JTC. A checklist for the coordinator will be included in the submission tool; this will include a list of the eligibility criteria and a list of all the steps that should be followed to succeed (e.g. contact each national contact point) the preparation and the submission of the proposal on due time. Finally, the Expression of interest tool that was set up in EuroNanoMed I in order to help the applicants finding partners and building consortia will be updated for EuroNanoMed II.
The existence of this tool will be largely communicated in a timely manner to the scientific community using the communication tools in WP4 (i.e. website, newsletter).

Task 2.5: Implementation of the joint transnational calls and the follow-up of the funded projects by the JCS according to the procedures (Task leader: VN, Italy)
Proposals will be collected, checked for compliance with administrative rules and further processed at the Call Office, according to the procedures and criteria developed and agreed to in task 2.3. The Joint Call Secretariat (JCS) will implement the evaluation procedure, contacting and inviting the selected reviewers (both external and for the peer review panel), organising the evaluation peer review panel meetings, providing official letters for selected and rejected projects to the respective consortia coordinator, etc. The coordinator will support the JCS in the organisation of the evaluation process and a CSC working group will be in charge of the allocation of each proposal to at least two external experts and at least two peer review panel (PRP) members.
In addition, the JCS will be the first point of contact for the coordinators of funded projects (both from EuroNanoMed I and II), and will thus collect the annual and final follow-up progress reports and organise the review seminars, on behalf of the Call Steering Committee.

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
1	ANR	4.00
2	IWT	1.00
3	SPW-DGO6	1.00
4	BMBF	0.50
5	VDI	1.00
6	RANNIS	3.00
7	CSO-MOH	1.00
8	IMH	1.00
9	VED	0.50
10	VN	32.00
11	LAS	1.50
12	RCL	1.00
13	RCN	1.00
14	NCBR	1.00
15	FCT	1.00
16	ANCS	1.00
17	UEFISCDI	1.00
18	ISCIII	3.00

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
19	SRC	1.50
20	SNSF	0.50
	Total	57.50

List of deliverables

Delive-rable Number [61]	Deliverable Title	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
D2.1	Report on selection of topics for JTC2015 & JTC2016	6	5.00	R	PP	22
D2.2	Report on actions to encourage young scientist participation	1	4.50	R	PP	24
D2.3	JTC2013 call documents	18	3.00	R	CO	2
D2.4	JTC2014 call documents	18	3.00	R	CO	13
D2.5	JTC2015 call documents	18	3.00	R	CO	25
D2.6	JTC2016 call documents	18	3.00	R	CO	37
D2.7	JTC2013: lists of funded projects and annexes	10	9.00	R	PU	9
D2.8	JTC2014: lists of funded projects and annexes	10	9.00	R	PU	21
D2.9	JTC2015: lists of funded projects and annexes	10	9.00	R	PU	33
D2.10	JTC2016: lists of funded projects and annexes	10	9.00	R	PU	45
		Total	57.50			

Description of deliverables

D2.1) Report on selection of topics for JTC2015 & JTC2016: [month 22]

D2.2) Report on actions to encourage young scientist participation: [month 24]

D2.3) JTC2013 call documents: Preannouncement Text, Memorandum of Understanding, Governance of the Call document, Call Text, Submission common form Delivery date depends on the start date of the project [month 2]

D2.4) JTC2014 call documents: Preannouncement Text, Memorandum of Understanding, Governance of the Call document, Call Text, Submission common form Delivery date depends on the start date of the project [month 13]

D2.5) JTC2015 call documents: Preannouncement Text, Memorandum of Understanding, Governance of the Call document, Call Text, Submission common form Delivery date depends on the start date of the project [month 25]

D2.6) JTC2016 call documents: Preannouncement Text, Memorandum of Understanding, Governance of the Call document, Call Text, Submission common form Delivery date depends on the start date of the project [month 37]

D2.7) JTC2013: lists of funded projects and annexes: Including Peer Review Panel composition and minutes of the PRP and CSC meetings Delivery date depends on the start date of the project [month 9]

D2.8) JTC2014: lists of funded projects and annexes: Including Peer Review Panel composition and minutes of the PRP and CSC meetings Delivery date depends on the start date of the project [month 21]

D2.9) JTC2015: lists of funded projects and annexes: Including Peer Review Panel composition and minutes of the PRP and CSC meetings Delivery date depends on the start date of the project [month 33]

D2.10) JTC2016: lists of funded projects and annexes: Including Peer Review Panel composition and minutes of the PRP and CSC meetings Delivery date depends on the start date of the project [month 45]

Schedule of relevant Milestones

Milestone number [59]	Milestone name	Lead beneficiary number	Delivery date from Annex I [60]	Comments
MS2	Commitments of partners to JTC2013 – MoU signed	1	1	Call publication subject to start date of the project
MS3	Commitments of partners to JTC2014 – MoU signed	1	12	Call publication subject to start date of the project
MS4	Commitments of partners to JTC2015 – MoU signed	1	24	Call publication subject to start date of the project
MS5	Commitments of partners to JTC2016 – MoU signed	1	36	Call publication subject to start date of the project

WT3: Work package description

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per Work Package

Work package number [53]	WP3	Type of activity [54]	COORD
Work package title	Regulatory Affairs, Ethical and Safety Issues		
Start month	1		
End month	48		
Lead beneficiary number [55]	5		

Objectives

Innovative medical products based on nanotechnology raise special concerns and regulatory questions, as different regulatory frameworks may apply for certain classes of products, leading to uncertainties among researchers and stakeholders. Nanotechnology-based drug delivery systems, like nanoparticles or drug-eluting stents for example, are considered medical devices or active pharmaceutical ingredients depending on their "primary mode of action" – that in some cases is subjected to regulatory agencies' interpretation. Market access of new nano-based imaging agents is often delayed by different timelines in the development of the diagnostic agents and the imaging machines. Finally, new therapies in the field of regenerative medicine employing engineered tissues or gene therapies are regulated as "Advanced Therapy Medicinal Products (ATMP)" and require marked approval via European notified bodies. It is essential that researchers take regulatory questions into consideration already at an early stage of their research to successfully transform innovative research in nanomedicine in marketable products and new therapies for patients. Furthermore, it is important to continue and foster the fruitful dialogue between stakeholders in nanomedicine (researchers, industry) with regulatory agencies and policy makers that has been started during the first period of EuroNanoMed. Equally important issues that this work package will address are ethical and safety aspects of the research involved in this developing area and the potential use of nano-medical products and technologies (devices and drugs) which are hoped to be the outcome of the research projects. Still, too little is known on the safety of the use of the newly arising innovative nano-products and the associated ethical concerns with it are important and should be considered.
Therefore, the objectives of this work package are to:
• Train EuroNanoMed funded researchers in regulatory, ethical and safety issues to be considered during their projects;
• Foster dialogue among nanomedicine stakeholders from research, industry, agencies & policy makers;
• Address ethical & safety issues that are pivotal for public acceptance of nanomedical products.

Description of work and role of partners

Task 3.1: Training on regulatory affairs for EuroNanoMed funded researchers (Task Leader: VDI, Germany)
The aim of this task is to inform and train researchers about regulatory requirements that nano-medical products will have to meet to pass from the research stage towards a later application or a fast entry into clinical trials, and how they should be considered during their research projects. Issues relating to intellectual properties should also be addressed. In order to achieve this, a workshop will be organised for researchers from EuroNanoMed (I&II) funded projects. Experts from industry, medical product agencies and notified bodies will be invited to give presentations and to participate in round tables. Beyond the training aspect, the workshop will also allow an interaction between the researchers and the experts – especially from agencies and EMA – to call the experts attention to the researchers' needs and problems. This workshop will be joined to a review seminar for funded projects.

Task 3.2: Framing nanomedicine ethical issues (Task Leader: CSO-MOH, Israel)
Since the emergence of the nanotechnology field, the ethical issues about nanomaterials have raised concern and have been discussed. As a result, the European Group on Ethics published in 2007 their "Opinion on the ethical aspects on nanomedicine" and, in 2008, the European Commission published the "Code of Conduct for Responsible Nanosciences & Nanotechnologies Research", as guidance for the responsible development of nanotechnologies. The goal of this task is to explore and frame the ethical issues associated with the

nanomedicine field with the aim of better taking ethics into account in the funded ENM projects and in future ENM II activities.
•Subtask 3.2.1: Mapping of European activities on ethical issues in nanomedicine (Subtask leader: ANCS, Romania)
The aim of this task is to map different national and European activities like the "Nanocode" project (http://www.nanocode.eu) and activities of Research Ethics Committees in approving research proposals. The results of this mapping will be analysed and a summary of relevant ethical issues and stakeholders' attitude with relevance to nanomedicine will be produced, which will be used as an input for task 3.3 and subtask 3.2.2.
•Subtask 3.2.2: Expert workshop on ethical issues in nanomedicine (Subtask Leader: CSO-MOH, Israel)
A workshop on ethics in nanomedicine research will be organised in collaboration with the Jerusalem Center of Ethics. Invited experts will relate, in both plenary sessions and a general discussion, to the unique ethical questions involving the use of nano-scale devices or drugs. Other Ethics organisations, such as the Ethics Resource Center (http://www.ethics.org/), the European Group of Ethics (http://ec.europa.eu/bepa/european-group-ethics/index_en.htm), the ETP Nanomedicine (http://www.etp-nanomedicine.eu/public,) or ELSA - Ethical Legal and Social Aspects of the Life Sciences and Technologies (www.ec.europa.eu/research/life/elsa/index.html) will be invited to contribute to the workshop. The workshop will be open to coordinators of ENM funded projects and will serve as a valuable input to Task 3.3.

Task 3.3: Expert dialogue and coordinators' training on regulatory affairs in nanomedicine (Task Leader: VDI, Germany)
During the last years, a fruitful dialogue has been started between all stakeholders in nanomedicine – researchers, industry, clinicians, regulatory agencies and policy makers – to address specific regulatory needs of medicinal products derived from nanotechnology. This has been done during a workshop organised in the first period of EuroNanoMed in 2009 and during EMA's first workshop on nanomedicine in 2010. To foster and strengthen this dialogue, a second EuroNanoMed expert workshop will be organised. It will gather the coordinators of ENM funded projects as well as experts in regulatory affairs from research organisations, pharmaceutical industry and clinics on the one hand and from regulatory agencies and policy makers on the other. In particular, experts from the EMA and the ETP Nanomedicine will be considered for the workshop and parallel activities from these organisations will be taken into account. A session about ethical and safety issues will be included in the workshop where the results of tasks 3.2 and 3.4 will be presented and discussed among the experts.
The workshop aims at identifying particular regulatory issues arising from nanomedical products and to find practicable solutions to provide patients more rapidly with effective and save nanomedicine-based therapies. The coordinators of ENM funded projects will play a crucial role in this workshop as, on the one hand, they will be updated about regulatory, ethical and safety issues and, on the other, their expertise will be used as input to the experts discussions.

Task 3.4: Framing nanomedicine safety issues (Task Leader: VN, Italy)
The aim of this task is to provide a periodic update on the relevant nanotoxicology research and regulation initiatives carried on at European level. Several projects, those already started networked actively in the EU NanoSafety Cluster (www.nanosafetycluster.eu), with other new projects starting in the near future, are supposed to provide information concerning the safety of nanomaterials, the use of validated methods for nano-risk assessment, roadmaps and priorities for future research, integrated and intelligent testing strategies, and the future regulatory framework for engineered nanomaterials. Nanomedicine is one of the key applications of engineered nanomaterials, and all these activities will have a substantial effect on biomedical applications of nanotechnology. Veneto Nanotech participates actively in the NanoSafety Cluster, as Deputy Coordinator of the CSA that will provide the backbone of the intelligent testing strategies to be included in the NanoEHS EU Research Strategy, as partner in the ERA-NET SIINN, in the large RTD project NanoValid and in the RTD project in the field of nanomedicine TRANS-INT, and will deliver to the ENM II Consortium constant updates, by means of two progressive reports, on the status of nanoEHS research. The information gathered during this task will be used as input to Task 3.3. The updated reports will be available on the ENM II website.

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
1	ANR	1.00

WT3: Work package description

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
4	BMBF	1.00
5	VDI	12.50
7	CSO-MOH	2.00
10	VN	2.00
16	ANCS	2.00
	Total	20.50

List of deliverables

Delive-rable Number [61]	Deliverable Title	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
D3.1	Report on training workshop on regulatory affairs	5	7.50	R	PU	14
D3.2	Report on ethical issues and stakeholders attitudes towards the code of conduct	16	2.00	R	PU	17
D3.3	Report on expert workshop on ethical issues in nanomedicine	7	2.00	R	PU	26
D3.4	Report on expert workshop and coordinators' training on regulatory affairs in nanomedicine	5	7.00	R	PU	38
D3.5	Report on relevant safety issues in nanomedicine	10	1.00	R	PU	6
D3.6	Update on relevant safety issues in nanomedicine	10	1.00	R	PU	44
		Total	20.50			

Description of deliverables

D3.1) Report on training workshop on regulatory affairs: [month 14]

D3.2) Report on ethical issues and stakeholders attitudes towards the code of conduct: [month 17]

D3.3) Report on expert workshop on ethical issues in nanomedicine: [month 26]

D3.4) Report on expert workshop and coordinators' training on regulatory affairs in nanomedicine: [month 38]

D3.5) Report on relevant safety issues in nanomedicine: [month 6]

D3.6) Update on relevant safety issues in nanomedicine: [month 44]

Schedule of relevant Milestones

Milestone number [59]	Milestone name	Lead beneficiary number	Delivery date from Annex I [60]	Comments

WT3: Work package description

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per Work Package

Work package number [53]	WP4	Type of activity [54]	COORD
Work package title	Communication and Dissemination		
Start month	1		
End month	48		
Lead beneficiary number [55]	7		

Objectives

• To disseminate the ENM II activities to the scientific community;
• To unfold the information on ERA-NET achievements to policy makers (EC, national);
• To build an information bridge between research and society emphasizing the benefit of research collaboration in the field of nanomedicine;
• To increase public awareness to the importance of research in this field and facilitate its acceptance, emphasizing the influence of the public on decision making in research.

Description of work and role of partners

The aim this work package is to disseminate the results of the ERA-NET, as well as general information on nanomedicine. The work package will be managed in close collaboration with the coordinator and in conjunction with other ERA-NET activities.
The work package will relate to three main target groups: general public (including patient organisations), scientific community and policy makers. Means will be established to disseminate research results and ERA-NET achievements to these target groups, including a web portal, which will be maintained to support the internal communication between partners, and with the other stakeholders and general public. Efforts will be directed to approach the target groups using measures that will overcome geographic and cultural boundaries. Internet tools and public relation activities will be significant elements of this work package.

Task 4.1: Website (Task leader : RCL, Lithuania)
The website set up for the ERA-NET EuroNanoMed I will be updated and improved for EuroNanoMed II. This website will be divided into three parts: a public part, a communication tool and a restricted area.
• The public part of the website will be used for publication of information related to the presentation of EuroNanoMed II, EuroNanoMed II publications, calls for proposals and results, help desk information, events and news, FAQ, etc. The website will be regularly updated with details of funded projects including abstract, partners, funding, a link to the project website and publications.
• Contact data base and communication tool: An advanced automatic tool will be developed in order to automatically disseminate information published on the website to relevant nanomedicine contacts (in a data base). This data base will include all applicants to the EuroNanoMed calls for proposals and will be continuously updated with people subscribing on the website.
• Restricted website area (available for ENM II members only): will serve to facilitate the communication between the ENM II partners. It will have both document management and project management software in order to facilitate both the exchange of documents and on-line project management (interactive calendar, information sheets, etc.). Access rights will be provided to each Work Package Leaders and Task Leaders for co-ordination activities. Video user-manuals of the private information system will be prepared.
The system will be technically maintained and information will be continuously updated, so that an efficient and timely exchange of information can be performed.

Task 4.2: Communication and relation with similar initiatives (Task Leader: NCBR, Poland and co-leaders: UEFISCDI / ANCS, Romania, ISCIII, Spain)
The aim of this task is to indicate initiatives currently involved in implementation of nanotechnology into medicine and to establish contact with them for information, dissemination, and cooperation.

The bodies with similar or partially overlapping scope, such as ERA-NETs, networks of excellence, funding organisations and safety and regulatory bodies (e.g. M-ERA.NET, ETP Nanomedicine, NANOFutures, NANOSAFETY CLUSTER, ERA-NET SIINN, EuMaT, SusChem, JTI IMI, ENIAC, AENEAS, the CSA NANOMED2020 and EMA) will be identified by Internet searching, through NETWATCH and ERA-LEARN, and by a short inquiry form that will be sent to ENM II participants. The aim of this survey will be to define contact persons in these initiatives and to create a contact list (D4.3) based on the knowledge possessed by the ENM II partners. In order to set up collaborations with similar initiatives, representatives will be invited to participate in ENM II meetings. The participation of ENM II partners to similar initiatives meetings will be also encouraged: information concerning meetings organised by similar initiatives will be collected and communicated to the ENM II partners. In addition, efforts will be made in order to organize ENM II meetings back-to-back with similar initiatives. Effective use of resources will be achieved by joining forces with other networks and bodies with similar or partially overlapping aims. The exchange of information should include their plans for future cooperation. The aim is to identify the best ways that could be applied for future cooperation after the end of the ENM II project. The envisaged activities will strength the links between ERA-NET initiatives, enhance the possibilities for new potential future cooperation schemes.

Task 4.3: Dissemination of results from the ERA-NET (Task Leader: CSO- MOH, Israel)
The aim of this task is to produce and disseminate documents on EuroNanoMed II main achievements. Different types of documents will be produced with the help of public relation experts to address the different publics targeted: the scientific community and policy makers. These include newsletters and press releases to communicate on the main events of the ERA-NET work, such as announcements and results of joint calls, information on projects funded in the joint calls (summaries and outcomes), and the results of workshops. Furthermore, a brochure presenting the ERA-NET results will be prepared for policy makers and be used for the WP6 on future cooperation. The documents will be disseminated using both printed and internet means. In addition, the ERA-NET and its achievements will be presented to the scientific and business communities at nanomedicine conferences and events (e.g. ETP Nanomedicine annual forum, Nanobio Europe conferences, CLINAM conferences, general nanotechnology conferences with a nanomedicine session, etc.) by the coordinator and the WP leaders highly involved in other nanomedicine-related initiatives.

Task 4.4: Introduction of pivotal issues on nanomedicine to the general public (Task Leader: CSO- MOH, Israel)
The aim of this task is to create tools to disseminate information on nanomedicine to the general public using different measures. Three short video clips will be produced related to the three subfields of nanomedicine: targeted drug delivery, diagnostics and regenerative medicine. These will be available on the EuroNanoMed II website, as well as on YouTube and Wikipedia.
In addition, a Facebook page will be prepared for EuroNanoMed II that will enable us to reach the general public with no geographical limits. The Facebook page will include the outcomes of EuroNanoMed I and II, links to the EuroNanoMed II webpage, press releases and other announcements, and to the video clips.

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
1	ANR	4.00
2	IWT	0.20
3	SPW-DGO6	0.20
5	VDI	0.20
6	RANNIS	0.20
7	CSO-MOH	13.00
8	IMH	0.20
9	VED	0.20
10	VN	0.20
11	LAS	0.20

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
12	RCL	5.00
13	RCN	0.20
14	NCBR	2.60
15	FCT	0.20
16	ANCS	0.20
17	UEFISCDI	2.30
18	ISCIII	0.50
19	SRC	0.20
20	SNSF	0.20
	Total	30.00

List of deliverables

Deliverable Number [61]	Deliverable Title	Lead beneficiary number	Estimated indicative person-months	Nature [62]	Dissemination level [63]	Delivery date [64]
D4.1	Public website updated for ENM II	12	3.00	O	PU	3
D4.2	Restricted area of the website and set up of the communication tools and database	12	3.00	O	PU	6
D4.3	List of contact persons for other nanomedicine initiatives	14	5.10	R	PU	6
D4.4	Report 1 on dissemination by the Eranet	7	3.00	R	PU	12
D4.5	Report 2 on dissemination by the Eranet	7	3.00	R	PU	24
D4.6	Report 3 on dissemination by the Eranet	7	3.00	R	PU	36
D4.7	Report 4 on dissemination by the Eranet	7	3.00	R	PU	48
D4.8	Brochure on EuroNanoMed II	7	3.00	R	PU	36
D4.9	Video clip 1	7	1.30	O	PU	9
D4.10	Video clip 2	7	1.30	O	PU	15
D4.11	Video clip 3	7	1.30	O	PU	21
		Total	30.00			

Description of deliverables

D4.1) Public website updated for ENM II: [month 3]

D4.2) Restricted area of the website and set up of the communication tools and database: [month 6]

D4.3) List of contact persons for other nanomedicine initiatives: [month 6]

D4.4) Report 1 on dissemination by the Eranet: [month 12]

D4.5) Report 2 on dissemination by the Eranet: [month 24]

D4.6) Report 3 on dissemination by the Eranet: [month 36]

D4.7) Report 4 on dissemination by the Eranet: [month 48]

D4.8) Brochure on EuroNanoMed II: [month 36]

D4.9) Video clip 1: [month 9]

D4.10) Video clip 2: [month 15]

D4.11) Video clip 3: [month 21]

Schedule of relevant Milestones

Milestone number [59]	Milestone name	Lead beneficiary number	Delivery date from Annex I [60]	Comments

WT3: Work package description

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per Work Package

Work package number [53]	WP5	Type of activity [54]	COORD
Work package title	Monitoring and optimisation of activities		
Start month	1		
End month	48		
Lead beneficiary number [55]	15		

Objectives

This WP is focused on the monitoring and (ex-post) evaluation of EuroNanoMed II programme, and involves three main objectives:
- Establishment of indicators for evaluation of the ENM II programme;
- Assessment of the achievements of EuroNanoMed programme and its activities;
- Monitoring and evaluation of the operational processes underlying EuroNanoMed II activities as well as monitoring of the progress of EuroNanoMed I and II funded research projects.

Three tasks were designed in order to accomplish the goals of this WP, which are described in detail below. The overarching goal is to constantly improve EuroNanoMed II work, both at the level of strategic planning (from monitoring the joint call outputs) and at an operational level.

Description of work and role of partners

Task 5.1: Choice of indicators as a key to assess EuroNanoMed II (Task leader: FCT, Portugal, co-leader: SPW-DGO6, Wallonia)
The aim of this task is to define a set of indicators to monitor both the ENM II programme and the funded research projects of ENM I and ENM II. The indicators will take into account (1) the aims of the ENM II programme (described in this document) and (2) the aims of the calls that had to be addressed by the applicants for joint research projects (described in the published call texts). Some examples of indicators that may be used for the monitoring are the following:
- For ENM II Programme – Amount of funding, projects funded, countries participating in the call, networking activities oriented, documents published, coordinated activities with other initiatives, etc.;
- For Funded Projects – Publications, citations, patents, licensing, mobility, networking, etc.

In addition, the experience gathered by contacts with similar ERA-NET programmes (e.g. Pathogenomics, E-Rare-2, and NEURON II) and with NETWATCH & ERA-LEARN will provide further insight for the indicators selection.
The final set of indicators will be defined in a small workshop for common understanding with the partners, and with the External Advisory Board members. This workshop has the ambition of defining the terms of reference for the ENM II programme monitoring (task 5.2) and the joint calls monitoring (task 5.3), in a way that meets the needs of policy makers and provides information for further strategy planning (WP6). These indicators will be embedded in the design of the reporting forms/procedures to be used in the follow-up activities of the future joint calls (WP2) to allow for an efficient and systematic collection of data.
The selected indicators will be used to continuously monitor ENM II activities and performance, and these will be confronted with the results regarding the expectations of the involved partner organisations (task 5.2).

Task 5.2: Monitoring of EuroNanoMed II: needs and expectations.(Task leader: FCT, Portugal)
At the start of the EuroNanoMed II programme, the network will initiate a structured monitoring process of the Consortium activities. It will be carried out by the partners themselves, referring to the goals given in this ERA-NET description of work. In a first step, the updated expectations of the EuroNanoMed II partners for the outcomes of the work programme will be discussed at the kick-off meeting. Then the expectations of partners will be gathered in a short questionnaire which will be analysed and presented to all partners. Yearly, these expectations will be re-examined to redefine the work programme in a timely manner. A survey to assess research applicants' feedback regarding ENM II joint transnational calls will also be performed. After 2 years, the EuroNanoMed II activities and successes will be discussed and compiled in a report. This continuous

evaluation process will further strengthen the cooperation and integration among partners and facilitate the preparation and definition of future collaboration of partners in nanomedicine (WP6). A final monitoring report will be written and delivered at the end of the ENM II period. As a starting point for building a long-term sustainable cooperation framework for Nanomedicine Research in the future, the needs of EuroNanoMed II partners will also be gathered, as well as other relevant ministries and funding agencies interested in a funding collaboration in nanomedicine, and what they expect for a future cooperation scheme.

Task 5.3: Monitoring of ENM funded projects (Task leader: SPW-DGO6, Wallonia)
Using the indicators developed in task 5.1, the achievements of the EuroNanoMed (I & II) joint calls will be assessed after the 3-year research period of the funded projects. The follow-up project reports of the funded projects and the conclusions from the research review seminars (task 2.5) will be thoroughly analysed towards the production of an overall call output report (one per call). The call output reports for the three ENM I joint calls (JTCs 2009, 2010, 2011) and for the first ENM II joint call (JTC2013 call) will be produced during the lifespan of this ERA-NET. These call output reports will be used as a basis to produce public reports on the joint call results to be disseminated via the EuroNanoMed communication tools in WP4 (i.e. website). These reports will also be used as input for planning further joint calls (WP2) as well as towards the development of long-term sustainable European cooperation on nanomedicine research (WP6).

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
1	ANR	1.00
2	IWT	0.10
3	SPW-DGO6	7.50
5	VDI	0.10
6	RANNIS	0.10
7	CSO-MOH	0.10
8	IMH	0.10
9	VED	0.10
10	VN	0.10
11	LAS	0.10
12	RCL	0.10
13	RCN	0.10
14	NCBR	0.10
15	FCT	12.00
16	ANCS	0.10
17	UEFISCDI	0.10
18	ISCIII	0.10
19	SRC	0.10
20	SNSF	0.10
	Total	22.10

List of deliverables

Delive-rable Number [61]	Deliverable Title	Lead benefi-ciary number	Estimated indicative person-months	Nature [62]	Dissemi-nation level [63]	Delivery date [64]
D5.1	List of indicators for EuroNanoMed II programme and ENM I & II funded projects	15	1.60	R	PP	8
D5.2	Summary table of ENM II partner's expectations regarding ENM programme and performance	15	1.50	R	PP	4
D5.3	Report of the stakeholders' needs and expectations for a long-term sustainable cooperation	15	1.50	R	PP	33
D5.4	Report on the applicants' feedback from the ENM II JTCs and transnational collaborations	15	1.50	R	PP	42
D5.5	Mid-term monitoring report of EuroNanoMed II procedures and progress	15	3.00	R	PP	24
D5.6	Final monitoring report of EuroNanoMed II procedures and progress	15	3.00	R	PP	48
D5.7	Call output report for JTC 2009	3	2.50	R	PP	12
D5.8	Call output report for JTC 2010	3	2.50	R	PP	24
D5.9	Call output report for JTC 2011	3	2.50	R	PP	36
D5.10	Call output report for JTC 2013	3	2.50	R	PP	46
		Total	22.10			

Description of deliverables

D5.1) List of indicators for EuroNanoMed II programme and ENM I & II funded projects: [month 8]

D5.2) Summary table of ENM II partner's expectations regarding ENM programme and performance: [month 4]

D5.3) Report of the stakeholders' needs and expectations for a long-term sustainable cooperation: [month 33]

D5.4) Report on the applicants' feedback from the ENM II JTCs and transnational collaborations: [month 42]

D5.5) Mid-term monitoring report of EuroNanoMed II procedures and progress: [month 24]

D5.6) Final monitoring report of EuroNanoMed II procedures and progress: [month 48]

D5.7) Call output report for JTC 2009: [month 12]

D5.8) Call output report for JTC 2010: [month 24]

D5.9) Call output report for JTC 2011: [month 36]

D5.10) Call output report for JTC 2013: [month 46]

WT3: Work package description

Schedule of relevant Milestones				
Milestone number [59]	Milestone name	Lead beneficiary number	Delivery date from Annex I [60]	Comments

WT3: Work package description

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

One form per Work Package

Work package number [53]	WP6	Type of activity [54]	COORD
Work package title	Strategic Research and Cooperation Agenda		
Start month	1		
End month	48		
Lead beneficiary number [55]	18		

Objectives

The main objective of this work package is to assure the strategic orientation of different activities of the ERA-NET (call topics choice (WP2); achieve sustainability for nanomedicine research, framing of nanomedicine-related issues (WP3), etc.). The ENM I strategic agenda will be updated, and it will be used as input for these ambitious objectives. A long-term cooperation framework will be designed to develop a self-sustained transnational funding programme concept. The aim is to produce a proposal for long-term sustainable cooperation between partners after ENM II's end. In order to achieve these ambitious goals, all partners of ENM II will participate in the present WP6. The activity and experience of the pre-existing ERA-NET EuroNanoMed I have led to a solid collaboration structure together with the willingness to profit from the acquired experience by all partners. It is expected that there will still be health problems that could benefit from nanomedicine research after the end of EuroNanoMed II. There is consequently a need to explore how the network of EuroNanoMed partners may further cooperate in a scheme that can operate on a self-sustained basis.
Therefore, the two key objectives of this work package are to:
• Produce a strategic agenda, including national strategies and programmes in nanomedicine, as input for all ENM II activities;
• Design a long-term sustainable RTD cooperation framework scenario supported by a business model to cover shared cost between partners.

Main achievements by EuroNanoMed I: Although this is a new WP in ENM II, a strategic agenda for EuroNanoMed activities was published

Description of work and role of partners

Task 6.1: Update and complement information on national strategies and programmes for nanomedicine (Task leader: UEFISCDI, Romania)
Within the framework of EuroNanoMed I, a survey was performed in early 2009 to gather information on national strategies and programmes and initiatives in nanomedicine among the partners, as well as on funding approaches among nanomedicine actors in Europe. This task envisages the update of the information on national strategies and programmes for nanomedicine on the future of the network collaboration. This survey will be updated by: a) sending the original questionnaire to partners that are either new or did not provide answers to the first questionnaire, b) submitting a brief questionnaire to all partners asking for relevant information on recent programmes or initiatives in nanomedicine and changes in their strategy for nanomedicine R&D.

Task 6.2: Strategic Agenda for EuroNanoMed II from present to future (Task leader: SRC, Sweden, co-leader: IMH)
Nanomedicine is a rapidly evolving field, and to ensure that the EuroNanoMed II joint activities aim to tackle the unmet clinical needs and the global competitiveness of the European nanomedicine RTD, it is important to monitor the current trends in the field and the unmet clinical needs. This will be performed in close collaboration with the European Technology Platform (ETP) Nanomedicine and using the documents they produce as input. The ENM I strategic agenda (http://www.euronanomed.net/files/Strategic_Agenda for EuroNanoMed.pdf) will be refreshed during ENM II. Questionnaires will be disseminated to relevant scientists, opinion-leaders and other stakeholders in the field of nanomedicine, The information compiled through these questionnaires will be analysed and confronted to other sources of information (ETP Nanomedicine documents), and an updated

"European Strategic Research Agenda on Nanomedicine" for ENM II will be produced. This strategic agenda will be produced in the first year of ENM II and will be used as input or reference for all the activities of ENM II: definition of research programmes and call topics in WP2, framing nanomedicine-issues in WP3, dissemination activities in WP4, monitoring activities in WP5. Finally, a second update of the strategic agenda will be made in the last year of ENM II for planning future sustainable collaboration in this field.

Task 6.3: Develop a cost model for maintenance of a collaboration network for RTD funding in nanomedicine (Task leader: IWT Flanders, co-leaders: ISCIII, Spain, UEFISCDI, Romania)
The aim of this task is to develop a cost model for future cooperation among partners after the end of this ERA-NET. A business plan will be developed to ensure that cooperation is possible without the EC "glue money". Based on benchmarking of experiences, common elements and approaches of similar initiatives (ERA-NETs, joint programming initiatives, joint programmes...) and the needs and expectations of EuroNanoMed II partners gathered in task 5.2, a cost model for a common joint management hub as well as administrative and legal architecture concepts and financial plans to share central management costs will be explored. For example, one possibility that will be examined would be for the partners to jointly fund a Joint Office after the present phase for coordination of the network. Possible financial models and administrative modes of cooperation with the associated cost models will be discussed in a workshop, with the aim of coming up with a solid business plan.

Task 6.4: Long-term cooperation framework for continued joint RTD funding in nanomedicine (Task leader: ISCIII, Spain, co-leaders: ANR, France; IMH, Italy)
The aim of this task is to build a self-sustained transnational funding programme in nanomedicine with regular funding initiatives, based on the updated EuroNanoMed II strategic agenda (task 6.2). A scenario for future sustainable cooperation of the network for a joint research programme in nanomedicine will be developed. The results of the workshop on financial and administrative models for sustained cooperation, as well as the strategic agenda in nanomedicine from task 6.2 will be used as input to propose a full scenario for a sustainable network. This scenario will be discussed and improved in a workshop with policy makers and funding organisation representatives of current and prospective partners. A workable scenario for future collaboration will be decided upon and documents for its framework (MoU/agreements, governance, procedures, financial plans, etc.) will be drafted. At the final EuroNanoMed II meeting, interested partners will discuss their commitment to the framework for continued collaboration (MS 6).

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
1	ANR	2.00
2	IWT	1.50
3	SPW-DGO6	0.10
4	BMBF	0.50
5	VDI	0.10
6	RANNIS	0.10
7	CSO-MOH	0.10
8	IMH	1.50
9	VED	0.10
10	VN	0.10
11	LAS	0.10
12	RCL	0.10
13	RCN	0.10
14	NCBR	0.10

Person-Months per Participant

Participant number [10]	Participant short name [11]	Person-months per participant
15	FCT	0.10
16	ANCS	0.10
17	UEFISCDI	1.80
18	ISCIII	8.80
19	SRC	3.50
20	SNSF	0.10
	Total	20.90

List of deliverables

Deliverable Number [61]	Deliverable Title	Lead beneficiary number	Estimated indicative person-months	Nature [62]	Dissemination level [63]	Delivery date [64]
D6.1	ENM II strategic research agenda, including national strategies in nanomedicine	19	5.90	R	PU	12
D6.2	ENM II strategic agenda update	19	5.00	R	PU	42
D6.3	Report on the cost model for a cooperation joint management hub	2	5.00	R	PU	44
D6.4	Report on the cooperation framework scenarios	18	5.00	R	PU	46
		Total	20.90			

Description of deliverables

D6.1) ENM II strategic research agenda, including national strategies in nanomedicine: The SRA will include the update of the information on national strategies and programmes for nanomedicine on the future of the network collaboration and an analysis of the information compiled through questionnaires addressed to relevant scientists, opinion-leaders and other stakeholders in the field of nanomedicine [month 12]

D6.2) ENM II strategic agenda update: The SRA will include the update of the information on national strategies and programmes for nanomedicine on the future of the network collaboration and an analysis of the information compiled through questionnaires addressed to relevant scientists, opinion-leaders and other stakeholders in the field of nanomedicine [month 42]

D6.3) Report on the cost model for a cooperation joint management hub: In view of a long-term sustainable RTD Joint Programme in nanomedicine [month 44]

D6.4) Report on the cooperation framework scenarios: [month 46]

Schedule of relevant Milestones

Milestone number [59]	Milestone name	Lead beneficiary number	Delivery date from Annex I [60]	Comments
MS6	Final meeting, commitment to future collaboration	1	47	Minutes

WT4: List of Milestones

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

List and Schedule of Milestones

Milestone number [59]	Milestone name	WP number [53]	Lead beneficiary number	Delivery date from Annex I [60]	Comments
MS1	Kick-Off meeting	WP1	1	1	Minutes
MS2	Commitments of partners to JTC2013 – MoU signed	WP2	1	1	Call publication subject to start date of the project
MS3	Commitments of partners to JTC2014 – MoU signed	WP2	1	12	Call publication subject to start date of the project
MS4	Commitments of partners to JTC2015 – MoU signed	WP2	1	24	Call publication subject to start date of the project
MS5	Commitments of partners to JTC2016 – MoU signed	WP2	1	36	Call publication subject to start date of the project
MS6	Final meeting, commitment to future collaboration	WP6	1	47	Minutes

WT5: Tentative schedule of Project Reviews

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

Tentative schedule of Project Reviews

Review number [65]	Tentative timing	Planned venue of review	Comments, if any
RV 1	19	To be decided on case by case basis	
RV 2	37	To be decided on case by case basis	
RV 3	46	To be decided on case by case basis	

WT6:
Project Effort by Beneficiary and Work Package

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

Indicative efforts (man-months) per Beneficiary per Work Package

Beneficiary number and short-name	WP 1	WP 2	WP 3	WP 4	WP 5	WP 6	Total per Beneficiary
1 - ANR	34.00	4.00	1.00	4.00	1.00	2.00	46.00
2 - IWT	0.00	1.00	0.00	0.20	0.10	1.50	2.80
3 - SPW-DGO6	0.00	1.00	0.00	0.20	7.50	0.10	8.80
4 - BMBF	0.00	0.50	1.00	0.00	0.00	0.50	2.00
5 - VDI	0.00	1.00	12.50	0.20	0.10	0.10	13.90
6 - RANNIS	0.00	3.00	0.00	0.20	0.10	0.10	3.40
7 - CSO-MOH	0.00	1.00	2.00	13.00	0.10	0.10	16.20
8 - IMH	0.00	1.00	0.00	0.20	0.10	1.50	2.80
9 - VED	0.00	0.50	0.00	0.20	0.10	0.10	0.90
10 - VN	0.00	32.00	2.00	0.20	0.10	0.10	34.40
11 - LAS	0.00	1.50	0.00	0.20	0.10	0.10	1.90
12 - RCL	0.00	1.00	0.00	5.00	0.10	0.10	6.20
13 - RCN	0.00	1.00	0.00	0.20	0.10	0.10	1.40
14 - NCBR	0.00	1.00	0.00	2.60	0.10	0.10	3.80
15 - FCT	0.00	1.00	0.00	0.20	12.00	0.10	13.30
16 - ANCS	0.00	1.00	2.00	0.20	0.10	0.10	3.40
17 - UEFISCDI	0.00	1.00	0.00	2.30	0.10	1.80	5.20
18 - ISCIII	0.00	3.00	0.00	0.50	0.10	8.80	12.40
19 - SRC	0.00	1.50	0.00	0.20	0.10	3.50	5.30
20 - SNSF	0.00	0.50	0.00	0.20	0.10	0.10	0.90
Total	34.00	57.50	20.50	30.00	22.10	20.90	185.00

WT7:
Project Effort by Activity type per Beneficiary

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

Indicative efforts per Activity Type per Beneficiary

Activity type	Part. 1 ANR	Part. 2 IWT	Part. 3 SPW-DGO	Part. 4 BMBF	Part. 5 VDI	Part. 6 RANNIS	Part. 7 CSO-MOH	Part. 8 IMH	Part. 9 VED	Part. 10 VN	Part. 11 LAS	Part. 12 RCL	Part. 13 RCN	Part. 14 NCBR
3. Consortium Management activities														
WP 1	34.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Management	34.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Work Packages for Coordination activities														
WP 2	4.00	1.00	1.00	0.50	1.00	3.00	1.00	1.00	0.50	32.00	1.50	1.00	1.00	1.00
WP 3	1.00	0.00	0.00	1.00	12.50	0.00	2.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
WP 4	4.00	0.20	0.20	0.00	0.20	0.20	13.00	0.20	0.20	0.20	0.20	5.00	0.20	2.60
WP 5	1.00	0.10	7.50	0.00	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10
WP 6	2.00	1.50	0.10	0.50	0.10	0.10	0.10	1.50	0.10	0.10	0.10	0.10	0.10	0.10
Total Coordination	12.00	2.80	8.80	2.00	13.90	3.40	16.20	2.80	0.90	34.40	1.90	6.20	1.40	3.80
4. Other activities														
Total other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	46.00	2.80	8.80	2.00	13.90	3.40	16.20	2.80	0.90	34.40	1.90	6.20	1.40	3.80

ALLEGATO A Dgr n ____ del

121/01

WT7:
Project Effort by Activity type per Beneficiary

Activity type	Part. 15 FCT	Part. 16 ANCS	Part. 17 UEFISCD	Part. 18 ISCIII	Part. 19 SRC	Part. 20 SNSF	Total
3. Consortium Management activities							
WP 1	0.00	0.00	0.00	0.00	0.00	0.00	34.00
Total Management	0.00	0.00	0.00	0.00	0.00	0.00	34.00
Work Packages for Coordination activities							
WP 2	1.00	1.00	1.00	3.00	1.50	0.50	57.50
WP 3	0.00	2.00	0.00	0.00	0.00	0.00	20.50
WP 4	0.20	0.20	2.30	0.50	0.20	0.20	30.00
WP 5	12.00	0.10	0.10	0.10	0.10	0.10	22.10
WP 6	0.10	0.10	1.80	8.80	3.50	0.10	20.90
Total Coordination	13.30	3.40	5.20	12.40	5.30	0.90	151.00
4. Other activities							
Total other	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	13.30	3.40	5.20	12.40	5.30	0.90	185.00

ALLEGATO A Dgr n. _____ del

71/127

WT8:
Project Effort and costs

Project Number [1]	321570	Project Acronym [2]	EuroNanoMed II

Project efforts and costs

Beneficiary number	Beneficiary short name	Estimated eligible costs (whole duration of the project)						Total receipts (€)	Requested EU contribution (€)
		Effort (PM)	Personnel costs (€)	Subcontracting (€)	Other Direct costs (€)	Indirect costs OR lump sum, flat-rate or scale-of-unit (€)	Total costs		
1	ANR	46.00	230,000.00	0.00	35,230.00	53,046.00	318,276.00	0.00	283,796.00
2	IWT	2.80	32,200.00	0.00	8,100.00	8,060.00	48,360.00	0.00	43,121.00
3	SPW-DGO6	8.80	44,000.00	0.00	8,100.00	10,420.00	62,520.00	0.00	55,747.00
4	BMBF	2.00	12,000.00	0.00	0.00	2,400.00	14,400.00	0.00	0.00
5	VDI	13.90	129,270.00	0.00	27,100.00	105,722.00	262,092.00	0.00	167,315.00
6	RANNIS	3.40	15,300.00	0.00	18,000.00	6,660.00	39,960.00	0.00	35,631.00
7	CSO-MOH	16.20	64,800.00	0.00	38,000.00	20,560.00	123,360.00	0.00	109,996.00
8	IMH	2.80	12,600.00	0.00	8,100.00	4,140.00	24,840.00	0.00	22,149.00
9	VED	0.90	6,300.00	0.00	8,100.00	2,880.00	17,280.00	0.00	15,408.00
10	VN	34.40	240,800.00	10,000.00	100,100.00	68,180.00	419,080.00	0.00	374,763.00
11	LAS	1.90	7,600.00	0.00	8,100.00	3,140.00	18,840.00	0.00	16,799.00
12	RCL	6.20	30,070.00	38,000.00	8,100.00	7,634.00	83,804.00	0.00	78,841.00
13	RCN	1.40	19,712.00	0.00	8,100.00	5,562.40	33,374.40	0.00	29,758.00
14	NCBR	3.80	13,300.00	0.00	8,100.00	4,280.00	25,680.00	0.00	22,898.00
15	FCT	13.30	46,550.00	0.00	11,100.00	11,530.00	69,180.00	0.00	61,685.00
16	ANCS	3.40	6,800.00	0.00	8,100.00	2,980.00	17,880.00	0.00	15,943.00
17	UEFISCDI	5.20	10,400.00	0.00	8,100.00	3,700.00	22,200.00	0.00	19,795.00
18	ISCIII	12.40	64,480.00	0.00	17,100.00	16,316.00	97,896.00	0.00	87,290.00
19	SRC	5.30	31,270.00	0.00	8,100.00	7,874.00	47,244.00	0.00	42,125.00
20	SNSF	0.90	7,723.00	0.00	8,100.00	3,164.60	18,987.60	0.00	16,930.00
Total		185.00	1,025,175.00	48,000.00	343,830.00	348,249.00	1,765,254.00	0.00	1,499,990.00

WT8:
Project Effort and costs

1. Project number

The project number has been assigned by the Commission as the unique identifier for your project. It cannot be changed. The project number **should appear on each page of the grant agreement preparation documents (part A and part B)** to prevent errors during its handling.

2. Project acronym

Use the project acronym as given in the submitted proposal. It cannot be changed unless agreed so during the negotiations. The same acronym **should appear on each page of the grant agreement preparation documents (part A and part B)** to prevent errors during its handling.

53. Work Package number

Work package number: WP1, WP2, WP3, ..., WPn

54. Type of activity

For all FP7 projects each work package must relate to one (and only one) of the following possible types of activity (only if applicable for the chosen funding scheme – must correspond to the GPF Form Ax.v):

• **RTD/INNO** = Research and technological development including scientific coordination - applicable for Collaborative Projects and Networks of Excellence

• **DEM =** Demonstration - applicable for collaborative projects and Research for the Benefit of Specific Groups

• **MGT =** Management of the consortium - applicable for all funding schemes

• **OTHER =** Other specific activities, applicable for all funding schemes

• **COORD =** Coordination activities – applicable only for CAs

• **SUPP =** Support activities – applicable only for SAs

55. Lead beneficiary number

Number of the beneficiary leading the work in this work package.

56. Person-months per work package

The total number of person-months allocated to each work package.

57. Start month

Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other start dates being relative to this start date.

58. End month

Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.

59. Milestone number

Milestone number:MS1, MS2, ..., MSn

60. Delivery date for Milestone

Month in which the milestone will be achieved. Month 1 marking the start date of the project, and all delivery dates being relative to this start date.

61. Deliverable number

Deliverable numbers in order of delivery dates: D1 – Dn

62. Nature

Please indicate the nature of the deliverable using one of the following codes

R = Report, **P** = Prototype, **D** = Demonstrator, **O** = Other

63. Dissemination level

Please indicate the dissemination level using one of the following codes:

• **PU =** Public

• **PP =** Restricted to other programme participants (including the Commission Services)

• **RE =** Restricted to a group spacified by the consortium (including the Commission Services)

• **CO =** Confidential, only for members of the consortium (including the Commission Services)

• **Restreint UE** = Classified with the classification level "Restreint UE" according to Commission Decision 2001/844 and amendments

• **Confidentiel UE** = Classified with the mention of the classification level "Confidentiel UE" according to Commission Decision 2001/844 and amendments

• **Secret UE** = Classified with the mention of the classification level "Secret UE" according to Commission Decision 2001/844 and amendments

64. Delivery date for Deliverable

Month in which the deliverables will be available. Month 1 marking the start date of the project, and all delivery dates being relative to this start date

65. Review number

Review number: RV1, RV2, ..., RVn

66. Tentative timing of reviews

Month after which the review will take place. Month 1 marking the start date of the project, and all delivery dates being relative to this start date.

67. Person-months per Deliverable

The total number of person-month allocated to each deliverable.

SEVENTH FRAMEWORK PROGRAMME
FP7-ERANET-2012-RTD

SEVENTH FRAMEWORK PROGRAMME

NMP.2012.1.2-3 ERA-NET on nanomedicine
EUROpean network for transnational collaborative RTD projects in the field of NANOMEDicine

Part B

Project acronym: EuroNanoMed II

Type of funding scheme: Coordination and support actions

Grant Agreement Number: 321570

Table of Contents

Abstract:

Nanomedicine, the application of nanotechnology to health, is a fast-growing field with a large potential for improving diagnostics and therapeutic solutions in many diseases. The EuroNanoMed II (ENM II) consortium, with 20 partners from 17 countries and regions, aims to foster the competitiveness of European nanomedicine actors through the support of translational research projects enhancing transnational and multidisciplinary collaborations between academia, clinical/public health communities and industry. ENM II will be a follow-up of the ERA-NET EuroNanoMed I (ENM I), which launched three joint transnational calls for proposals in three years. The increasing number of submitted proposals in the successive ENM I joint calls and their quality show the need amongst the nanomedicine scientific community for such a targeted initiative. ENM II will be built on the basis of the ENM I accomplishments, and will continue to support transnational innovative RTD projects in nanomedicine through the launch of yearly joint calls for proposals. In addition, ENM II aims to extend the cooperation among its partners through the development of other activities: i) foster the participation of young European researchers to ENM II activities; ii) develop a strategic agenda for ENM II in close cooperation to the ETP Nanomedicine; iii) create more interactions within the European nanomedicine community and improve communication on nanomedicine to the public; iv) frame and address regulatory, safety and ethical issues associated with nanomedicine; v) monitor the results of the ENM I & ENM II funded research projects and the activities of the ENM II network; and, vi) develop a long-term cooperation framework for European nanomedicine research. Therefore, through joint funding of translational nanomedicine projects and its other activities, ENM II will contribute to enhance coordination of research and resources in this field, thereby shaping the European Research Area in nanomedicine.

Abbreviations:

CA	Consortium agreement
CSC	Call Steering Committee
EAB	External Advisory Board
EC	European Commission
EMA	European Medicines Agency
ENM	EuroNanoMed
ETP	European Technology Platform
EU	European Union
JCS	Joint Call Secretariat
JTC	Joint Transnational Call
NMP	Nanosciences, Nanotechnologies, Materials and new Production Technologies
NSC	Network Steering Committee
OG	Operating group
PRP	Peer Review Panel
RTD	Research and Technology Development
SME	Small and Medium Enterprise

B1. Concept and objectives, contribution to the coordination of high quality research, quality and effectiveness of the coordination mechanism and associated work plan

1.1. Concept and objectives

1.1.1. Nanomedicine, a challenge for Europe

Definition: Nanomedicine is the opplicotion of nanotechnology to medicine and healthcare. The field takes advantage of the physicol, chemical and biological properties of materiols ot the nonometre scole to be used for diagnosis, treatment and follow-up of diseases.

One of the key strategic challenges Europe has to face in the next decades is to provide its ageing population with effective and affordable health care and to assure its wellbeing. To achieve this goal, sustainable efforts in research and innovation are necessary to find new and personalised ways to prevent, manage, treat and cure disease, disability and reduced functionality and for making medicines and treatments available and affordable to all.

One promising tool to meet these challenges that has evolved in the last decade is the use of nanotechnology for medical applications. This new area of research – usually referred to as "**nanomedicine**" - has been rated among the **six most promising Key Enabling Technologies** (KET) by the High Level Group on KET in its final report (EU Commission, June 2011). Therefore, nanomedicine is one of the most important emerging areas of health research expected to achieve earlier and more precise, individual diagnosis, better targeted therapies and better therapy monitoring. Disease areas that are presumed to benefit most from nanomedicine are cancer, cardiovascular diseases, neurological (especially neurodegenerative) diseases, diabetes, inflammatory diseases as well as orthopaedic and other medical conditions needing regenerative medicine. Nanomedicine is a research area at the intersection of different scientific fields. To be successful it has to federate key players from biology, physics, chemistry, medicine and engineering. Furthermore, nanomedicine needs coordinated input from all actors along the value chain to effectively **move scientific results to innovation**: academic scientists, pharmaceutical and medical device companies and clinicians in a **translational approach**.

Since the early 2000's, **nanotechnologies** are a priority for Europe. They have been identified as one of the thematic priority areas for the European Union (Communication from the Commission "Towards a European strategy for nanotechnology" (COM 2004-338 final); An action plan for Europe (COM 2005-243 final)) and they are one of the six Key Enabling Technologies to assure Europe's Industrial Leadership addressed in the draft of the Horizon 2020 framework programme. In this draft, **nanomedicine** is expected to be one of the cross-cutting actions "vital in stimulating the interactions between the societal challenges and the enabling and industrial technologies needed to generate major technological breakthroughs".

Europe has a good starting position in the field of nanomedicine with excellent scientists all over the member states, a large number of innovative SMEs and some leading pharmaceutical companies. The bridge between these actors will consolidate and improve the competitiveness of the European industry that will be very important in the worldwide competition in this sector. As these actors are usually spread over different member states, a **transnational approach** is necessary to bring together the most appropriate partners.

Even if European countries invest a substantial amount of money in research and innovation funding, most of the national programmes do not support transnational projects. Pure nationally funded programmes often face difficulties to successfully translate fundamental research in first clinical stages, as in many member states there are too few players in the specific domain of nanomedicine. Therefore, **the main goal**

of the EuroNanoMed II ERA-NET initiative is to go further in supporting transnational research and innovation projects, in order to achieve a critical mass of actors translating scientific results from the lab to patient's bedside. EuroNanoMed complements national and European funding activities as nanomedicine is often not the main focus of the national or European calls for proposals.

The **EuroNanoMed II** consortium with 21 partners from 18 countries and regions (comprising 18 partners already members of EuroNanoMed I) is a **strong, established partnership** of relevant member states' funding bodies, willing to attribute a part of their national funding budget to transnational research and innovation projects in nanomedicine and to make nanomedicine an important contributor to the future European healthcare system. This will have a beneficial impact on improved treatment for patients, as well as an economic impact through an improved and cost-effective health care.

1.1.2. EuroNanoMed: an efficient tool to fund transnational nanomedicine research

The first ERA-NET EuroNanoMed (ENM I), involving 24 governments, ministries and agencies from 15 EU Member States and Associate countries, and 3 regions in Europe was launched in 2009, supported by the European Commission under the NMP programme for 3 years.

The main aim of EuroNanoMed was to foster the competitiveness of European nanomedicine actors through the support of **transnational, collaborative and multidisciplinary** Research and Technology Development (RTD) projects, with participants ranging from academia, clinical/public health communities, and industry (particularly small and medium-sized enterprises). The ENM I consortium has successfully achieved this goal, surpassing the initial expectations of the consortium, particularly taking into account that the partners and the persons representing their organisations had not worked together previously in this context. The ERA-NET scheme represented a unique opportunity for the partners involved in ENM I to join their efforts in order to start up a European–wide integrated programme with coordinated funding in the field of nanomedicine.

From 2009 to 2011, EuroNanoMed launched three joint transnational calls (JTCs) for proposals. A total of 24 RTD projects in nanomedicine are being funded involving 126 partners from 19 countries. These projects were supported with 25 M€ of direct funding from the participating national and regional funding organisations. In addition, the partners from the funded projects contributed a further 21 M€ of their own funding, so that more than 46 M€ in total were dedicated to transnational research in nanomedicine in the frame of the ERA-NET EuroNanoMed.

The aim of the three calls was to support translational research proposals in the field of nanomedicine, encouraging transnational collaborations (at least three different countries) and collaborations between researchers from academia, clinical sector and industry. The projects had to aim at an application, either clinical or industrial, and, as such, the projects had to include teams from at least two of the following areas: academic research, clinical research or industrial research (small, medium or large business). In fact, more than half of the submitted proposals involved the three categories of actors (despite only two categories being required in the eligibility criteria). This is a key point to foster true translational projects where basic research results are brought forwards to enter preclinical and first clinical stages and maximise the potential of the nanomedicine product to reach the market. This was also recognised as very important by the peer review panel, as is evident from the funded projects: the proportion of projects including the three categories of actors increased to 62% in the funded projects from 53% in the submitted proposals (Fig. 1). In order to encourage the selection of translational research projects, industrials and clinicians with translational know-how were included in the peer review panels.



Fig. 1. Categories of consortia members in submitted proposals and in funded projects for the three JTCs. More than half of the submitted proposals involved the 3 categories of actors. The proportion of projects including the 3 categories of actors increased to 62% in the funded projects from 53% in the submitted proposals.

The participation of the European nanomedicine community increased in every call, with more proposals involving more European teams being submitted at each call (Fig. 2). In total, through the three calls for proposals, EuroNanoMed achieved a critical mass of actors, with almost 100 proposals submitted and the participation of more than 500 research teams from 25 countries/regions (including countries not participating in the ERA-NET).



Fig. 2. Increasing participation of the European nanomedicine community in the JTCs of ENM I over the years. Overall, almost 100 proposals involving 500 research teams were submitted to the three JTCs.

The three JTCs aimed at funding transnational research projects on the three strategic research priorities of the ETP Nanomedicine: targeted delivery systems, diagnostics and regenerative medicine. The 24 funded projects encompassed these three strategic priorities, and covered diverse medical issues such as cancer; inflammatory diseases; cardiovascular diseases; infectious diseases; as well as tissue regeneration of several organs. All the funded projects aim at developing applications to be rapidly transferred towards clinic or industry. As an example, we can cite the development of new specific fluorescent organic nanocrystals as probes for increasing the sensitivity of confocal endoscopy for the early detection of dysplastic lesions or adenocarcinoma within the gastrointestinal tract (coordinated by Dr. Fery-Forgues in France), the development of a Hepatitis C vaccine by targeted delivery of nanogel RNA-replicon constructs (coordinated by Dr. McCullough in Switzerland) or the development of hybrid nanostuctured hydrogels for osteoregenerative medicine, in order to address the growing cumulative stress on the skeletal system due to the increase in life expectancy (coordinated by Dr. Silva Santos in Portugal). All the funded projects are described in the two newsletters published on the EuroNanoMed website (www.euronanomed.net).

EuroNanoMed is a funding tool complementary to the nanomedicine funding landscape. Compared to the EU FP7, ENM I was perceived as an easier and more flexible funding mechanism to perform transnational research in the field (results of survey "Applicants' expectations for ENM calls" conducted among all ENM applicants in 2011). By providing fast allocation of seed funding for translational nanomedicine research projects, ENM helps bridge the gap between the developments in basic nanomedical research at the academic level and their application to the benefit of patients.

EuroNanoMed is a well-adapted tool for the construction of a European Research Area (ERA) in nanomedicine. EuroNanoMed I has been a great opportunity for countries/regions to encourage and support the participation of their research groups in the European Research Area in nanomedicine. As shown in Fig. 2, ENM fostered the participation of a growing number of applicants from the first to the third call (+ 77%). This increase involved applicants from almost all regions/countries participating in the calls, and was particularly noticeable for new member states (*i.e.* Romania, Poland) (Fig. 3). Especially for small countries, even the participation of only one research group to a EuroNanoMed funded project represents a high added value in terms of European contacts and collaborations. In comparison, the same budget committed to a purely national project would have a much lower impact on the research group's networking opportunities and international reputation.



Fig. 3. Number of submitted proposals and funded projects by country in each JTC. The increase of the participation of applicants from the first to the third call (+ 77%) involved applicants from almost all regions/countries participating in the calls, and was particularly noticeable for Romania & Poland.
NPC (non-participating country): applicants from countries not member of the ENM I consortium.

Partners from non-EuroNanoMed I countries (Denmark, UK, Russia, Slovenia, Ireland, Norway, Italy,...) also applied, enlarging the critical mass of actors and showing the huge interest of researchers for such a funding tool. In fact, Norway, Italy and Flanders have now decided to join EuroNanoMed II in order to encourage more Norwegian, Italian and Flemish researchers, clinicians and companies to participate to the joint calls and to fund them in the frame of the ERA-NET. In addition, the UK, Ireland and Slovenia have shown a strong interest in EuroNanoMed II, and, despite them not be able to commit to joining at this point, they hope to be able to participate in one (or more) of the joint calls.

For the projects funded in the first EuroNanoMed I call, a mid-term review seminar was organised in November 2011 where the eight funded projects presented their progress. This was a great success and showed that most of the projects are expected to have clinical relevance with either a therapeutic or a diagnostic outcome. The chair of the EuroNanoMed Peer Review Panel, Professor Frank Barry (Director, National Centre of Biomedical Engineering Science, National University of Ireland, Galway), attended the mid-term seminar as a reviewer and commented: *"The quality of science, innovation and delivery are all exceptionally good. There is no doubt that this transnational initiative will achieve the desired outcome of clinical applicability and commercial development. The EuroNanoMed initiative is certain to enhance European competitiveness in nanotechnology and nanomedicine and will lead to significant economic development"*.

1.1.3. Strategic objectives of EuroNanoMed II

The proposed EuroNanoMed II project is based on the foundations of ENM I and will be built on the achievements and experience gained from it. As stated above, the main goal of ENM I was to build the grounds for a transnational research programme in nanomedicine that responds to the needs identified in the field (ENM I strategic agenda, ETP Nanomedicine). The results of the three JTCs launched in the frame of ENM I show a real success concerning this goal and EuroNanoMed is now a well-known and recognised tool. ENM I also carried out other activities intended to accompany the establishment of a common RTD programme in nanomedicine, such as the systematic mapping of the on-going programmes, the establishment of a strategic agenda and the development of actions to address issues on regulatory affairs. In addition, ENM I carried out monitoring and optimisation activities that allowed the consortium to improve the procedures from call to call and to establish an efficient collaboration between agencies based on trust and common understanding. A questionnaire to gather applicant's feedback showed the positive impact that ENM I had on European researchers, but also helped to identify unmet needs that the consortium intends to fulfil by continuing its collaboration. The ERA-NET scheme represents a unique opportunity for the ENM consortium to continue its efforts and achieve the EuroNanoMed II long-term goal of contributing to fostering the competitiveness of European nanomedicine actors through the joint funding of transnational innovative research projects.

There is an important need for improving the translation of public healthcare nano-research in Europe as pointed out in the white paper of the ETP Nanomedicine[1]. In addition, now is the right time to put some extra efforts in the field of nanomedicine since some highly promising concepts and technologies are currently emerging (e.g. stimuli-responsive polymers, amphiphilic core–shell nanoparticles, molecular targeting approaches for nanocarriers, etc. [2]). It is therefore essential to support nanomedicine in Europe in the coming four to five years in order to secure their translation to the clinic and to industry and secure their proof of concept. Based on the experience of EuroNanoMed and in continuation of this first initiative, the main objective of EuroNanoMed II is to foster the competitiveness of European nanomedicine actors through the support of projects enhancing translational collaborations between research teams from academia, clinical/public health communities, and industry. EuroNanoMed II aims to continue its support to transnational RTD projects in nanomedicine through the launch of four joint calls for proposals.
The main objectives of ENM II initiative are to:

- Fund in common transnational, innovative and translational RTD projects in nanomedicine;
- Launch joint calls for proposals that are in line with the strategic priorities of the ETP Nanomedicine and the NMP expert advisory group;
- Develop a strategic agenda for EuroNanoMed II and for future cooperation, in close cooperation to the ETP Nanomedicine;
- Continue the European coordination of research and programmes in nanomedicine, integrating new members (already Norway, Italy and Flanders, and more planning to join);
- Develop specific actions to foster the participation of young researchers in nanomedicine projects and help them build their research career;
- Create more interactions within the European nanomedicine community through joint calls, review seminars, dissemination of ENM II activities, etc.;

[1] White paper to the Horizon 2020 Framework Programme for Research and Innovation from the ETP Nanomedicine: Improving Translation of Public Healthcare Nano-Research in Europe
[2] In Focus: Nanomedicine, Biointerphases, 2012, Volume 7.

- Keep close relations with the relevant stakeholders (especially the ETP Nanomedicine) and the research community in order to react flexibly to the needs and new developments in nanomedicine research;
- Improve communication on the nanomedicine field towards the general public;
- Go further to identify and address the non-technological innovation barriers in terms of later exploitation and market access for companies in the field of nanomedicine based on the work already achieved in ENM I;
- Frame and address ethical and safety issues in nanomedicine;
- Follow the progress of the EuroNanoMed (I&II)-funded projects and analyse the outcome of the joint calls;
- Monitor the activities of EuroNanoMed II with an aim of continuous improvement;
- Develop a concept for a sustainable cooperation between EuroNanoMed partners after the end of the ERA-NET taking into account the financial and administrative constraints as well as the needs and expectation of the stakeholders.

These objectives will be delivered through six work packages, with the following aims:

WP1: Management

In this work package, a practical infrastructure that will manage the administrative, technical and financial aspects of the ERA-NET will be established. The key aims are to:

- Set up the organisational structures for the network;
- Manage the consortium day-to-day;
- Ensure communication within the network and with the EC;
- Give input and support to the tasks of all the work packages;
- Make sure that the ENM II website contains updated information and is a gateway to other stakeholders and the community.

WP2: Joint funding activities in nanomedicine

The key aims of this work package are to plan and implement four transnational joint calls for research proposals (one per year), supporting the selection process and the coordination of funding for the successful projects. The first two calls of EuroNanoMed II (2013 & 2014) are planned to be broad and organised around the three sub-topics: targeted drug delivery, diagnostics and regenerative medicine, which are the priorities of the ETP Nanomedicine. Then, based on the strategic agenda of ENM II and input from the External Advisory Board and other experts, the topics of the further joint calls (2015 & 2016) will be defined. In addition, the procedures regarding the implementation and evaluation of the joint calls (topic selection, preparation, publication, evaluation of proposals, funding decision and national implementation) will be re-examined and adapted for each call. This best-practice approach will deliver a continuously developing, commonly-agreed framework of call governance and procedures.

Issues linked to the joint calls will also be addressed in the frame of this work package. Specific actions regarding young researchers will be developed to increase the attractiveness of nanomedicine research within the younger generation. These may include networking activities in the review seminars, incentives for outstanding research achievements, as well as funding measures in the joint calls to encourage their participation. Finally, the follow-up of EuroNanoMed (I&II)-funded projects will be done in this WP2.

WP3: Regulatory Affairs, Ethical and Safety Issues

Research in nanomedicine is generating a bunch of revolutionary new therapeutic and diagnostic solutions that can offer a better therapy and a higher quality of life to patients. Many of these advancements have

overcome the classical separation between medical and pharmaceutical products so that classical regulatory frameworks are sometimes inappropriate or even inapplicable to these products. The lack of specific protocols of practices and standard criteria for these brand new nanomedicine products is turning out to be an important imponderable that may considerably hinder industrial R&D and delay market access of innovative products. Therefore, it is essential to establish an EU-wide dialogue on regulatory issues in nanomedicine to facilitate a faster exploitation and market access for companies and to shorten the time from the research to clinical application and to the patient. As these questions are today more and more directed at the European level (EMA) it is necessary to consider these issues at a European rather than at a national level. This is critical to avoid any loss of resources and efforts for member states, companies and research/clinical communities and to ensure that new products - supported through the EuroNanoMed calls - could get fast market authorization to finally benefit the patient.

When talking about new drugs and technologies, the safety of end users and patients has necessarily to be considered as well as ethical aspects or social risk perception. These points are fundamental for a new discipline like nanomedicine where a common coordination of safety and ethical issues is still missing.

In the frame of EuroNanoMed I, a fruitful dialogue on regulatory issues involving experts from industry, public research, clinic, regulatory agencies and public authorities has been started and a mapping of relevant nanomedicine related safety issues has been prepared. These two activities should be continued and intensified during EuroNanoMed II completed by training activities on regulatory aspects for EuroNanoMed (I & II)-funded researchers and the consideration of ethical issues.

The objectives of WP3 are:

- To continue and intensify the dialogue between stakeholders from industry, research, clinic, regulatory agencies and public authorities (in close cooperation with the EMA and the ETP Nanomedicine), to identify bottlenecks in existing regulations with respect to the needs of nanomedicine and to propose practical solutions;
- To train and inform EuroNanoMed funded researchers about regulatory issues that should be taken into account in research to facilitate the entry into clinical trials and market access at the end of their project;
- To continue and update the mapping of nanomedicine related safety issues from relevant sources and in cooperation with initiatives like the NanoSafety Cluster or the ERA-NET SIINN, with which there are already many links (partners in common) and regular exchanges are planned;
- To identify and address nanomedicine related ethical issues involving relevant initiatives like the Ethics Resource Center or the European Group of Ethics.

WP4: Communication and Dissemination

While communication activities have already been developed in EuroNanoMed I, the aim of WP4 is to improve the process, informing more systematically the nanomedicine community, the policy makers, and the general public about the ERA-NET activities. This mission will be carried out in close collaboration with the coordinator and will be fed from all other ERA-NET activities. Firstly, the website set up for the ERA-NET EuroNanoMed I will be updated and improved for EuroNanoMed II. During the time course of the project, newsletters and press releases providing information related to the calls launch, results, funded projects, but also related to the other ERA-NET activities (workshops, publications, etc.), will be published on the website and/or disseminated. In parallel, relation with sister and similar initiatives will be set up to benchmark on common activities. Finally, tools for dissemination towards the larger public will be developed, such as video clips explaining the three subfields of nanomedicine: targeted delivery systems, diagnostics and regenerative medicine.

WP5: Monitoring and optimisation of activities

The aim of this work package is to analyse and monitor both the EuroNanoMed II activities & the output and added-value of EuroNanoMed (I & II) joint calls. This will provide support for short- and long-term strategic planning activities and will allow the partners to continuously improve ENM II work. It will be achieved by defining indicators to measure the success of the joint calls and other EuroNanoMed II activities and applying them through a structured monitoring process, which will take into account the expectations of ENM II partners, as well as the views on ENM II joint calls of the involved nanomedicine research community.

WP6: 'Strategic Research and Cooperation Agenda

The aims of this work package are: i) to monitor the current trends in European nanomedicine RTD and to ensure that the EuroNanoMed II joint activities aim to tackle the unmet clinical needs and the global competitiveness in the field; and ii) to develop a common research funding framework for nanomedicine, which will reach beyond EuroNanoMed II aiming to sustain and possibly broaden the scale of its activities. A strategic agenda will be produced in the first year of ENM II and will be used as reference for all ENM II activities and to set up a future cooperation framework. In collaboration with the partners of ENM II and other interested stakeholders and after benchmarking with similar initiatives, the financial, administrative and legal conditions to develop such a funding framework concept will be explored and a scenario for a long-term sustainable cooperation for research funding in nanomedicine will be proposed. If successful, the results of this WP will lead to a self-sustained transnational funding programme with regularly repeated funding initiatives

In conclusion, the objectives of the proposed Coordinating Action EuroNanoMed II directly correspond to the FP7 call topic NMP.2012.1.2-3 ERA-NET on nanomedicine: *"This ERANET aims at coordinating the research efforts of the participating Member States and Regions in the field of nanomedicine and to implement joint transnational calls for proposals to fund multinational innovative research initiatives in nanomedicine."*

1.2. Contribution to the co-ordination of high quality research

EuroNanoMed II will have a clear added value for the field of nanomedicine through its mechanism to support European transnational and translational research projects in nanomedicine. In brief, the following points highlight the contribution of ENM II to the coordination of high-quality research in nanomedicine:

- EuroNanoMed II will support new RTD projects in nanomedicine by using and improving the mechanisms already set up during ENM I. The aim is to support focussed transnational projects that meet specific needs in the field of nanomedicine.
- The successful translation of research results into clinical applications or the development of drugs and other therapeutic or diagnostic products needs to be tackled in multidisciplinary collaboration, involving clinical and industrial partners. The EuroNanoMed II joint calls aim to give an impulse to transfer the results of nanomedical research to applications that benefit the patients (e.g. nano-sized drugs, delivery systems, nanostructured biomaterials, nano-engineered cells and diagnostic tools) by enhancing European partnerships between academic, industrial, and/or clinical/public health teams.
- Translational collaborations are much more successful when the best European partners work together. With 18 countries/regions involved, a critical mass is achieved, which represents about 70-80% of total European activities in the field. The complementation of expertise and competences in various countries make it possible to jointly implement more ambitious projects targeting excellence and taking benefit from synergies.

- The EuroNanoMed II funding scheme is complementary to other initiatives. National programmes generally cannot fund transnational projects and often the critical mass of actors in the specific domain of nanomedicine is lacking in one defined country. FP7 (and probably the future Horizon 2020 programme) can be limited due to its top-down topics and relatively big funding levels. The relatively small size of the EuroNanoMed transnational consortia seems to be well adapted to the researchers' needs without requiring too much coordination effort.
- EuroNanoMed II will increase the interaction between nanomedicine research communities, by organising three big review seminars bringing together the partners of the EuroNanoMed (I&II) funded projects, young researchers involved in the funded projects, as well as high-level invited scientists, and European and national representatives.

The 18 participating countries/regions fund nanomedicine projects at a national or regional level, but often not with a specific dedicated nanomedicine programme. In most cases, nanomedicine is covered nationally in a general nanotechnology programme or in a general health innovation programme (sometimes even in completely open, blue-sky programmes). This has some disadvantages for translational nanomedicine projects since the reviewers do not always have hands-on know-how in developing clinical solutions based on nanomedicine. Therefore, the EuroNanoMed I participating organisations learned enormously from participating in the joint calls. In general, participation in EuroNanoMed I has also stimulated the allocation of funding to the specific field of nanomedicine, as is the case for France, Spain and Germany. The funding in ENM I corresponded to approximately 20% of the sum of the participating organisations' national/regional budget for supporting nanomedicine applications. This proportion is expected to increase in ENM II as the 21 participating organisations have committed to participate substantially to the ENM II planned joint transnational calls. In conclusion, through the coordination of 21 funding organisations for joint nanomedicine funding in Europe, EuroNanoMed II contributes to the overarching goal of creating a strong European Research Area in this field.

1.3. Quality and effectiveness of the coordination mechanisms, and associated work plan

1.3.1 Overall strategy and general description

Structure of the workplan



Strategy for the workplan

The objectives of EuroNanoMed II are to establish an effective and sustainable cooperation of research funding organisations throughout Europe towards joint activities in nanomedicine, particularly to jointly support European research groups in nanomedicine.

WP1 aims at establishing a dedicated management resource for the whole project and at developing the necessary infrastructures (joint secretariat, the management boards, etc.). In addition, this WP will ensure the coordination of the work planned in WP2 – WP6.

WP2 focuses on the design, processes, procedures and implementation of the joint transnational calls (JTCs) for proposals. The aim is to launch four JTCs in four years, by opening a joint call at the beginning of each year. For the first ENM II call, the procedures will not be changed from that of ENM I calls (1 step submission process, same eligibility criteria and same broad topic) in order to allow the quick and efficient launch of the first joint call at month 2. For the subsequent joint call, the procedures and topic will be re-evaluated by the partners, with the aim to keep the three subfields: targeted drug delivery, diagnostics and regenerative medicine. A strategy for the further two joint calls will be discussed with experts and topics

will be defined through input by experts and based on the strategic agenda developed in WP6. Finally, activities to foster young researchers' participation in ENM II calls will be explored.

WP3 addresses regulatory affairs, safety and ethical issues that could turn out to be considerable "non-technological innovation barriers", delaying the transfer from bench to bedside for innovative nano-therapies or influencing public acceptance for nanomedicine if not addressed in a proper way. The WP aims at: continuing and enhancing the fruitful expert dialogue on regulatory issues started in ENM I; training EuroNanoMed-funded researchers on regulatory, safety and ethical issues and help them to consider relevant issues as soon as possible in their research projects; continuing the mapping and updating of nanomedicine related safety issues started in EuroNanoMed I; considering ethical issues relevant to nanomedicine.

The dissemination of EuroNanoMed II activities and achievements towards relevant stakeholders (nanomedicine community, policy makers, etc.) will be ensured by **WP4** through the ENM II website, newsletters, press releases and other publications. Relation with similar initiatives will be set up to benchmark on common activities. Finally, tools for dissemination towards the larger public will be developed, such as video clips explaining nanomedicine.

In **WP5**, the project activities and performance will be monitored so that processes can be adjusted if needed, and continuously optimised. Both the output of the EuroNanoMed (I&II)-funded projects will be monitored as well as the ERA-NET consortium work in general. Such a continuous evaluation of procedures will lead to the optimisation of the collaboration of ENM II partners, with the aim of establishing a self-sustained network.

Through **WP6**, the partners will monitor the current trends in European nanomedicine RTD to ensure that the EuroNanoMed II joint activities tackle the global competitiveness in the field and to explore how to instigate a long-lasting European cooperation in the area of nanomedicine. In order to achieve these goals, a strategic agenda will be produced and a long-term cooperation framework will be designed, which will allow the development of a self-sustained transnational funding programme concept that would serve as a plan to be implemented by the partners after EuroNanoMed II's end.

Risks assessment and associated contingency plans

The EuroNanoMed II work plan carries potential risks as encountered in any other transnational project that gathers national administrations with different cultures and strategies. However, based on the EuroNanoMed I experience, the overall level of risk foreseen here appears to be low. The governance structure was built to optimise communication among partners and ensure that problems can be handled and solved. The Coordination Unit will assess the progress of the work plan and identify difficulties through regular contacts with the partners. In addition, the Operating Group call conferences will ensure that problems occurring at the WP level (if any) will be identified. Ways to solve any problem that arises will be decided collectively (NSC). In addition, the majority of partners have learned to work together effectively in EuroNanoMed I which leads to a strong consensus-oriented collaboration. The new partners joining this second ERA-NET (Norway, Italy, Flemish region) also have experience with successful network management from other ERA-NETs. The advancement of the workplan and integration among EuroNanoMed II partners will be monitored by the partners themselves within the framework of WP5.

The main risks that may reduce the impact of the EuroNanoMed ERA-NET are relevant to the implementation of the four planned transnational joint calls for proposals. In order to reduce these risks, the consortium management will adopt the following strategies:

- *Difficulties to agree on common procedures or common topics for the joint calls:*

During the first ERA-NET EuroNanoMed I, good compromises were reached for these issues and this is expected to continue. Open communication and systematic exchange of information between the partners will be employed to minimize the risks. For that purpose, task 2.3 aims to adapt the framework for each call in collaboration with all the partners participating in that call. In addition, all partners will be involved in the definition of topics of the call and the participating organisations' scientific, medical and industrial priorities will be taken into account. The final decision on topics for each call will be taken by the funding agencies participating in the call.

- *Budget reductions, lack of funding from some countries (economic crisis):*

The availability of public funding is of crucial importance for the success of the EuroNanoMed II joint calls. The programme owners responsible of R&D funding programme commit themselves to do as much as possible to provide funding for projects presented and selected in the frame of EuroNanoMed II. For each call, the national/regional budgets are earmarked in advance and a Memorandum of Understanding is signed. The earmarked budgets will be scaled as much as possible with the potential number of partners expected from this country/region. Finally, the EuroNanoMed partners have extensive joint funding experience, including in the case of a funding blockage due the funding limit of one country/region. Solutions employed so far include negotiations with successful applicants about budget reduction, transnational support by other partners.

- *A low number of proposals are submitted within the joint call for proposals:*

Before each call for proposals, information related to the joint call will be disseminated and advertised at national and European level in collaboration with the European Technology Platform. In EuroNanoMed I, the number of proposals submitted increased every year and this is expected to continue in the EuroNanoMed II calls, especially since the European nanomedicine community is now well aware of the EuroNanoMed initiative.

1.3.2 Timing of the different work packages and their components: Gantt chart

		1st year				2nd year				3rd year				4th year			
Workpackage / Task	Lead	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
WP1 Management and strategy	ANR	MI 1															
1.1 Management structure establishment	ANR	D1.1	D1.2														
1.2 Administrative, legal and financial management of the project	ANR																
1.3 Project management	ANR	D1.3		D1.4	D1.5			D1.6	D1.7			D1.8	D1.9			D1.10	D1.11
WP2 Joint funding activities in nanomedicine	VN	MI 2				MI 3				MI 4				MI 5			
2.1 Design of strategic priorities for JTC2015 & JTC2016	RANNIS								D2.1								
2.2 Foster the participation of young researchers	ANR								D2.2								
2.3 Design of the procedures and preparation of the Joint Transnational Calls documents	ISCIII	D2.3				D2.4				D2.5				D2.6			
2.4 Setting-up of the call office	VN																
2.5 Implementation of joint transnational calls & follow-up of the funded projects	VN			D2.7				D2.8				D2.9				D2.10	
WP3 Regulatory Affairs, Ethical and Safety Issues	VDI																
3.1 Training on regulatory affairs for EuroNanoMed funded researchers	VDI					D3.1											
3.2 Framing nanomedicine ethical issues	CSO-MOH				D3.2					D3.3							
3.3 Expert dialogue and coordinators' training on regulatory affairs in nanomedicine	VDI													D3.4			
3.4 Framing nanomedicine safety issues	VN		D3.5													D3.6	
WP4 Communication and Dissemination	CSO-MOH																
4.1 Website	RCL	D4.1	D4.2														
4.2 Communication and relation with similar initiatives	NCBR		D4.3														
4.3 Dissemination of results from the ERA-NET	CSO-MOH				D4.4				D4.5				D4.6 D4.8				D4.7
4.4 Introduction of pivotal issues on nanomedicine to the general public	CSO-MOH				D4.9				D4.10				D4.11				
WP5 Monitoring and optimisation of activities	FCT																
5.1 Choice of indicators as a key to assess EuroNanoMed II	FCT			D5.1													
5.2 Monitoring of EuroNanoMed II: needs and expectations	FCT		D5.2						D5.5			D5.3			D5.4		D5.6
5.3 Monitoring of ENM funded projects	SPW-DGO6				D5.7				D5.8				D5.9				D5.10
WP6 Design of a long-term sustainable cooperation framework for nanomedicine research	ISCIII																MI 6
6.1 Update and complement information on national strategies and programmes for nanomedicine	UEFISCDI																
6.2 Strategic Agenda for EuroNanoMed II from present to future	SRC				D6.1										D6.2		
6.3 Develop a cost model for maintenance of a collaboration network for RTD funding in nanomedicine	IWT															D6.3	
6.4 Long-term cooperation framework for continued joint RTD funding in nanomedicine	ISCIII																D6.4

B2. Implementation

2.1. Management structure and procedures

The management structure of ENM I was based on two levels of organisation: the strategic and the operational level. Two different boards were organised: (i) the Network Steering Committee (NSC), composed of one senior director level representative for each ENM I partner, was in charge of the strategic decisions; (ii) the Executive board was composed of representatives of ENM I partners who were in charge of the operational management of the WPs. Based on our previous experience, the management structure of ENM II will be simplified and both levels of decision making will be fused in one: the NSC.

Because of the positive experience from the ENM I project, the remaining components of the ENM I shall be maintained. An overview of the project management structure, based on its simplicity and few decision steps, is summarized in the scheme below:



A dedicated website will ensure the continuation of the distinct and relevant identity achieved during ENM I. The internal password protected area for all the participants will be improved, enabling the virtual networking (electronic communication platform). A webmaster will be subcontracted for the updating of this website. Modern electronic communication systems as well as project management software systems will be used in all project management tasks.

a) Network steering committee (NSC)

The Network Steering Committee (NSC) will be composed of **one representative from each ENM II partner organisation** and it is the highest responsible body of ENM II. It will decide on all major and strategic issues addressed during the course of the project, which will substantially affect the scope, direction and content of the project, including the following issues:

- Approval of the consortium agreement;
- Monitoring of the work plan and decision on corrective actions (if needed);
- Agreement on modification of tasks (if needed);
- Agreement of the timing and scope of ENM II meetings;
- Approval of ENM II reports (for the EC, for specific stakeholders, for the general public);
- Selection of high-level experts for the EAB;
- Decision on modifications of the budget distribution (if needed);
- Consent on dissemination activities;
- Approval of new partners joining ENM II (which may require formal amendment to the grant agreement);
- Appointment of a new coordinator in case of leaving or of low performance (which may require formal amendment to the grant agreement).

To fulfil these functions, the NSC will have the support from the Coordination Unit (CU). The NSC will meet two times per year (if necessary extra-meetings or conference calls shall be organised). The meetings will be organised in rotating order by the respective NSC members, with support from the CU. The NSC will be chaired by a rotating NSC Chairman, elected for a period of one year (ref. "Consortium Agreement" art III). The NSC Chairman is assisted by a co-chair who is also elected every year. The coordinator will chair the first NSC meeting (kick-off meeting).

In general, the NSC will aim at reaching consensus decisions, agreed upon unanimously by all NSC members. In exceptional cases, a decision can be taken by voting according to the simple majority principle (i.e. >50%), with all NSC partners having equal votes. If two ENM II partners act as an "institutional couple" i.e., if they come from the same country and manage the same research budget, they will have one vote only.

Potential new partners of ENM II could be invited to the NSC meetings to participate as observers, but will not have voting rights. If new partners join the consortium, they will be integrated into the NSC as Associated Members: they will not receive funding, since the budget is already attributed to the existing partners, but they will have the same voting rights as described above. Approval of new partners joining ENM II will be done by the NSC members, who will also decide if a formal amendment to the grant agreement is necessary or not.

b) **Operating Group (OG)**

The Operating Group (OG) is composed of **some of the members of the NSC: the coordinator, the work package leaders and the NSC Chairman**. This small and reactive OG will assist and advise the coordinator, suggesting appropriate solutions to any emerging questions, during the preparation of the NSC meetings and the implementation and follow-up of the NSC decisions. The coordinator will assure a timely and efficient communication among OG members, who have phone meetings as often as required, and meet in person if necessary.

The overall objectives of ENM II will be achieved through the implementation of the work packages, each of which will be managed by a work package leader and sometimes task leaders.

b.1. Work package leaders

The WP leaders are responsible for the management and delivery of their respective work packages, including reports and specific communication activities. Among the responsibilities of the WP leaders are:

- Efficient management of the WP and coordination among the partners involved in each WP (task leaders);
- Overseeing delivery of WP tasks and deliverables;
- Produce WP reports required by the coordinator and EC;
- Active participation in the OG meetings and assure the coherence of its WP with other WPs in the network.

b.2. Task leaders

The task-leaders will assist the work package leaders and will be responsible for:

- Management of individual tasks;
- Delivery of WP tasks and deliverables;
- Collaborate with the WP leader and other partners involved in the WP.

c) Call steering committee (CSC)

The Call Steering Committee (CSC) will be formed for each joint call and composed of those **NSC members taking part in the joint call** ("variable geometry" principle), and additional partners outside the consortium which may join the calls. The WP leaders, together with the coordinator, will actively pursue the integration of new partners for the planned calls from outside the ENM II consortium, therefore if countries that are not member or associated partners of ENM II participate the JTC, their representatives will also be a member of the CSC. As detailed for the NSC decisions, agreements should be reached by consensus and, if not possible, voting outcomes (one vote per call partner country) will follow the simple majority principle. As detailed in WP2, a Joint Call Secretariat (JCS) will be set up for all operational tasks of the JTC implementation. It will be the central contact point for the applicants and will be responsible for organising the scientific evaluation together with the Peer Review Panel (PRP).

d) Coordination Unit

The Coordinator will be supported by a Coordination Unit (CU), which will be established at the coordinator's location and will consist of two additional scientists, a secretary support and a financial officer. The tasks of the CU include all aspects of the administrative support of the coordinator and the other management bodies as well as all the entire communication and interaction with the European Commission.

The coordinator is a scientific officer from the French National Research Agency (ANR, partner 1), it is the contractor with the European Commission on behalf of the ENM II partners and thus responsible for all administrative, legal and financial issues. The coordinator is responsible for establishing an efficient management of the consortium and for coordinating and monitoring the activities of the ERA-NET, so that the objectives of the project are met. Specific functions of the coordinator include:

- Preparation of the consortium agreement;
- Thorough preparation of NSC and OG meetings (including reports);
- Timely delivery of regular reports (both on work progress and finances) to the European Commission;
- Central management of audit certificates for each ENM II partner;
- Communication with the European Commission, the NSC, the EAB and other stakeholders;

- To ensure an effective communication between ENM II partners and stakeholders; Representation of ENM II.

e) External Advisory Board (EAB)

Based on our previous experience in ENM I, the EAB will be partly renewed at the beginning of ENM II, in order to gather new expertise in strategic domains for ENM II. At the beginning of ENM II, about 8 persons will be chosen by the NSC as EAB members and nominated, on a personal-basis appointment, for the duration of the project. The members will include experts from the nanomedicine scientific community from academia, clinic/hospital, and industry. They should represent the whole scale of translational nanomedicine research, from basic, pre-clinical and clinical. At least one of the members will be part of the European Technology Platform for nanomedicine. In addition, the consortium aims to include someone from National ethics Committees to assist the consortium on ethical issues, and an expert on regulatory issues from a regulatory authority. The EAB will meet regularly in conjunction with NSC meetings, where strategic decisions will be made (e.g. concerning the scope the planned joint transnational calls). Some members of the EAB with specific expertise might be consulted on an *od hoc* basis for relevant input to certain issues.

f) Meetings

The meetings of the consortium will be organised consecutively by the partners and will be organised by the local host. To reduce travel costs, workshops and review seminars will be organised in synergy with NSC meetings and evaluation meeting for the JTCs. As a result, nine meetings are planned over the four years of the ERA-NET (see list below). Experts will be invited only to the relevant part of the meetings.

Name	Month	**Content & main expected output** (Milestones are in bold)
Kick off meeting – M1	1	• NSC meeting • **Common understanding of the EuroNanoMed II work plan** • Common understanding on the management of the ERA-NET • Decision on NSC chair • Planning the External Advisory Board • **Common understanding & commitments of the partners to the JTC2013**
JOINT TRANSNATIONAL CALL 2013 (launch Dec 2012)		
M2	7	• NSC meeting • Peer Review Panel meeting and Call Steering Committee meeting • Definition of indicators for monitoring • Discussion of actions to increase young researchers participation
M3	12	• NSC meeting • Training workshop on regulatory affairs for funded partners with experts • Review seminar for funded projects (JTCs 2009, 2010 & 2011) • **Common understanding & commitments of the partners to the JTC2014**
JOINT TRANSNATIONAL CALL 2014 (launch Dec 2013)		
M4	19	• NSC meeting • Peer Review Panel meeting and Call Steering Committee meeting • Scientific workshop on defining topics for JTC2015 & JTC2016 with EAB and experts
M5	24	• NSC meeting

		• Review seminar for funded projects (JTCs 2011 & 2013) • Workshop on ethical issues • **Common understanding & commitments of the partners to the JTC2015**
JOINT TRANSNATIONAL CALL 2015 (launch Dec 2014)		
M6	31	• NSC meeting • Peer Review Panel meeting and Call Steering Committee meeting
M7	36	• NSC meeting • Workshop with experts on regulatory affairs in nanomedicine • Workshop on defining a business model for future collaboration of the partners • **Common understanding & commitments of the partners to the JTC2016**
JOINT TRANSNATIONAL CALL 2016 (launch Dec 2015)		
M8	43	• NSC meeting • Peer Review Panel meeting and Call Steering Committee meeting • Workshop for a common vision for sustainable cooperation
Final meeting - M9	47	• NSC meeting • Review seminar for funded projects (JTCs 2013, 2014 & 2015) • Final monitoring of EuroNanoMed II work • **Decision of the partners for future collaboration**

2.2. Beneficiaries

Partner No.	1
Organisation Name	**Agence Nationale de la Recherche (ANR)**
Division / Department	Biology and Health Department
Country	France
Contact Person	Natalia Martin
E-Mail	natalia.martin@agencerecherche.fr

General description:
The ANR was established by the French government in 2005 to fund research projects, based on competitive schemes giving researchers the best opportunities to realise their projects and paving the way for ground-breaking new knowledge. The role of the Agency is to bring more flexibility to the French research system, foster new dynamics and devise cutting edge-strategies for acquiring new knowledge. By identifying priority areas and fostering private-public collaborations, it also aims at enhancing the general level of competitiveness of both the French research system and the French economy. Since its creation, the Agency's budget has been growing, stabilising at 854 M€ in 2010. 6390 applications were received and evaluated in 2010, and 1373 of them were funded. ANR funds are available in all scientific fields, for both fundamental and industrial research. 50% of the agency's grants are distributed via top-down thematic programmes, which respond to economic, environmental and societal demands as well as areas of scientific or technological priority. The other 50% of the budget goes to non-thematic programmes which cater for researchers' creativity through a clear bottom-up process.

Developing European and international collaborations is one of the priorities of the ANR. The ANR has participated / is participating in many ERA-NETs, such as ERASysBio, NanoSci-ERA, Pathogenomics, EMIDA, Priomedchild, E-RARE-2, NEURON II, as well as the article 185 AAL, and multiple bi- and multi-lateral collaborations. In addition, the ANR is currently coordinating the ERA-NET CHIST-ERA and preparing to coordinate the ERA-NET INFECT-ERA. The ANR has been an active funding member of the three calls launched during the ERA-NET EuroNanoMed, and was deeply involved in defining the procedures and planning the evaluation process for those three calls.

With respect to EuroNanoMed II, the ANR funds research projects in the field of nanomedicine through four national programmes: a public-private thematic programme on biomedical innovation, a thematic programme on nanoscience, a public-private thematic programme on technologies for health, as well as a specific panel in the non-thematic programme open to all physics, life chemistry and biotechnological innovations projects. The transnational calls of EuroNanoMed I have also been a very important part of ANR's nanomedicine funding (about 40%), and this is planned to continue and increase in EuroNanoMed II.

Role in the project:

- Coordination of ENM II
- WP 1 leader
- Leader of tasks 1.1, 1.2, 1.3 and 2.2
- Co-leader of tasks 2.3 and 6.4
- Contributing to all WP

Key personnel involved:

- **Dr Natalia Martin**, scientific officer for transnational collaborations in the Biology & Health department. After 12 years of research in the biomedical field and an MBA training, she managed a 3-year European CSA project (Rare Disease Platform) before joining the ANR in September 2010.
- **Dr Mariana Lassalle**, scientific officer for transnational collaborations in the Biology & Health department.
- **Dr Jean-Michel Heard**, head of the Biology & Health department and an active scientist.
- **Dr Didier Théron**, programme director for the ANR nanoscience programme and an active scientist.
- **Sophie Despinoy**, administrative and financial officer for ERA-NETs.

Partner No.	2
Organisation Name	Agency for Innovation by Science and Technology (IWT)
Division / Department	Life Sciences
Country	Belgium (Flanders)
Contact Person	Dirk Veelaert
E-Mail	DV@IWT.BE

General description

IWT-Flanders, the Agency for Innovation by Science and Technology, is a governmental agency established by the Flemish Government in 1991. Since innovation policy is a regional matter in Belgium, IWT-Flanders is the key organisation for support and promotion of R&D and innovation in Flanders. The total funding of IWT-Flanders amounts to 300 million Euros in 2011. IWT is both a programme owner and a programme manager (selection and follow-up of research and innovation projects).

The scope of existing funding is quite broad including industrial R&D projects, EUREKA-projects, feasibility studies and innovation projects for SME's, support to industrial networks (sectorial research, technological advisory services, innovation stimulation), support to universities for strategic basic research, support to higher education engineering schools for technology diffusion actions, individual grants for PhD and post-doc research, support to universities for exploitation of their R&D-results.

Companies can make use of services such as information dissemination about international actions and more especially about the Framework Programme and assistance in the preparation of FP7 project proposals, guidance in the innovation process, advice on IPR-issues, transnational technology transfer.

Besides promotion of innovation through funding of R&D-projects and services, one of the main tasks of IWT-Flanders is the co-ordination of the regional innovation actors as regional development agencies, technological advisory services, sectorial research centres and industrial federations.

The participating programme is IWT bedrijfssteun ("General Programme") which is a bottom-up funding initiative open to all industrial research and development projects by companies. In 2011 alone, about 120 M€ were paid to companies working on the development of new products and technologies, including Life Sciences as one of the most important thematic area with an amount of approx. 35 M€. Apart from technical quality and risk, the precondition for support from the fund is a realistic chance of being able to exploit the results of the project commercially.

IWT has a strong expertise concerning ERA-NET projects, being partner in approximately 15 ERA-NET consortia. IWT is partner in 2 Life Sciences ERA-NETs: EuroTransBio and ERA-IB.

Role in the project:

- Leader of task 6.3
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Dr. Dirk Veelaert (PhD, MBA), Coordinator Life Sciences.
Dr. Katrien Swerts (PhD), Project officer.
In addition some other Scientific Advisors in IWT will also be involved in the project.

Partner No.	3
Organisation Name	Service Public de Wallonie (SPW-DGO6)
Division / Department	Directorate General operational for Economy, Employment and Research
Country	Belgium
Contact Person	Nicolas Delsaux
E-Mail	nicolas.delsaux@spw.wallonie.be

General description

The Directorate General Operational for Economy, Employment and Research (DGO6), belonging to the Public Service of Wallonia (SPW), is the legal regional administration in charge of implementing and controlling aids granted to industries, academia and research centres for economic policy, employment and training, and research, including European research Programmes. It is the key advisory body for the Regional government authorities involving research and innovation policy (Programme owner and manager). In 2010, the total budget of SPW-DGO6 amounts to € 1.9 billion. The human resources are of approximately 505 employees (475 FTE). The funding of international research project in ERA-Nets is assumed by a specific budget of € 10 millions.

Since more than ten years, the DGO6 has been actively supporting novel research that is related to the EuroNanoMed topics. In one hand, the nanosciences and nanotechnologies sectors are one of the most promising sectors in Wallonia. Wallonia includes two main producers: Nanocyl and Nanopole which is a cluster of about 20 partners involved in nanotechnologies. Recently, Wallonia has invested € 5 millions in an excellence project named Nanotoxico in order to help the commercialization of nanoproducts through the study of their toxicity. On the other hand, since 2002, programmes related to "Technologies for medical applications and health" are launch every 3 years and reveal the interest to support this field of research.

The DGO6 has largely improved its international collaboration through participation in ERA-NET programmes (COMPERA, CORNET, EURONANOMED, EUROTRANS-BIO, ECO-INNOVERA, ERA-SME, MANUNET, MATERA, MNT, M-ERA and SIINN), coordination of two ERA-NET programmes: ERA-STAR and LEAD-ERA, participation in Regions of Knowledge (RoK) programmes and Joint Programming initiatives (JPI). DGO6 has gained good experience in the implementation of common procedures for international collaborations which will be valuable for integration of newcomers.

Role in the project:

- Leader of task 5.3
- Co-leader of task 5.1
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Dr. Nicolas Delsaux, ERA-NETs Projects Officer at the DGOEER since January, 2009. He studied bio-engineering at the Agricultural University of Gembloux (Belgium) and passed his doctorate there in Molecular Modeling.

Personnel may also include **Ms. Julie Jasmes**, ERA-NETs Projects Officer at the DGOEER and **Dr. Baudouin Jambe**, specialist in the nanotechnology field and International Projects Officer at the DGOEER.

Partner No.	4
Organisation Name	**German Federal Ministry of Education and Research (BMBF)**
Division / Department	Division "New Materials, Nanotechnology"
Country	Germany
Contact Person	Frank Wolf
E-Mail	Frank.Wolf@bmbf.bund.de

General description

The Federal Ministry of Education and Research in Germany (BMBF) is the ministry primarily responsible for defining and executing the German federal government's educational and research policy. The BMBF performs a number of different tasks within the scope of its constitutional responsibility:

- regulation of non-school vocational education and training and continuing education and the necessary policy and coordination tasks,
- Support for research,
- Legislation governing training assistance and its financing (together with the *federal states*),
- Talent promotion, support for young researchers, and
- Promotion of the international exchange of trainees, students, participants in continuing education programmes, instructors, academics and scientists.

By means of special funding programmes, which are based on public competitive calls and peer-review evaluations, the Federal Ministry of Education supports innovative projects in various research sectors; e.g. in basic sciences, sustainable development, information and communications technologies, life sciences, chemistry and materials science, transport or space research.

The Federal Ministry of Education and Research has been directed by Federal Minister Prof. Dr. Annette Schavan since November 2005. The Ministry has around 750 staff members at its main office in Bonn and around 250 at its Berlin office. The Federal Ministry of Education and Research is the owner of the national funding programme "WING - Werkstoffinnovationen für Industrie und Gesellschaft", which will be the German national programme participating in the joint calls of the proposed ERA-NET on nanomedicine. (http://www.bmbf.de/de/3780.php)

Role in the project:

- Contributing to WP2, WP3 and WP6

BMBF will be operating in EuroNanoMed II via their accredited Project Management Agency VDI. Although VDI is in charge of implementation aspects of EuroNanoMed II, the political and strategic orientations as well as any final decisions are taken at the level of BMBF. As such, BMBF will be involved in all WPs and in particular for the Joint Calls (WP2), the regulatory affairs (WP3) and the strategic and cooperation agenda (WP6).

Key personnel involved:

Dr. Herbert Zeisel is head of the Division "New Materials, Nanotechnology" of the BMBF and responsible for European and international cooperation.

Dr. Frank Wolf is scientific officer at the Division "New Materials, Nanotechnology" of the BMBF. He is the programme officer responsible for the nanomedicine section of the WING-Programme. Dr. Wolf will be the representative of the BMBF in the ERA-NET EuroNanoMed II.

Partner No.	5
Organisation Name	VDI Technologiezentrum GmbH (VDI)
Division / Department	Division EINS
Country	Germany
Contact Person	Olaf Rotthaus
E-Mail	rotthaus@vdi.de

General description

The VDI Technologiezentrum GmbH is a private company located in Duesseldorf. It has about 170 employees, mainly natural scientists, engineers, social and political scientists and economists. The main focus of company's work is on

- Research and innovation advancement
- Consulting and moderation of innovation networks
- Technology consulting and innovation assistance

Within the field of "Research and Innovation Advancement", the VDI Technologiezentrum GmbH operates as an executive programme management agency of the German Federal Ministry of Education and Research (BMBF – Partner N°4), managing the national funding programmes in the following thematic areas:

- Optical Technologies
- Nanotechnology and Materials Science
- Plasmatechnology
- Security Research
- Electronics.

The VDI Technologiezentrum GmbH also has a vast experience in managing and supporting EU-activities. The two National Contact Points of Nanotechnology and Security Research are located within the company. Apart from this, the VDI Technologiezentrum GmbH participates in 12 EU-projects.

Role in the project:

- WP3 leader
- Leader of tasks 3.1 and 3.3
- Contributing to WP 2, 3, 4, 5 and 6

Key personnel involved:

Dr. Olaf Rotthaus is senior programme manager and head of the team "Nanotechnology, Materials Science" and responsible for the funding activities managed by the VDI Technologiezentrum GmbH in the frame of the German WING programme. He has been involved in EuroNanoMed I since the beginning and is Mirror Group Chair of the ETP Nanomedicine. Olaf Rotthaus holds a PhD in Chemistry and spent seven years as a researcher for the CNRS in France before joining the VDI Technologiezentrum GmbH.

Dr.-Ing. Joachim P. Kloock is programme manager in the health / nanomedicine part of the WING-Programme at the VDI Technologiezentrum GmbH. He is responsible for the national funding measures "Bioactive Implants", "BioDisposables" and "Molecular Imaging". Dr. Kloock holds a PhD in electrical engineering from the Technical University of Ilmenau.

Dr. Marie-Therese Kuhnert is programme manager in the nanomedicine part of the WING-Programme at the VDI Technologiezentrum GmbH. She is organizer of the Medi-WING symposium and responsible for the Medi-WING website which is summarising the German funding activities in the frame of the WING programme (www.medi-wing.de). Dr. Kuhnert holds a PHD in physics from the University of Bonn.

Partner No.	6
Organisation Name	The Icelandic Centre for Research (RANNIS)
Division / Department	
Country	Iceland
Contact Person	Katrin Valgeirsdottir
E-Mail	katrin@rannis.is

General description

The Icelandic Centre for Research (RANNIS) reports to the Ministry of Education, Science and Culture. Its mission is to provide professional assistance to the preparation and implementation of science and technology policy in Iceland. RANNIS serves the Icelandic science community across all fields of science and humanities.

Its main duties are the following:

- To operate the public competitive funding system for research and technological development, including the Research Fund and the Graduate Education Fund, under the Ministry of Education and Culture and the Technological Development Fund (TDF) under the Ministry of Industry, Energy and Tourism.
- Provide services and information to the Science and Technology Policy Council and its committees on scientific research and technology development, nationally and internationally.
- Coordinate and promote Icelandic participation in international cooperation in science and technology and interact with corresponding agencies and research councils in other countries
- Monitor the resources and performance of R&D, evaluate the results and impact of scientific research, technical development and innovation and participate in international benchmarking of the results
- Promote public awareness of research and innovation.
- Funding for calls in ENM II will be through the TDF. The role of the fund is to support research and development activities, which aim towards innovation in Icelandic industry.

Role in the project:

- Leader of task 2.1
- Contributing to WP 2, 4, S and 6

Key personnel involved:

On the behalf of RANNIS the work will be done by **Dr. Katrin Valgeirsdóttir** who holds a Ph.D. in Biology and extensive experience in teaching and basic research at university level. Dr. Valgeirsdottir is a Senior Advisor in the International Division of RANNIS. She is a national expert and NCP in FP7 Cooperation Theme 1.2 and 4. and NCP in the ERC programme Ideas and has participated in ERA-Instruments and EuroNanoMed.

Partner No.	7
Organisation Name	**Ministry of Health (MOH)**
Division / Department	Chief Scientist Office (CSO)
Country	Israel
Contact Person	Benny Leshem
E-Mail	benny.leshem@moh.health.gov.il

General description

The Chief Scientist Office (CSO) of Israeli Ministry of Health (MOH) through its Medical Research Administration is a pivotal organisation in Israel for managing and funding of bio-medical and medical research.

Our strategic approach is to support investigator-initiated, health-related research projects performed in hospitals, universities and research institutes.

Grant proposals sent in response to public Calls for Applications issued by the Research Fund, are peer-reviewed in various research-disciplines review committees (Study Sections). Funding of feasibility studies and fellowships to Physicians-Researchers is also available. CSO-MOH is also mandated to regulate animal experimentation, genetic human experimentation and homeland security aspects of biomedical research in Israel.

CSO-MOH is a partner in several active ERA-NETs besides EuroNanoMed: ERA-Age-2, FUTURAGE, E-Rare 2, ERA-PathoGenoMics, ERA-IB, TRANSCAN, SIINN, and ERA-NET NEURON II. As leading the issue of communication/dissemination and on Science to Society in both ERA-PathoGenoMics and ERA-Neuron, we maintained an interactive teaching tool, produced short explanatory video clips, flyers, newsletters, brochures and press releases. Dissemination was carried out nationally and internationally, by active presentations in meetings, stakeholders mailing lists and electronic portals (e.g. business wire). In ERA-NET EuroNanoMed, we produced newsletters, a brochure and issued press releases.

Role in the project:

- WP 4 leader
- Leader of tasks 3.2, 4.3 and 4.4 and leader of sub-task 3.2.2
- Contributing to WP 2, 3, 4, 5 and 6

Key personnel involved:

Dr. Benny Leshem, PhD, Director of the Medical Research Administration at CSO-MOH, is a Tumor-Immunologist by training and as the director of the Medical Research Fund, has an extensive experience in research-funding procedures. Dr Leshem is an NSC member in 6 ERA-Nets, the NSC chair in ERA-NET PathoGenoMics and NSC Vice chair in EuroNanoMed and TRANSCAN.

Dr. Irit Allon, DMD, is the national coordinator of ERA-NET PathoGenoMics, ERA-Age, Futurage and ERA-EuroNanoMed at CSO-MOH, has gained experience in working with ERA-Nets. Since 2005 she is in charge odScience to Society and communication/dissemination issues.

Mrs. Leah Geula is the- ICT officer in CSO-MOH, supporting the technical and financial aspects of ERA-NET activities.

Partner No.	8
Organisation Name	**Italian Ministry of Health (IMH)**
Division / Department	General Directorate for Health, Biomedical Research and Health Research Institutions' Supervision
Country	Italy
Contact Persons	Gaetano Guglielmi (officer of the Italian Ministry of Health) Furio Gramatica (scientific advisor of the Italian Ministry of Health)
E-Mail	g.guglielmi@sanita.it & fgramatica@dongnocchi.it

General description

Italian Ministry of Health is the bodies of the Italian Government for Health, in particular it's manage the National Health System and in this field support with specific resources the biomedical and translational research performed in tha National Health Institution in particular with the National Network of the Excellence Center for Research and Healthcare (IRCCS). The Italian Ministry of Health, in the framework of EuroNanoMed II project, will play both the roles of Programme Manager and Programme Owner.

Nanomedicine is an emerging topic in the landscape of Italian research activities on the clinical side. More than one research hospital (Italian acronym is IRCCS) is actively exploring this field of applications of enabling technologies, like nanotechnologies and nanobiophotonics, to the solution of unmet clinical needs. This has a special relevance in the domains of high-sensitivity and specificity in-vitro and in-vivo diagnostics (biomarker discovery and monitoring for early diagnosis, evaluation of responsiveness to therapy, assessment of minimal residual disease), targeted drug delivery by means of nanoparticles, regenerative medicine. In this effort, IRCCSs are supported by the Italian Ministry of Health in establishing high-level relationships with international renowned centres in Europe and US. A national network links IRCCSs – more devoted to clinical translational research – to academia, providing them with the necessary support for more fundamental aspects. The Italian Ministry of Health, through some of the IRCCS in its network, actively participates to international initiatives in nanomedicine, like European Technology Platform of Nanomedicine (ETPN), European platform for Smart Systems (EPOSS), network of excellence in nanobiophotonics (Photonics for Life) and other European initiatives aimed at scientific and policy making objectives.

The Italian Ministry of Health has previous experience in ERA-NET programmes. It is coordinator of ERANET-TRANSCAN and was involved as partner in ERA-NET NEURON and support Italian partner in call PROMEDCHILD, JPND and COEN.

Role in the project:

- Co-leader of tasks 6.2 and 6.4
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Dr. Gaetano Guglielmi, medical doctor, specialized in Public Health and in Nuclear Medicine, was born in Rome in 1957, He is the director of the office for the Health Research - General Directorate for Health, Biomedical Research and Health Research Institutions' Supervision – Ministry of Health. In this position he is in charge for the IRCCS research activities Supervision and Control and for the Peer Review System for the Italian National Grant. In this position he manage the funding system for Italian Ministry of Health to support Italian NHS Institution in ERANET and JPI Projects From 2007 to 2009 He was in charge for the European Relations of the Italian Ministry of Health.

Dr. Furio Gramatica, physicist, was born in Milano in 1964. Since 2008 he is the director of the Biomedical Technology Department "Polo Tecnologico" at Don Gnocchi Foundation – an Italian chain of 30 healthcare and research centres specialized in rehabilitation – where he also leads the Biophysics and Nanomedicine Laboratory. Formerly, he spent several years at CERN (Geneva), INFN, some industrial groups. Dr. Gramatica is fellow professor of physics at Milan University Medical School, member of the Enlarged Executive Board of the European Technology Platform of Nanomedicine; member of the American Controlled Release Society; member of the board of experts, evaluators and reviewers of the European Commission and of Wellcome Trust.

Partner No.	9
Organisation Name	Regione del Veneto (VED)
Division / Department	Project Unit Research and Innovation
Country	Italy
Contact Person	Caterina De Pietro
E-Mail	caterina.depietro@regione.veneto.it

General description

The Veneto Region is one of the 20 regional governments making up the Italian political and administrative system.

The activity of the regional administration goes from planning to implementing laws and programmes at regional level. Indeed, RV pays a special attention on the economic policy field.

Concerning the R&D matters, RV created in 2005 a special department on R&D with the general aim to reach the 3% of GDP in research and development.

The Project Unit Research and Innovation aims to implement the regional policies in the field of innovation, research and productive districts.

It has a close relationship with the scientific and technological parks and its mission is to support research activities, the processes and the networks of innovation, to create enterprises in sectors with high technology content.

The objective is to foster the research and the collaboration on innovation, valorise at international level all the potential and expertise present on the territory, contribute to the progress of knowledge, competitiveness and excellence in the Veneto Region. Through the Project Unit, the Veneto Region funds industrial research activities, experimental development, innovation and technological transfer, formation and use of qualified human resources and a number of related activities.

A special regional law on Research and Development entered into force in 2007, the "Regional Law 18 May 2007, n. 9 - Promotion and coordination of scientific research, economic development and innovation in the regional productive system".

Its overall aims are the promotion of the R&D, Technology Transfer and Innovation in the economic system, with a particular attention on the link between Research and Industry.

From 2009 to 2011 the Project Unit has been partner, with Veneto Nanotech, of the project "EuroNanoMed - EUROpean network of trans-national collaborative RTD projects in the field of NANOMEDicine", the ERA-Net for research programmes on nanomedicine funded under the ERA-Net scheme of the European Commission for the period of 2009-2012, and since 2011 of the project "SIINN - Safe Implementation of Innovative Nanoscience and Nanotechnology", the ERA-NET on Nanotechnologies, including Nanotoxicology.

The relevant policies of RV on R&D deal with the creation of a regional economy based on knowledge and technological innovation through the co-operation between universities, research centres and enterprises and the establishment of a regional framework where human resources can be reinforced and knowledge can be spread and integrated to obtain a general competitive advantage for the whole regional system.

Veneto Region is a programme owner and is the main stakeholder of Veneto Nanotech.

Role in the project:

- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Caterina DE PIETRO – Director of the Project Unit Research and Innovation. She has got a degree in Political Sciences and International Relations. Since 2005 she has been Director of the Department for the Budget of the Veneto Region. She is Director of the Project Unit Research and Innovation since September 2010.

Partner No.	10
Organisation Name	Veneto Nanotech Scpa (VN)
Division / Department	
Country	Italy
Contact Person	Giorgia Merlin
E-Mail	giorgia.merlin@venetonanotech.it

General description

Veneto Nanotech (www.venetonanotech.it) is a company established in 2003 by the Universities of Padua, Venice and Verona as well as by the Veneto Region in cooperation with the Italian Ministry of University and Research (MIUR), several public institutions and private companies, aiming at coordinating the initiatives and at unifying the strategic vision of the Italian Nanotechnology Cluster.

Veneto Nanotech's goal is to familiarize companies with nanotechnologies in order to promote process and product innovation as well as the creation of high-tech companies. Furthermore, Veneto Nanotech aims at fostering and developing private investments in research and at supporting high-tech centres for the development of research projects and promotion of high-tech transfer.

Veneto Nanotech manages some facilities operating in research activities:

(i) Nanofab scarl - Nanofabrication Facility – Its scientific focus concerns surface treatments using many deposition methods for new nano-structured and nano-treated materials, chemical and bio-chemical nanosensors development and microarrays. (www.nanofab.it);

(ii) ECSIN - European Centre for the Sustainable Impact of Nanotechnology - is an international centre for studying the nanotechnology impact on human health and environment and for evaluating the ethical aspects on the (human) society. It deals mainly with risk assessment for companies, evaluation on nano and econanotoxicology and juridical-sociological research linked to the use and/or exposition to nanoparticles and/or nanomaterials (www.ecsin.ue);

(iii) LaNN - Nanofabrication and Nanodevices Laboratory - falls within the framework of a collaboration strategy among the VN Cluster, the University of Padua and CNR (National Research Council). The laboratory is focused on the research on bio-nanophotonics devices nanofabrication in the areas of nems, mems, lab-on-chip, cleantech.

VN was in charge of the joint call secretariat in EuroNanoMed I for the 3 calls (2009, 2010 and 2011).

-> Veneto Nanotech is Programme Manager and the Programme Owner is Veneto Region (P11).

Role in the project:

- WP 2 leader
- Leader of tasks 2.4 (joint call secretariat for the joint calls), 2.5 and 3.4
- Contributing to WP 2, 3, 4, 5 and 6

Key personnel involved:

Nicola Trevisan, CEO of VN, has a strong experience in CSA projects;

Enzo Sisti, Corporate Manager of VN, he has extensive experience in National and European projects as project manager;

Giorgia Merlin, involved in the Projects Unit of the Cluster. She was responsible for the Joint Call Secretariat in EuroNanoMed I and will be responsible for task 4.5 and 4.6 in this project;

Iolanda Olivato, Master in Science in Nanotechnology. She is the scientific coordinator of the ECSIN lab and project manager for some European projects;

Stefano Pozzi Mucelli, PhD in Nanotechnology, is in charge of the Risk Assessment Technology Unit in ECSIN lab. Experienced in molecular biology and nanobiotechnology, responsible for database activities of NanoSustain and NanoValid projects;

Lisa Bregoli, PhD, in charge of the Human Health Technology Unit in ECSIN lab, has expertise in cellular biology, molecular biology and biochemistry. She is also experienced in human immunology, histology, single cell technologies and gene expression analysis. She is VN team leader in the large RTD nanomedicine project TRANS-INT.

Partner No.	**11**
Organisation Name	**Latvian Academy of Sciences (LAS)**
Division / Department	
Country	Latvia
Contact Person	Yuri Dekhtyar
E-Mail	dekhtyar@latnet.lv

General description

The Latvian Academy of Sciences (LAS) is the institution under the authority of the Ministry of Education and Science (MoES). The main tasks of the LAS are the favouring research in the basic and applied sciences, especially the interdisciplinary research; promoting studies in Latvian history, culture and the development of the Latvian language; active participation in the establishing Latvian science policy and consultation of the Government on scientific issues; care about publishing of scientific literature, organisation of congresses, conferences, discussions, and competitions, popularization of scientific achievements and history of Latvian sciences; maintenance of international contacts of Latvian scientists; protection, maintenance, and perfection of research ethics, discussion principles, and traditions.

The LAS is the organizer of the science in Latvia and is fully integrated in the European research area. As regards organisation of science, the LAS is involved in the designing of Latvian science strategy as well as in the evaluation and monitoring of the Latvian state research programmes and projects. Under the supervision of the MoES the LAS is involved in the management of certain state research programmes related to the research priorities which have been approved by the Government.

The main tasks of LAS involve:

- research
- prognoses on the development of Latvia
- promotion of the innovation in technologies
- expertise and evaluations of the projects
- promotion of international cooperation
- participation at the development of the science politics in Latvia
- consulting
- publishing of the scientific books, journals
- organisation of the scientific meetings
- promotion of the young researches activities.

MoES has delegated LAS (Agreement from 01.02.2008) to implement the ERA-NET projects of FP7 in Latvia. LAS is a partner in the following ERA-NET projects: Priomedchild, Matera+, SmartGrids, Ruragri, ICT-Agri, Wood-WidomNet-2, EuroNanoMed, Transcan. From 2012 LAS participates in the implementation of ERA-NETs: ERASynBio, M-ERA.NET, ERACAPS. LAS is partner in FP7 projects eInfraNet, VISION RD4SD and has coordinated 4 Reserachers' Night projects in Latvia. LAS represents national government also in the European Joint Initiatives, in COST, EUREKA, Eurostars and BONUS (Baltic Sea Research) programmes.

Role in the project:

- Co-leader of task 2.2
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

The representative of LAS in the project, **Prof. Yuri Dekhtyar** is well recognized researcher, he is the full member of LAS, has the experience to participate, evaluate and coordinate international projects.

Dr. Dace Tirzite, project coordinator of European programme centre of LAS. Dr.Tirzite is LAS representative in ERA-NET projects: WoodWisdomNet-2, Ruragri and ICT-Agri. Dr. Tirzite has experience of administrative work in Latvian Ministry of Education and Science and is Latvian National Contact point for Framework programme.

Partner No.	12
Organisation Name	**Research Council of Lithuania (RCL)**
Division / Department	
Country	Lithuania
Contact Person	Eugenijus Butkus
E-Mail	eugenijus.butkus@lmt.lt

General description

The Research Council of Lithuania:

- Implements the science policy of Lithuania

The Council is a counsellor of the Lithuanian Parliament and the Government on research and researchers training issues. It advises on the formulation and implementation of science, education and R&D policy. The Council also takes active part in programme based competitive R&D funding, as well as promotes the development of Lithuanian researcher resources, fosters research activities of science and higher education institutions, and raises the prestige of science.

- Carries out the expertise, provides suggestions

The Council participates in the development of the legislation of the Lithuanian science and studies system, carries out the expertise, and provides suggestions on the funding issues of state research programmes, the qualification requirements for researchers and other issues.

Council provides conclusions on the establishment of new and functioning of existing science and education institutions as well as on the requests of the institutions to acquire the right to train doctoral candidates and grant doctoral degree.

In order to ensure competent and fair expert evaluations, since 2008 the Council compiles a database of experts, including experienced researchers, practitioners and experts from foreign countries.

- Develops international relations

The Council participates in the European Research Area issues. The Council is a member of several ERA-NETs (e.g., is an associate of HERA - Humanities in European Research Area - consortium) and a member of the European Science Foundation.

Representatives of the Council also participate in the committees of the European Union's 7th Framework Programme, in the European Research Area Committee (ERAC, the former CREST), the JRC Board of Governors, and other working groups. The Council became involved in European research Joint Programming (JP) initiatives. Part of the JP initiatives are related to the national research programmes, such as "State and nation: heritage and identity", that has links with the JP initiative "Cultural heritage, climate change and security".

- Administers competitive funding for researchers programmes

Since 2009 the Council programme based competitive R&D funding and regularly publishes the calls to submit proposals for research projects in scientific fields. Other scientific activities are also being supported on the competitive basis. The focus is on the financing of high-level frontier research projects. Over the year the Council publishes around 40 calls for proposals based on various Lithuanian, bilateral or international programmes.

The Council participated in EuroNanoMed I. The Council was mainly responsible for the task "Set up and run of infrastructures for joint activities support" of the "Management and support" work package. This experience ensures successful input of our organisation into EuroNanoMed II project.

Role in the project:

- Leader of task 4.1
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Prof. Eugenijus Butkus was appointed the Chairman of the Science Council of Lithuania in 2003, and the latter was transformed into the Research Council in 2008, he was reappointed as the Chairman. Prof. E. Butkus is an Editor of the Central European Journal of Chemistry and a member of the Editorial board of the Lithuanian journal of Chemistry. He is an expert member of the evaluation of the research institutes and programmes as well as university study programmes. He is a member of the ERC Ideas programme committee.

Partner No.	**13**
Organisation Name	**Research Council of Norway (RCN)**
Division / Department	Division for Innovation
Country	Norway
Contact Person	Vidar Skagestad
E-Mail	vsk@rcn.no

General description

The Research Council of Norway (RCN) has been established to serve as a common public administrative and allocating agency for all disciplines and segments within the research sector. RCN is Norway's official body for the development and implementation of national research strategy and reporting to the Norwegian government. RCN is responsible for enhancing Norway's knowledge base and for promoting basic and applied research and innovation to help meet research needs within society and works actively to encourage international research cooperation.

The RCN comprises of four research divisions and one division for administrative affairs. The research divisions are: Division for Science, Division for Energy, Resources and the Environment, Division for Society and Health and Division for Innovation. Norway employs a variety of channels in its internationalisation efforts. Priority is given to EU framework programmes, as well as bilateral relations with partner countries such as the USA, Canada, India, Japan, China and Russia.

In 2010, RCN's annual budget amounts to around € 870 million. The project portfolio contains around 5,650 on-going funded projects, a total project funding of appr. € 2,500 million. The Ministry of Education and Research and the Ministry of Trade and Industry are the most important contributors to the budget of the Research Council of Norway. RCN has some 440 employees.

The research programme NANO2021, managed in the Division for Innovation, is the participating funding programme in EuroNanoMed II. NANO2021 aims at enhancing the national knowledgebase within nanotechnology and advanced materials to meet high international standards. The main objectives are sustainable technological solutions as basis for innovation and to address central societal challenges, thematically matching the scope of the EuroNanoMed II action.

RCN is the national contact agency for the EU R&D framework program, and has long experience from full participation in many ERA NET's. RCN was part of the initial group establishing MATERA and MATERA+. NANO2021 also participate as full member in M-ERA.NET (2012-2016).

Role in the project:

- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

The responsible person in the Working Group from RCN is **Dr. Vidar Skagestad**, special adviser and programme manager for NANO2021. He holds a PhD. in chemistry. He joined RCN 6 years ago. Previously (1995-2006), he was senior scientist, PI and R&D manager in several biotech companies. He has a long experience from work task leader in MATERA and MATERA+.

The responsible person in the Steering Board from RCN is **Dr. Aase Marie Hundere**, senior adviser in NANO2021. She holds a PhD in materials science. She is vice-chair of the ESRF financing and administrative committee and observer in the steering board for the Swiss-Norwegian Beam line at ESRF.

Partner No.	14
Organisation Name	**National Centre for Research and Development (NCBR)**
Division / Department	Department for Applied Research Programmes
Country	Poland
Contact Person	Aleksandra Moscicka-Studzinska
E-Mail	a.moscicka@ncbir.gov.pl

General description

The National Centre for Research and Development (NCBR) is a governmental agency established in order to implement tasks in the area of science and innovation policy. NCBR has operated from July 2007 and its mission is to support Polish scientific institutions and enterprises in order to develop their capabilities in creating applications and solutions based on R&D results and strengthening the economy as well as for the benefit of society. The main task is the realization of strategic scientific research and experimental development programmes – high-budgeted programmes defined by the Minister of Science and Higher Education in the *National Research Programme* and national defence and security programmes. Annual budget of NCBR in 2009 was approximately 108 M EUR, in 2010 approximately 120 M EUR. Every year minimum 10% of the state budget for science is allocated to NCBR.

The *National Research Programme* is divided into seven Priority Research Areas covering main research areas. The ENM II scope refers to the category no. 2. *Civilization diseases, new drugs and regenerative medicine* form the *National Research Programme.*

One of the tasks of the National Centre for Research and Development is to perform activities in the following international projects: ERA- NET and ERA-NET PLUS – the NCBR is a partner in 20 different ERA-NETs, five new projects are in the negotiation process; EUREKA – Poland is a member of EUREKA Initiative since 1995; EUROSTARS - projects implemented on the basis of Article 169 of the EU Treaty; Joint Technology Initiatives ENIAC – European Nano-electronics Initiative Advisory Council; Joint Programme AAL - Ambient Assisted Living. The Centre is funding research projects also within bilateral collaboration - in cooperation with MATIMOP – the Centre of Industrial Research in Israel. In 2010 the NCBR announced together with foreign agencies 14 calls for international research projects (MNT II, NEURON, MATERA, EUROSTARSJU ENIAC, PIANO+, EuroNanoMed, AAL, MARTEC, CHIST-ERA, BIOENERGY, Aspera 2, EN+. 121 proposals with Polish participants were submitted in the calls.

Role in the project:

- Leader of task 4.2
- Contributing to WP 2, 4, 5 and 6

NCBR has an experience as a task and work package leader in ERA-NET scheme projects. In ENM II, NCBR is a leader of Task Communication with similar initiatives.

Key personnel involved:

Aleksandra Moscicka-Studzinska, is a Project Coordinator in the Section for research programmes BIOMED and is involved in the area of biomedical engineering, biotechnology and genetic engineering. She is in the NCBR since 2007. She has an experience in cooperation within ERA-NET and ERA-NET PLUS scheme projects (MATERA, SKEP, EuroNanoMed and MATERA+). At the national level participates in Innovative Medicine Programme. She has got M.Sc. Eng. degree in Industrial Biotechnology from Warsaw University of Technology and is involved in researches on drug delivery systems.

Marcin Chmielewski, is a person responsible for ERA-NET E-Rare-2, NEURON II and Transcan in the National Center for Research and Development. He received an M.Sc. in Biology at the University of Warsaw and is completing his PhD studies in a field of Immunology at Medical University of Warsaw. He was involved in two domestic research projects in the field of immunology.

Partner No.	15
Organisation Name	**Fundação para a Ciência e a Tecnologia (FCT)**
Division / Department	
Country	Portugal
Contact Person	Cristiana Leandro
E-Mail	Cristiana.Leandro@fct.pt

General description

Fundação para a Ciência e Tecnologia (FCT) is the Portugal's main funding agency for research and it is responsible for following the bilateral and multilateral international agreements in science and technology. FCT is a public autonomous institute under the aegis of the Ministry of Science, Technology and Higher Education. FCT covers all fields of science, from natural sciences to humanities, normally in a responsive mode, aiming at capability enhancement and research excellence.

FCT's mission consists in continuously promoting the advancement of scientific and technological knowledge in Portugal, exploring opportunities that become available in any scientific or technological domain to attain the highest international standards in the creation of knowledge, and to stimulate their diffusion and contribution to improve education, health, environment, and the quality of life and well being of the general public.

This mission is mainly accomplished through the financing subsequent to the evaluation of the merit of proposals presented by institutions, research teams or individuals in public open calls, and also through cooperation agreements and other forms of support in partnership with universities and other public or private institutions.

FCT's budget for 2009 is around 660 million €. Funding is structured around the following schemes: promotion of training and career development (fellowships, scholarships, mainly for PhD, Post-doc and PhD in industry), support of centres of excellence (associated laboratories) and research centres (institutional funding), support to infrastructures, promotion and development of scientific activity (research projects) and for diffusion of scientific culture.

FCT also provides the institutional framework for the Research Councils. The Research Council for Life and Health Sciences will be in the future the main responsible for setting up priorities and propose specific research programmes in nanomedicine research.

Role in the project:

- WP 5 leader
- Leader of tasks 5.1 and 5.2
- Contributing to WP 2, 4, 5 and 6

FCT has experience in coordinated actions at national level (join calls with other Ministries) and at the European level; FCT participates in several ERA-Nets coordinated actions.

Key personnel involved:

Dr. Cristiana Leandro studied Chemistry at Faculty of Sciences, University of Lisbon (PT), got a post graduation in Analytical Chemistry in 2003 at the same University, and got her PhD in 2006 at University of York (UK). She worked as a Chemical Analysis Applications Specialist at Waters Corporation (Manchester, UK). From 2007 to 2009 she was Translational Research and Proteomics Postdoctoral Research Assistant at the University of Dundee (UK). Her current scientific officer position at the Department for European, Bilateral and Multilateral Relations, FCT, involves the management of ERA-NETs in the field of Biotechnology and Life Sciences (e.g. TRANSCAN).

Dr. Anabela Isidro studied Microbial Biology and Genetics at the School of Sciences, University of Lisbon (PT) and got a PhD in Molecular Biology in 2002 at the Institute for Chemical and Biological Technology, New University of Lisbon (PT). From 2002 to 2004 she got Postdoctoral training period at the Centre National de Recherche Scientifique (CNRS). From 2005 to 2009 she was a Pos-doc at the Institute for Biological Chemistry, New University of Lisbon (PT) and later got a principal investigator position at the Faculty for Veterinary Medicine till 2010. Her current scientific officer position at the Department for European, Bilateral and Multilateral Relations, FCT, involves the management of ERA-Nets in the field of Medical and Life Sciences (e.g. HIVERA).

Partner No.	16
Organisation Name	National Authority for Scientific Research (ANCS) on behalf of the Ministry of Education, Research, Youth and Sports (MECTS)
Division / Department	
Country	Romania
Contact Person	Elena Dinu
E-Mail	elena.dinu@ancs.ro

General description

ANCS is the specialized organisation of the central public administration applying the strategies and programmes of the Romanian Government in the field of R&D and responsible with the implementation and promotion of the 7th Framework Programme in Romania. ANCS exercises the following functions:

- political (to present & harmonize the political viewpoint regarding research development & innovation);
- strategic (plans and ensures the elaboration and implementation of the policies in the field of research-development and innovation);
- administrative (forecasts, plans, assigns, monitors and evaluates the use of resources for the implementation of the policies in the field);
- monitors, evaluates and controls the policies in the field of research, development and innovation;
- elaborates the normative and methodological framework, functional, operational and financial framework in which the policies in the field are carried out;
- communicates both with other structures of public administration and with the civil society and citizens;
- international co-operation - which ensures the application of international agreements in the related field and the promotion of new agreements;
- state authority – which ensures the monitoring and control of the settlements in its field;
- representing – which ensures, on behalf of the government, its representation in national, regional and international bodies and organisations, as a state authority for its field.

The statute of ANCS is settled by the Governmental Decision no.1449/17th November 2005. ANCS is responsible for the execution of the National Romanian Plan for Research 2007-2013.

ANCS participates as partner or coordinator in many ERA-NET projects: BS-ERA.NET, HIVERA, NET-HERITAGE, SEE-ERA.NET Plus and SEERA-EI. Furthermore, ANCS manages the NCP network for FP7 and a large number of other scientific cooperation, including a bilateral component, with diverse countries from and outside the European Union, insuring also for some of them the contracting and monitoring. Thus, ANCS is working with experienced personnel in international relations.

Role in the project:

- Leader of sub-task 3.2.1
- Co-leader of task 4.2
- Contributing to WP 2, 3, 4, 5 and 6

Key personnel involved:

Ms Ioana Ispas holds a master degree in Molecular Biology and another master in European Institutions and Community Rights at University of Bucharest. Extensive working experience in public administration sector at the national level (Romanian Ministry of European Integration, Romanian Ministry for Education and Research) as Advisor for Bioethics, Genomics and Health and at EU level within European Commission for 4 years (DG ENV, DG RTD, DG SANCO) and in research field as scientist in area of GMO detection methods at Genetics Institute Bucharest. Teaching experience as Assistant Professor at the University of Ecology, Chemistry Department. Experience in research bioethics with more than 30 publications. General Secretary of Romanian National Research Ethics Council. Romanian delegate for FP7 Health & FP7 Food.

Ms Elena DINU holds a master degree in biomaterials and master degree in European policy, a Ph.D. in bionanomaterials and a post-doctorate in bionanomedicine. Working experience in public administration - Romanian Ministry of European Integration, Romanian Ministry for Education and Research, as european affairs counsellor. Delegated and NCP for Nanosciences, nanotechnologies, Materials and new Production Technologies (NMP).Teaching experience as associate university professor and experience research in the bionanomaterials and composite biomaterials (24 publications, leader for 4 grants, involved in 18 grants).

Partner No.	17
Organisation Name	Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)
Division / Department	International Cooperation Department
Country	Romania
Contact Person	Mihaela Manole
E-Mail	mihaela.manole@uefiscdi.ro

General description

UEFISCDI is a public entity of the Central Administration under the ultimate authority of Ministry of Education, Research, Youth and Sport (MoERYS). UEFISCDI was established in July 2010, based on the Governmental Ordinance nr. 74/2010 by merging three organisations with responsibilities for the management and administration of various programmes, in the field of higher education, research, development and innovation.

UEFISCDI plays the role of executive agency for seven advisory councils of the MECTS with responsibilities in the fields of higher education, research, development and innovation.

UEFISCDI implements, under the supervision of its advisory councils, four out of the six programmes of the National Plan for Research, Development and Innovation 2007-2013 (PN II), i.e.: Human Resources (exploratory research), Ideas (exploratory research), Partnerships in Priority S&T Areas (applied research), Innovation (innovation and technology transfer).

Between December 2008 and November 2011, UEFISCDI implemented 6 Strategic Projects for Higher Education (funded through European Social Fund). Starting with December 2011 other 3 strategic projects are implementing for completion and consolidation of the results of the previous ones and the improvement of the HE system in Romania. Externally, UEFISCDI acts for the promotion of Romanian R&D and its integration in the international scientific community, by:

- √ Cooperating with similar organisations in Europe and worldwide
- √ Supporting to Romanian R&D actors to develop international partnerships

UEFISCDI is involved in 17 international projects, most of them under ERA-NET Scheme/FP6 and FP7.

UEFISCDI has strategic partnerships & cooperation agreements with the following organisations: *European Science Foundation – ESF, Swiss National Science Foundation – SNSF, L'Agence nationale de la recherché – ANR, Deutsche Forschungsgemeinschaft –DFG, National Science Foundation – NSF , USA, Netherlands Organisation for Scientific Research.*

UEFISCDI is member of different European associations (EARMA, EARTO), offers support to SMEs by EUREKA, EUROSTARS, and administrates the Romanian participation to the Joint Technology initiatives – JTI/JU (ENIAC, Artemis, Clean Sky, Fuel Cells, IMI).

Role in the project:

- Leader of task 6.1
- Co-leader of tasks 4.2 and 6.3
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Mrs. Claudia ROMAN joined IMT-Bucharest in 2002, working in the Laboratory for Microsystems in biomedical and environmental application. She has been developing management activities for several international and national projects (3 SSA projects in FP6, promoting the cooperation between Eastern and Western Europe research organisation in micro-nano domain, the Romanian Nanomedicine Network RO-NANOMED). She graduated from the Faculty of materials science, University "Polytechnic" of Bucharest, has a master and PhD from the same university. She was also actively involved in EuroNanoMed.

Mrs. Mihaela MANOLE graduated from the Financial Management Faculty – Academy of Economic Studies, Bucharest in 1999, has a master's in public administration. Mrs. Manole gained expertise in coordination and implementation of national projects which promoted participation in European and international research programme in the national R&D program: Research for Excellence. She was also actively involved in EuroNanoMed

Partner No.	18
Organisation Name	**National Institute of Health Carlos III (ISCIII)**
Division / Department	Documents & Technical Studies Department
Country	Spain
Contact Person	Rafael De Andres Medina
E-Mail	rdandres@isciii.es

General description

The National Institute of Health Carlos III (ISCIII) is a public autonomous body for the scientific and technical support of the National Health System (SNS). ISCIII manages the Strategic Action for Health Research (AES) which is a part of the National Plan for R+D+I with the aim of promoting quality research in the field of Bio-medicine and other Health Sciences. ISCIII's public appropriations are stated in the Annual National Budgetary Act (total budget in 2010 = 333 M €; 249M€ devoted to extramural research funding managed thorough the Fund for Health Research). The schemes for extramural research funding via a competitive year call for proposals are: projects, networks, non-commercial clinical trials, medium size infrastructure equipment, pre-doctoral fellowships and junior post-doctoral, senior researchers and technical manpower job contracts and sabbaticals for health care workers. Beneficiary institutions are health care and public health settings, academia and public research performing institutions, as well as private non for profit actors with a health care mission and research track records. Proposals are subjected to scientific assessment and strategic and opportunity evaluation thorough the respective peer review processes in yearly competitions. ISCIII is also funding -OMICs platforms. The European Projects Office (OPE) of ISCIII is run by the FCIEN Foundation, which should be considered as a third party to allow the participation of the staff involved in this project.

ISCIII has been an active funding member of the three calls launched during the ERA-Net EuroNanoMed. ISCIII participates in several ERA-NETs (such as E-RARE-II, NEURON II and TRANSCAN). ISCIII is an active actor as funding body in article 185 initiatives (such as EDCTP and AAL). ISCIII also actively participates in the decentralized BMS (Biological and Medical Sciences) of the ESFRI, the European Strategy Forum on Research Infrastructures (such as ECRIN-PPI, EATRIS, ELIXIR, ERINHA and BBMRI). ISCIII participates in IRDiRC (International Research Disease Research Consortium) and ICCG (International Collaborative Cancer Group). And finally, ISCIII is also an active partner of the following Joint Programming Initiatives (JPIs): JPND (Joint Programme in Neurodegenerative Diseases), JP MYBL (More Years Better Lives), JP HDHL (Healthy Diet for a Healthy Life), JP AMR (Antimicrobial Resistance).

Role in the project:

- WP 6 leader
- Leader of tasks 2.3 and 6.4
- Co-leader of tasks 4.2 and 6.3
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Dr. Rafael De Andrés Medina, Chief of the Department of Documentation and Technical Studies at the Fund for Health Research of the ISCIII, since 2004. He was previously Deputy Director, Institute for Research on Rare Diseases (Madrid, 2004), Centre for Toxic Oil Syndrome and Rare Diseases Research (Madrid, 2002-2003), National Centre for Fundamental Biology (Majadahonda, 1997-2001) and National Centre for Cell Biology and Retroviruses (Majadahonda, 1991-1996) at the Institute of Health Carlos III (Spain). National AIDS Coordinator of Spain (Ministry of Health and Consumption, Madrid, 1987-1990). Since 1986, he has actively participated in numerous international Committees and is currently member of the Executive Board of Art. 179 AAL, as Treasurer.

Dr. Hans H. Riese, PhD MBA. Technical Officer at the European Projects Office, Department of International Research Programmes and Institutional Affairs. Instituto de Salud Carlos III. Areas: FP7, IMI, ERA-NETs, JPIs.

Ignacio Baanante, BVSc. Technical Officer at the Fund for Health Research of ISCIII. He was working for the European Programmes Unit of the Ministry of Science and Innovation (2009-2011). Since 2008 he has actively participated in several FP6 and FP7 ERA-NETs.

Partner No.	19
Organisation Name	**Swedish Research Council (SRC)**
Division / Department	Department of Research Funding
Country	Sweden
Contact Person	Johan Nilsson
E-Mail	johan.nilsson@vr.se

General description

The Swedish Research Council (SRC) is a government agency that provides funding for basic research of the highest scientific quality in all disciplinary domains. Besides research funding, the agency works with strategy, analysis, and research communication. The objective is for Sweden to be a leading research nation. The Swedish Research Council, which distributed about SEK 4.5 billion in research support in 2010, is the largest state funder of basic research at Swedish higher education institutions and research institutes. Every year numerous grant applications are submitted to the Research Council. These applications are assessed and prioritised in terms of scientific quality and the applicants' expertise by evaluation panels. The panels are appointed by the Scientific Councils and Committees of the Swedish Research Council, which serve as expert bodies: the Scientific Council for Medicine, the Scientific Council for Humanities and Social Sciences, the Scientific Council for Natural and Engineering Sciences, the Committee for Educational Sciences, and the Committee for Research Infrastructures. The bulk of the Research Council's research support goes to project initiated by researchers themselves and deemed most promising by other researchers in the process of peer review.

The SRC participated in the first two joint transnational calls of EuroNanoMed, contributing a total of SEK 18 million (about € 2 million) and financing in total six Swedish research groups within the framework of EuroNanoMed. The Swedish Research Council was also the leader of Work Package A of EuroNanoMed: Systematic mapping of the ongoing programmes and strategic agenda for joint activities.

The SRC is involved in a number of European research initiatives, including ESF, ERC, EUROHORCs, EUROCORES, ESFRI, as well as several ERA-NET initiatives. The SRC participates in two joint programming initiatives of medical relevance: JPND (neurodegenerative diseases) and JPAMR (antimicrobial resistance).

Role in the project:

- Leader of task 6.2
- Co-leader of task 2.2
- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Dr. Johan Nilsson received a PhD in medical biochemistry at the Karolinska Institute in 2004. After two postdoctoral research projects, he was employed as a research officer at the Swedish Research Council in 2009. He has been involved in the WPA activities of EuroNanoMed as well as in the JPAMR proposal preparation, the JPAMR secretariat, and the mapping activities of JPND.

Partner No.	20
Organisation Name	**Swiss National Science Foundation (SNSF)**
Division / Department	Division of Biology and Medicine
Country	Switzerland
Contact Person	Christoph Meier, Ayşim Yılmaz
E-Mail	cmeier@snf.ch, ayilmaz@snf.ch

General description

The Swiss National Science Foundation (SNSF) is Switzerland's leading provider of scientific research funding. With its federal mandate, it supports basic research in all disciplines, from philosophy and biology to the nanosciences and medicine.

The focus of its activities is the scientific endorsement of projects submitted by researchers. The best applicants are funded by the SNSF with an annual total amount equalling approximately CHF 700 million.

Established in 1952 as a foundation under private law, the SNSF has the autonomy it needs to promote independent scientific research. The SNSF is committed to promoting young scientists and works to ensure that scientific research in Switzerland has the most favourable conditions for developing internationally. It also encourages dialogue between scientists and representatives in society, politics and the economy.

The SNSF is EuroNanoMed Programme Owner and Programme Manager for Switzerland.

The SNSF has participated in the three joint calls of EuroNanoMed I and has supported Swiss partners in seven EuroNanoMed consortia.

Role in the project:

- Contributing to WP 2, 4, 5 and 6

Key personnel involved:

Dr. Ayşim Yılmaz, PhD, Head, Division of Biology and Medicine, NSC representative.

Dr. Christoph Meier, PhD, Head, Unit of Clinical, Social and Preventive Medicine, CSC representative.

2.3. Consortium as a whole

The EuroNanoMed II consortium includes 20 partners from 14 countries and 3 regions, reflecting the huge interest and the expectations generated by this initiative. The **17 countries/regions** involved consist of:

- 11 European Union countries, including 4 new EU Member States (Latvia, Lithuania, Poland and Romania);
- 3 FP7 associated countries (Iceland, Israel and Switzerland);
- 3 European regions (Wallonia and Flanders in Belgium, and Veneto region in Italy).

Compared to the EuroNanoMed I consortium, two countries (Turkey and the Netherlands) and one region (Basque region) had to leave the consortium due to strategies changing and budget reductions. In addition, during the ENM II negotiations, the Hungarian National Office for Research and Technology (NIH) who was initially involved in the proposal could not commit officially to the project due to internal administrative reasons. They will join the consortium at a later stage when this is resolved. When Hungary joins the project, there will be the same total number of countries and regions (18) in the EuroNanoMed I and the EuroNanoMed II consortia. This is due to the joining of three new partners: Norway, Italy and Flanders. In addition, the UK, Ireland and Slovenia expressed a strong interest in EuroNanoMed II but were not able to commit to the initiative. Nevertheless, we hope that they will be able to participate in one (or more) of the joint calls.

With the exception of the three new countries/regions (Norway, Italy and Flanders), all of the EuroNanoMed II partners have participated in at least one of the EuroNanoMed I call – most of them in all three – and intend to participate in further calls through EuroNanoMed II. The organisations from the three new countries/regions (Norway, Italy and Flanders) are programme owners as well as managers and have also committed to participate in EuroNanoMed II calls. Therefore, it is expected that the 17 countries/regions will participate in the EuroNanoMed II joint calls for proposals.

The composition of the consortium appears to be well-balanced with respect to the significant critical mass achieved in the field and the specificities of the existing national/regional actors in nanomedicine. The consortium involves complementary partners to meet the objective of pulling the technology from research to preclinical and first stages of clinical trials. Most partners fund the three categories of actors (academia, clinic, industry), with some having more experience and knowledge in funding a specific type of actor. Finally, the consortium benefits from the complementarities and the experience of the partners. Most of the partners are also involved in other ERA-NET initiatives, which will allow to share experiences and to take benefit from lessons learned for a better achievement of the ERA-NET tasks, especially when it comes to sustainability of the network.

Sub-contracting

Only the development, tuning and maintenance of technical tasks aiming at setting up tools are subcontracted:

- the website for internal and external communication (WP4) – partner N°12 (RCL)
- and the optimisation of the existing electronic tools for the call office and submission of the proposals (WP2) – partner N°10 (VN)

Both are necessary for the implementation of the ERA-NET activities and require a technical competence not available among the partners. All subcontracting will be done following national legislation, and will be in compliance with article II.7.2 of the EC Grant agreement.

Third parties (other than subcontractors): N/A

Funding for beneficiaries from "third countries": N/A

2.4. Resources to be committed

Overview of requested funding per beneficiary:

Participant short name	Participant n°	Person-months	Personnel Costs (€)	Travel & Subsistence (€)	Other direct costs (€)	Subcontracting (€)	7% Indirect costs (€)	Total requested funding (€)
ANR	1	*46*	230 000	13 000	22230		18 566	**283796**
IWT	2	*2.8*	32 200	8 100			2 821	**43 121**
SPW-DGO6	3	*8.8*	44 000	8 100			3 647	**55 747**
BMBF	4	*2*	0	0			0	**0**
VDI	5	*13.9*	129 270	8 100	19 000		10 946	**167 315**
RANNIS	6	*3.4*	15 300	9 000	9 000		2 331	**35 631**
CSO-MOH	7	*16.2*	64 800	15 000	23 000		7 196	**109 996**
IMH	8	*2.8*	12 600	8 100			1 449	**22 149**
VED	9	*0.9*	6 300	8 100			1 008	**15 408**
VN	10	*34.4*	240 800	8 100	92 000	10 000	23 863	**374 763**
LAS	11	*1.9*	7 600	8 100			1 099	**16 799**
RCL	12	*6.2*	30 070	8 100		38 000	2 672	**78 841**
RCN	13	*1.4*	19 712	8 100			1 947	**29 758**
NCBR	14	*3.8*	13 300	8 100			1 498	**22 898**
FCT	15	*13.3*	46 550	8 100	3 000		4 035.5	**61 685**
ANCS	16	*3.4*	6 800	8 100			1 043	**15 943**
UEFISCDI	17	*5.2*	10 400	8 100			1 295	**19 795**
ISCIII	18	*12.4*	64 480	8 100	9 000		5 710.6	**87 290**
SRC	19	*5.3*	31 270	8 100			2 756	**42 125**
SNSF	20	*0.9*	7 722	8 100			1 108	**16 930**
Total		***185***	**1 013 174**	**166 600**	**177 230**	**48 000**	**94 988**	**1 499 990**

NB: Work package leaders are underlined.

Personnel costs correspond to the cost of manpower of each beneficiary, necessary for the implementation of the project (person-months). A critical mass of 185 person-months is to be mobilized over the 4 year period. This corresponds approximately to 3.8 FTE (full time equivalent) per year over the duration of the project. Personnel costs represent 68 % of the total requested funding, which is in agreement with the scope of ERA-NETs as an instrument of networking, information exchange and concept development. It is important to note that this amount does not include the personnel resources which will have to be allocated to the project by partners' at their own cost. Indeed, in addition to the EC grant, the EuroNanoMed II partners have committed to mobilise their own resources to achieve EuroNanoMed II tasks and goals.

Partners specificities:

Partner n°4 (BMBF) does not request any EU funding but will contribute to the EuroNanoMed II ERA-NET in the following ways:

- Preparation and participation in NSC meetings
- Participation in workshops organized by ENMII
- Consultation and coordination with the German programme manager (VDI, partner N°5) – WP3

- Participation in the Joint Transnational Calls for proposals – WP2
- Linking to national and international activities in nanomedicine – WP6

The estimated budget for these activities will be 2 PM distributed as follows:0.5 PM in WP2, 1 PM in WP3, 0.5PM in WP6 for a total of 12 000€ in direct costs.

Partner N°8 (IMH) has personally appointed Mr. Grammatica as an unpaid advisor to represent the Ministry of Health in EuroNaNomed II for scientific aspect. Therefore, the partner n°8 will not claim any personnel cost related to the involvement of Mr Grammatica in the project.

Travel & subsistence: an average cost of 900 € per partner and per meeting was assumed. In order to reduce travel costs, various meetings (e.g. NSC, PRP, CSC, workshops, review seminars) are planned to be organised together and a meeting calendar has been set up (see section 2.1f) – as a result, only 9 meetings are planned over the 4 years of the ERA-NET. Therefore, each partner was allocated a flat rate 8 100 € for travel and subsistence costs. For two partners, CSO-MOH (Israel) and RANNIS (Iceland), the average cost of travel to mainland Europe is higher, and as such a slightly higher flat rate was allocated to them (9 000 €). In order to go to conferences (WP4), extra budget was allocated to the WP4 leader and the coordinator. The total travel costs amounts to 166 600 €, which represents about 11.8% of the total requested funding.

Other direct costs:
The other direct costs amounts to 177 230 € (direct costs), which represents about 11.8% of the total requested funding.

Organisation of meetings/workshops:

- WP1: Consortium meetings (Kick-off meeting and 2 NSC meetings per year) **(9 200€ - ANR)**
- WP2: Peer Review Panel meetings for the four joint calls and three review seminars for funded projects **(92 000€ - VN)**
- WP2: A scientific workshop on strategy and defining topics for the calls **(9 000€ - RANNIS)**
- WP3: Two workshops on regulatory affairs **(19 000€ -VDI)**
- WP3: A workshop on ethical issues **(5 000€ - CSO-MOH)**
- WP6: Two small workshops on defining sustainability model for future collaboration **(9000€ - ISCIII).**

This also includes budget for reimbursing travel expenses of EAB members and other experts attending the meetings/workshops.

Dissemination costs

- WP4: Printing costs (e.g. brochures, reports) **(18 000€ - CSO-MOH).**

In addition, the funding planned for the Hungarian partner (NIH), which amounts to **13 030€**, has been temporary allocated to the other direct cost of the coordinator (**WP2 – ANR**). This amount is dedicated to NIH if joining the consortium at a later stage, but its use can also be decided by the NSC.

Sub-contracting: costs corresponding to technical tasks aiming at setting up and updating tools necessary for the project (see details in 2.3.2), amounting to 38 000 € for the website and 10 000 € for the project submission tool.

Indirect costs: According to the financial rules of the FP7 for coordination actions an indirect cost rate of 7% to all cost allocations except subcontracting should be applied. The ENII budget was calculated accordingly.

Mobilisation of resources per work package:

The requested costs items are also detailed per work package in the table below. Travel and subsistence costs were not included in this table, since each planned meeting will cover tasks from more than one work package and, as such, travel costs cannot be assigned to a particular work package.

		WP1	WP2	WP3	WP4	WP5	WP6
Personnel	*person-months*	*34*	*57*	*19.5*	*30*	*22.1*	*20.4*
	costs (€)	170 000	359970	147 250	129922	94 291	111741
Other direct costs (€)		9200	114 030	24 000	18 000	3 000	9 000
Subcontracting (€)			10 000		38 000		
Indirect costs (€)		12 544	32 268	11 987	10 354	6 810	8 451
Total requested funding (€)		**191744**	**517 180**	**183 237**	**196 276**	**104 101**	**129 192**

B3. Impact

3.1. Strategic impact

EuroNanoMed I gathered the participation of partners from 18 countries and regions and generated the support of 24 RTD projects in nanomedicine through three calls for proposals. ENM I achieved a critical mass of actors, arousing translational collaborations between three research communities: *academic, industrial* and *clinical* research, with projects covering the three main subfields of nanomedicine, i.e. targeted drug delivery, diagnostics and regenerative medicine. However, the EuroNanoMed I initiative was limited to 3 years only and the majority of the partners consider that the continuation of ENM I with ENM II is of major importance in order to:

- Support more transnational projects to foster the European research community in nanomedicine with the objective of creating a European Research Area in nanomedicine. New calls for proposals will take benefit of the communications already disseminated with regards to the ENM I calls.
- Promote the topics considered as priorities for the NMP unit and for the ETP Nanomedicine, in particular the translational aspects of nanomedicine[1,2].
- Foster the participation of young researchers.

In addition, EuroNanoMed II will contribute to EU policies and priorities, such as strengthening the European Research Area, advancing the transition to personalised and targeted medicine, boosting translational and clinical research, and focusing on transferring scientific results towards innovation in healthcare in Europe.

The strategic impact of the ERA-NET EuroNanoMed II can therefore be considered at different levels.

3.1.1 Improve coordination and reduce fragmentation in the fields of research of nanomedicine

➢ **EuroNanoMed II will improve the coordination of national programmes in nanomedicine**

In EuroNanoMed I, although only two joint transnational calls were planned to be launched in 2009 and 2010, the consortium decided to launch an additional call before the end of the ERA-NET, showing the involvement and the willingness of the partners to coordinate their programmes in nanomedicine. With this proposal for a second ERA-NET, involving the majority of partners of ENM I plus three new partners, the consortium aims at improving the coordination of the research programmes already set up during ENM I. ENM II will greatly benefit from the tight links between partners and the experience achieved in ENM I.
The coordination of European programmes in nanomedicine will be improved through the common work planned in this project:

- Fostering a network of national/regional programme managers working closely together and learning from each other. This builds mutual understanding and trust that have long lasting effects.
- Defining the common procedures, practices and documents for each of the four planned joint transnational calls for proposals;
- Organising the implementation and the follow-up of the funded projects; this will require sustainable work in synergy between the partner funding agencies over many years.

Moreover, the final goal of ENM II is to propose and establish a sustainable cooperation framework after the end of this second ERA-NET. This ambitious goal will be achieved through the WP6, which is specifically

1 ETP Nanomedicine White paper to the horizon 2020 FP "Improving Translation of Public Healthcare nano-research in Europe"
[2] NMP Expert Advisory Group: Position Paper on future RTD activities of NMP for the period 2010-2015

dedicated to the preparation of this future cooperation towards a common joint programme in nanomedicine. All aspects of a future cooperation will be explored with a step by step approach: benchmarking with sister initiatives; gathering the needs and expectations of the partners; identifying the administrative and financial constraints of the partners. The aim is to achieve a realistic cooperation between the funding agencies allowing the support of transnational nanomedicine research after the end of the ERA-NET and hopefully over many years.

- **EuroNanoMed II will reduce fragmentation in the key fields of research of nanomedicine**

The four joint transnational calls for proposals in nanomedicine planned to be launched through EuroNanoMed II will contribute *per se* to reduce the fragmentation of the ERA in nanomedicine. The impact of these calls on fragmentation is expected to be significant since they will be launched in continuation to ENM I. Therefore, they will take benefit from the visibility and the success of the calls launched through ENM I. Considering the 18 countries/regions involved in ENM II, the joint calls for proposals will allow the support of partnerships between the majority of the European nanomedicine actors, contributing to the construction of the ERA in nanomedicine.

EuroNanoMed II fills existing gaps in the European landscape and is complementary to existing initiatives. There is a real need for support for the different stages of the value creation chain in medical applications of nanotechnology and specifically through an industry/application/patient driven-approach. As already done in ENM I, ENM II will provide fast allocation of seed funding for innovative ideas and concept, where a limited number of partners is required and with this translational approach. This ERA-NET is therefore highly complementary to FP7 large scale projects funding tools (*e.g.* EUREKA, Eurostar, IMI) and FP7 programmes (NMP, HEALTH) with a heavier and longer application process and support for larger projects. Moreover, the existing ERA-NETs do not include explicitly nanomedicine as a key target or have rules that are not really relevant to nanomedicine projects:

- *SIINN* deals with the potential risks of engineered nanomaterials for the environment, human health, and safety. This is very complementary to the ENM II research programme on using nanotechnology for medical applications. Many links have already been made with the ERA-NET SIINN since 8 partners are involved in both SIINN and ENM II and the coordinator of ENM II, ANR, is in charge of the work package on joint calls in SIINN.
- *EuroTransBio* aims to foster the competitiveness of the European biotechnology industry, which is a border to some specific actions of nanomedicine. However, nanomedicine, or even nanobiotechnology, is not included specifically in their programme. In addition, the constraint for proposals to be coordinated by an SME and to include at least 2 SMEs per project is not applicable to the nanomedicine field which is less mature than biotechnology.
- *MANUNET II* is strictly focusing on market-oriented enterprise-led R&D projects related to the application and practical use of manufacturing technologies.

As the continuation of ENM I, ENM II will gain in efficiency and will allow a more durable impact on nanomedicine research. ENM II will therefore contribute to the development of innovative therapeutic solutions for the patient and to the competitiveness of the European health industry. The aims of ENM II are thus in line with the European and NMP policy stressing the importance of solid and nationally-funded research efforts allowing cross-border cooperation between the best researchers from public and private sectors[1].

[1] NMP Expert Advisory Group: Position Paper on future RTD activities of NMP for the period 2010-2015

3.1.2 Achieve critical mass and ensure a better use of limited resources in the fields of research of nanomedicine

- **EuroNanoMed II achieves a critical mass of actors and focuses on translational collaborations**

To achieve products in nanomedicine, the critical issue is to enable fundamental research to enter into preclinical and first clinical stages. To this aim, it is necessary to facilitate cross-fertilisation between the different actors (industry, clinic and academia) and to reach a critical mass of actors at the European level. With 21 partners from 18 countries/regions, ENM II covers the major part of the European research community. Moreover, considering the results already achieved in ENM I (*i.e.* the participation of more than 500 applicants to the three ENM I calls and the increased number of proposals from one call to the next) and the visibility of the ERA-NET, ENM II expects to have a significant impact on the European nanomedicine RTD landscape. In order to facilitate the transfer from research to companies and patients, there is a need to have enough academic teams, clinical teams and companies within research consortia. As such, in ENM I, translational collaborations were required through the calls eligibility criteria. Each consortium had to involve at least two categories of partners among clinical, industrial and academic research teams. ENM II will also encourage translational collaborations and will gather a sufficient number of actors of all categories, taking together the 18 countries/regions partnering in the initiative.

- **A greater impact with EuroNanoMed II joint transnational calls for proposals than the sum of the national ones**

National programmes have difficulties to support transnational projects and, in the specific field of nanomedicine, there are often too few players at the national levels to achieve a critical mass. In addition, although nanomedicine has significant implications on the major diseases in Europe, the national calls for proposals are usually focused on specific diseases, making the more methodological field of nanomedicine less prioritised. On the other hand, the EU programmes (FP7 and the future Horizon 2020) have budget limits for each field, and often many good projects cannot be supported. ENM II will continue and improve the funding mechanism created by ENM I to support transnational collaborative RTD projects between academia, companies (especially SMEs) and/or clinical/health care settings in nanomedicine, based on actual needs.
The effectiveness and the uniqueness of the ENM II funding programme will result from the association of three characteristics:

- It is fully dedicated to nanomedicine;
- It is directly funded by national and regional funding organisations;
- It fosters translational collaborations favouring the development of patient/person-oriented and/or industry-oriented projects.

3.1.3 Sharing good practices in implementing common research programmes

ENM II will contribute to the improvement and harmonisation of the public policies aiming at supporting collaborative innovative RTD projects between academics, companies/SMEs and/or hospital/health care settings. During ENM I, a mapping and analysis of the practices existing in participating organisations led to agreeing on best practices that were implemented in the calls. ENM II will update this mapping and analysis and will also benchmark with similar initiatives. This will be very valuable towards improvements in the call procedures and to help identify different schemes for a sustainable cooperation of the ENM II partners after the end of the ERA-NET (WP6). In addition, the lessons learned (WP5) from each call and the

continuous systematic exchange of information will suggest the best ways for improving existing practices. This iterative process will help in meeting the goal not only to share good practices but to effectively use these practices.

EuroNanoMed II thus contributes to the preparation and use of European standards, with respect to:

- The "systematic" approach for compiling and comparing research programmes (i.e. congruence of terms, standard data formats, software solutions);
- Best practices with regards to programme management and administration as well as innovation issues in R&D funding;
- To define and validate appropriate tools and procedures for the selection of multinational projects and for the monitoring and assessment of multinational procedures;
- To harmonise evaluation practices of public funding bodies in Europe, especially the common use and precise definition of criteria and terms like e.g. "scientific excellence", technology transfer, market relevance, clinical/public health needs, etc.;
- General agreements and principles for transnational research activities in the long-term (e.g. rules for a contractual and legal framework, models for transnational funding scenarios);
- Consistent IPR arrangements in transnational research funding;
- Dissemination of EMA applicable standards to nanomedicine clinical validation steps within the "nano community".

3.1.4 Promote transnational collaborations and generate new knowledge

EuroNanoMed II calls for proposals will make transnational collaboration mandatory and the added-value of this transnational collaboration will be an evaluation criterion. For the national players, ENM II will broaden their opportunities to participate in collaborative innovative RTD projects. It extends the field of partnership to all the 18 countries/regions members of the initiative, exploiting the domains of expertise of public researchers, of clinicians and of private researchers. The access to a very large number of potential partners will stimulate creativity of the different actors of the field, generating new knowledge and more knowledge transfer than national projects. The fostering effect of the ENM II transnational joint calls for proposals will improve the quality of submitted proposals by:

- Making it easier to find specific competencies and skills;
- Facilitating European collaborations and synergies;
- Facilitating multidisciplinarity, a crucial issue in the field of nanomedicine;
- Generating more robust, ambitious and structured innovative RTD projects.

Finally, EuroNanoMed II will organise three big review seminars for the partners of the EuroNanoMed (I&II) funded projects and young researchers involved in the funded projects, with the participation of high-level invited scientists and European and national representatives. These events will bring together the key actors in the European nanomedicine research communities and will thus further promote interactions and collaborations at a European level.

3.2. Spreading excellence, exploiting results, disseminating knowledge

Based on the knowledge acquired during ENM I and on the experience from partners involved in the other ERA-NETs, the communication of ENM II will be greatly improved. To this aim, WP4 has been specifically dedicated to communication and dissemination. The leaders of this WP will work with all the ERA-NET partners and with all the other WPs to disseminate the activities and results of ENM II.

The **key messages** to be disseminated are:

- EuroNanoMed II description, objectives, news, information on the procedures (for benchmarking), information on the joint calls for proposals (announcement of the launch, documents and contacts to apply, etc.), results of the joint calls for proposals;
- Description of the EuroNanoMed II-funded projects and key results from these projects;
- Presentation of the nanomedicine field;
- General information related to nanomedicine events and news.

Different target audiences have been identified depending on the messages to be delivered. As already done in ENM I, the main audience targeted will be the research community and the policy makers (EC and national). Moreover, in ENM II, some information will also be specifically prepared and dedicated to the general public through for example video clips in order to present and explain the nanomedicine field in a comprehensive way. Indeed, the aim is to build an information bridge between research and society in order to increase public awareness to the importance of research in nanomedicine, showing the potential benefit of such research to the patients.

The ENM II **website** will be the main support for dissemination of all ERA-NET data. The website set up for ENM I will be updated and improved for ENM II in order to provide all relevant information with a more efficient dissemination process (WP4). This website will enable the consortium to generate an effective flow of information and publicity about the objectives and results of the ERA-NET, the contributions made to European knowledge and scientific excellence, the value of collaboration on a Europe-wide scale, and the benefits to EU citizens in general. The website will also allow for visitors to subscribe to the website in order to receive news and updates. In addition, dissemination of ENM II work and results will be done through reports (public deliverables), links to national programme websites, press releases and newsletters. Finally, a data base of "Expression of Interest" will enable potential applicants to publish their project ideas in order to set up partnerships.

EuroNanoMed II will make use of the NETWATCH web site to disseminate information and will provide input to the NETWATCH platform whenever important new developments occur, such as joint calls. The coordinator will ensure all contacts with NETWATCH and will be responsible for continuous updates. EuroNanoMed II will use this learning platform for further internal improvement and enlargement of the consortium.

A close **cooperation** with specific European stakeholders is essential to achieving the objectives of ENM II and fostering a long-term cooperation framework for a joint funding programme in nanomedicine. The EuroNanoMed Coordinator and the related WP leaders will be in charge to conduct on a regular basis discussions and exchanges with the following networks:

- The European Technology Platform (ETP) on Nanomedicine;
- Other ERA-NETs (e.g. SIINN, EuroTransBio);
- The European Joint Technology Initiative for Innovative Medicine (IMI);
- The CSA NANOMED 2020 currently being planned;
- The CLINAM (network of clinicians working in Nanomedicine).

The collaboration with the **ETP Nanomedicine** already set up during ENM I will be strengthened in ENM II. A representative of the ETP Nanomedicine Executive Board will be invited to attend the ENM II NSC meetings as observer. This ETP representative will convey to ENM II the voice of the platform, meaning the position

of the private and public researchers. *Vice versa*, a representative of the ENM II consortium will participate in the Executive Board of the ETP Nanomedicine. Moreover, since some EuroNanoMed NSC members are Mirror group members of the ETP Nanomedicine (Public Authorities representatives at national, regional and European level), they have the possibility to convey their position to the board of the ETP Nanomedicine. The channel of communication between ENM II and the ETP will thus function in both directions. This collaboration with the ETP Nanomedicine will be necessary for the implementation of the workshops foreseen in work packages 2 and 3. Moreover, other possible collaborations have already been discussed during the last mirror group meeting of the ETP Nanomedicine (Barcelona, October 2011), in particular the organisation of nanomedicine partnering events by the ETP Nanomedicine in the perspective of EC and EuroNanoMed calls for proposals.

B4. Ethical Issues

The Coordination work of the EuroNanoMed II Consortium, being essentially a network of national agencies in order to mutualise their activity for the benefit of the nanomedicine research community throughout Europe, does not raise in itself any particular ethical issue. However, the members of EuroNanoMed II will address the following ethical issues:

- *Fairness and transparency in operational procedures:*

Decisions at all levels of the EuroNanoMed II project will be made after thorough discussion among the participating partners. Wherever possible, the principle of consensus will be applied.

Transparency and fairness towards the research community are especially important in the procedures for the joint transnational calls. Based on experiences from EuroNanoMed I, an impartial process for peer review and selection of projects to be funded will be implemented (see WP2).

- *Ethical issues in the research projects submitted to the Joint Transnational Calls:*

In the evaluation of proposed research projects, special attention will be reserved for potential ethical issues (e.g. research on humans or animals; privacy of data and biomaterials; informed consent; etc.). Only projects that fulfil the legal and ethical international/EU and national and institutional standards will be funded. In procedural terms, this means that funding for this kind of projects will be dependent on a positive vote from the responsible ethical and legal committees. All procedures involving human beings will conform to the Helsinki Declaration.

- *Ethical issues in nanomedicine research:*

Since the emergence of the nanotechnology field, ethical issues about nanomaterials have raised concern and lead to debates and discussions. Therefore, a task in EuroNanoMed II is dedicated to exploring and framing the ethical issues associated with the nanomedicine field (task 3.2).